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ABSTRACT 
 
Alexander Samuel Breskin: The effects of hepatitis C infection, treatment, and  
population interventions on all-cause mortality among people living with HIV 
(Under the direction of Daniel Westreich) 
 
 
 Approximately 25% of people living with HIV (PLWH) in the United States are co-infected 
with hepatitis C virus (HCV), which, if left untreated, causes mortality through decompensated 
cirrhosis and hepatocellular carcinoma. Direct-acting antiviral (DAA) treatment for HCV can 
produce sustained HCV virologic response in nearly all PLWH and HCV (PLWH+HCV). 
However, in the era of effective antiretroviral therapy (ART), the effects of HCV infection, 
treatment, and population interventions on mortality are not clear for PLWH.  
 Using data from 3,056 PLWH in the Women’s Interagency HIV Study and Multicenter AIDS 
Cohort Study from 1994 to 2015, we used the parametric g-formula to estimate the effects of 
HCV infection and DAA treatment on 10-year all-cause mortality. We also estimated the effects 
of DAA treatment policies in which different groups are treated with DAAs: all PLWH+HCV, 
PLWH+HCV who met two existing Medicaid treatment criteria – achieving HIV suppression 
and having severe fibrosis or cirrhosis, and PLWH+HCV chosen at random with proportions 
treated equal to those under the Medicaid criteria. All estimates occurred after a hypothetical 
intervention to have all PLWH initiate ART at baseline, as modern guidelines suggest ART for 
all PLWH regardless of CD4 cell count. 
 The estimated 10-year mortality risk difference (RD) for HCV infection was 4.3% (95% CI: 
0.4%, 8.9%). The RD for DAA treatment was -3.7% (95%CI: -9.1%, 0.6%). The RD for treating 
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those with HIV suppression and severe fibrosis or cirrhosis was -1.1% (95% CI: -2.8%, 0.6%). 
Under this policy, 51% (95% CI: 38%, 59%) of PLWH+HCV would be treated with DAAs. The 
RD for treating the same proportion of PLWH+HCV chosen at random was -1.9% (95% CI: -
4.7%, 0.3%). The population attributable risk difference for treating all PLWH+HCV with direct 
acting antivirals (DAA) was -0.7% (95% CI: -1.8%, 0.1%). 
 These results show that HCV is a major cause of mortality among PLWH, and that DAA 
treatment is effective at reducing mortality in this population. They also suggest that common 
DAA access criteria may be suboptimal and expanding access to these medications could lead to 
a substantial survival benefit among PLWH. 
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CHAPTER 1: INTRODUCTION 
In the following section, key concepts related to hepatitis C virus (HCV) and human 
immunodeficiency virus (HIV) are highlighted. First, important topics for HCV and HIV are 
reviewed separately, including their virology, pathogenesis, natural history, epidemiology, and 
treatment. Next, a thorough overview of HIV/HCV coinfection is presented, including the 
reasons for the high prevalence of coinfection, the way each virus affects the other, the 
implications of coinfection for treatment of each disease, and current challenges and unanswered 
questions. 
1.1 Hepatitis C virus 
Virology of the hepatitis C virus 
Hepatitis C virus (HCV) is a single-stranded, positive-sense RNA virus of the family 
Flaviviridae (Chevaliez & Pawlotsky 2006). The virus is introduced into a host via contact with 
infected blood (Liang et al. 2000). After exposure, the virus enters host cells through a 
combination of receptors referred to as a “receptor complex,” which includes (but is not limited 
to) the SRB1, CD81, CLDN1, OCLN, EFGR, EphA2, NPC1L1, and LDL receptors (Kim & 
Chang 2013; Scheel & Rice 2013; Dubuisson & Cosset 2014). Of particular importance are the 
SRB1 and NPC1L1 receptors, as these are highly expressed in the liver and are likely part of the 
reason why the virus primarily infects hepatic cells (Dubuisson & Cosset 2014).  
Upon entry into the cell, the positive-sense RNA is released and is directly translated by the 
host into the viral polyprotein. The polyprotein is cleaved by host and viral proteases into 10 
 2 
 
proteins, 3 structural - Core, E1, and E2 - and 7 non-structural - NS2, NS3, NS4A, NS4B, NS5A, 
NS5B, and p7 (Kim & Chang 2013). The structural proteins are used to form the virion itself, 
with core being a component of the viral capsid and E1 and E2 being proteins that bind to cell 
receptors and aid the virus in entering the host cell. The non-structural proteins include an RNA-
dependent RNA polymerase (NS5B) involved in replicating the viral genome, proteases for 
processing the viral polyprotein (NS2, NS3, NS4A), and other proteins with various functions. 
Of these other proteins, the most important is perhaps NS5A, which alters the host cell to 
increase viral replication efficiency. The NS3/NS4A proteases, NS5A multi-function protein, 
and NS5B RNA polymerase are the targets of many modern HCV drugs. 
The viral genome is reproduced by creating a negative-sense RNA template from the 
positive-sense RNA, and then using that template to create additional positive-sense strands 
(Chevaliez & Pawlotsky 2006). These newly created positive-sense strands are then used for 
further translation into viral protein and for packaging into new virions. Of note, the liver-
specific microRNA miR-122 is necessary to facilitate viral replication, further explaining why 
the liver is the primary target for the virus. (Dubuisson & Cosset 2014). Because of the lack of 
efficient infectious cell culture systems until 2005 as well as the limitations of most in vitro 
models (Tariq et al. 2012), many aspects of the pathobiology of HCV remain poorly understood 
(Scheel & Rice 2013; Hoshida et al. 2014). 
HCV does not enter the host cell’s nucleus and does not integrate into the host genome, and 
thus the virus must continuously replicate (Hoshida et al. 2014). The virus is extremely efficient 
at replication, with a single person with HCV producing as many as 1012 virions per day 
(Jackowiak et al. 2014). This, along with the lack of proofreading ability of the viral RNA, leads 
to constant mutation and extraordinary diversity both within and between people with HCV 
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(HIV shares many of these properties, see Virology of HIV). To date, 7 HCV genotypes (referred 
to as 1-7) and dozens of subtypes (referred to with letters) have been identified (Jackowiak et al. 
2014). Each genotype shares only 70% of its genome with other HCV genotypes, and each 
subtype shares only 85% of its genome with other subtypes of the same genotype. This rapid 
mutation leads to HCV existing as a “quasispecies,” with substantial genetic variability within a 
host (Jackowiak et al. 2014). The extreme diversity of HCV makes it difficult for the host 
immune response to fully clear the infection and makes vaccine development challenging. 
Pathogenesis of HCV 
HCV is non-cytopathic, and instead damages the host through indirect mechanisms (Irshad et 
al. 2013; Hoshida et al. 2014). HCV triggers relatively weak humoral and cellular immune 
responses to infection. Due to the high mutation rate within a host, the humoral response is 
typically unable to completely neutralize the virus (Liang et al. 2000). The cellular immune 
response is characterized by a weak T-cell response, which often fails to control the virus and 
instead leads to chronic inflammation, hepatocellular injury, and fibrosis (Liang et al. 2000; 
Hoshida et al. 2014). Additionally, a complex interaction between HCV and lipoproteins may 
shield the virus from the host immune response (Dubuisson & Cosset 2014). 
Fibrosis is a response to liver injury that results in the increased production and deposition of 
extracellular matrix (in lay terms, the formation of scar tissue), which in turn diminishes liver 
function and increases the risk of malignant mutations (Hoshida et al. 2014). Liver fibrosis is 
driven by the activation of hepatic stellate cells, a type of cell found in the liver with poorly 
understood purpose or function (Hoshida et al. 2014). HCV induces fibrosis by stimulating 
profibrogenic mediators and inducing the production of inflammatory chemokines and cytokines. 
Additionally, HCV promotes oxidative stress, insulin resistance, and steatosis, all of which may 
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lead to fibrosis, though the exact mechanism is not fully understood (Irshad et al. 2013). Because 
insulin resistance and steatosis are also caused by obesity, weight management is an important 
aspect of HCV care. 
Natural history of HCV 
HCV is transmitted through contact with infected blood, either directly through inoculation 
(e.g. through injection drug paraphernalia) or transfusion of contaminated blood products, or 
indirectly through breakage of a cutaneous or mucosal barrier, as may happen with sexual or 
perinatal transmission (Liang et al. 2000). HCV remains stable on surfaces for extended periods 
of time, and as such the sharing of many types of drug paraphernalia beyond needles and 
syringes, such as spoons, tourniquets, cotton balls, or water glasses, can potentially lead to HCV 
transmission. HCV transmission through contaminated blood products is virtually non-existent in 
the United States, as the blood supply has been screened for HCV since 1992 (Centers for 
Disease Control and Prevention 2016).  
Acute infection, which is generally defined as occurring during the initial 6 months after 
acquisition of the virus, is asymptomatic in most cases (Seeff 2002). Due to the mildness of acute 
HCV infection, it is challenging to properly characterize the natural history of the disease, as 
most cases are not identified until their later stages; therefore the onset and duration of disease is 
usually not determined (Seeff 2002). A large meta-analysis found that approximately 25% of 
people with HCV spontaneously clear the acute infection without treatment, with the remaining 
progressing to chronic HCV infection (Micallef et al. 2006). Chronic HCV infection can persist 
for decades with no symptoms, despite the potential for accumulation of fibrosis related to viral 
replication in the liver. 
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 Patients who accumulate enough fibrosis to be classified as cirrhotic may succumb to end-
stage liver disease, hepatocellular carcinoma (HCC), and other liver-related causes of death. 
Cirrhosis develops in 10-20% of patients after 20-30 years of chronic infection, but the pace 
differs substantially from person to person depending on the presence of other risk factors, such 
as older age at infection, male sex, coinfection with HIV or hepatitis B virus, obesity, heavy 
drinking, smoking, type 2 diabetes, and hepatic steatosis (Seeff 2002; Hajarizadeh et al. 2013; 
Westbrook & Dusheiko 2014). Once cirrhosis develops, patients experience a 1-5% annual risk 
of HCC and a 3-6% annual risk of hepatic decompensation, defined as the failure of normal liver 
function due to cirrhosis (Westbrook & Dusheiko 2014). Although episodes of hepatic 
decompensation may be reversible with medical therapy, once a patient has experienced 
decompensation for the first time, their annual risk of death is 15-20% (Westbrook & Dusheiko 
2014).  
Epidemiology of HCV 
The incidence of HCV and its risk factors are a challenge to investigate, as most acute cases 
are undiagnosed, and chronic cases are discovered years after infection. For instance, in 2014, 
out of an estimated 30,500 incident cases of HCV infection in the US, only 2,194 were reported 
to the CDC (Centers for Disease Control and Prevention 2017d). Therefore, most of the 
understanding of HCV incidence and risk factors comes from biological knowledge of how the 
virus operates and from prevalence estimates, and therefore many aspects of the disease are still 
not fully understood. 
The global prevalence of HCV infection is estimated at 2-3%, meaning 130-170 million 
people are infected worldwide (Hajarizadeh et al. 2013). In the United States, the prevalence has 
been somewhat stable since HCV was first discovered to be the causative agent of “non-A, non-
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B” hepatitis in 1989 (Bukh 2016). Between 1988 and 1994, an estimated 1.3% of adults in the 
US had chronic HCV based on the National Health and Nutrition Examination Survey 
(NHANES) (Alter et al. 1999). In a follow-up study from NHANES conducted between 1999 
and 2002, the prevalence remained stable at 1.3% (Armstrong et al. 2006). Finally, the most 
recent NHANES study estimated the prevalence of chronic HCV infection in the United States to 
be slightly lower at 1.0%, corresponding to 2.7 million chronic cases (Denniston et al. 2014). 
The majority of HCV in the US is genotype 1 (primarily 1a, followed by 1b) (comprising 70% of 
cases), but genotypes 2 and 3 are also prevalent (Scheel & Rice 2013). 
The prevalence in the US varies within subpopulations, with the highest prevalence being 
among 40-49 year-olds, males, and non-Hispanic blacks (Denniston et al. 2014). The epidemic is 
rapidly evolving, however, with increasing proportions of cases occurring in younger, non-
Hispanic white PWID (Suryaprasad et al. 2014). Certain other subpopulations in the US face a 
substantially increased burden of HCV, for instance people born between 1945 and 1965 (Smith 
et al. 2012) and people with HIV, as discussed in section 2C: HIV-HCV Coinfection. 
The primary mode of HCV transmission in the US is related to injection drug use (IDU) 
(Klevens et al. 2012). Between 2003 and 2010, an estimated 51.5% of chronic HCV cases had 
reported ever injecting drugs (Denniston et al. 2014), and in 2009 56% of individuals with acute 
HCV infections reported IDU (Klevens et al. 2012) (it is important to note that these are likely 
severe underestimates due to underreporting of IDU (Klevens et al. 2012)). Other behaviors and 
characteristics that may predispose someone to come into contact with infected blood, such as 
participating in high risk sexual practices, getting tattoos from unsterilized equipment, perinatal 
transmission, and working in healthcare settings (especially hemodialysis centers), have a role in 
HCV transmission in the US (Klevens et al. 2012) 
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HCV infection remains the leading cause of liver transplantation in the United States 
(Thuluvath et al. 2010). In 2007, the number of deaths in the US attributed to HCV exceeded 
those due to HIV for the first time (Ly et al. 2012). In 2014, nearly 20,000 deaths in the United 
States were attributed in whole or in part to HCV infection (Centers for Disease Control and 
Prevention 2017d).   
Treatment of HCV: historical context  
Successful treatment for HCV is defined as achieving a sustained virologic response (SVR), 
which means a loss of detectable HCV RNA during treatment, and a continued absence for at 
least 12 weeks after therapy ends (American Association for the Study of Liver Diseases & 
Infectious Diseases Society of America 2017). SVR is durable in over 95% of patients (Feld & 
Hoofnagle 2005), and Patients who achieve SVR have improved clinical outcomes (Veldt et al. 
2007).  
Shortly after HCV was discovered in 1989, interferon-α (IFN) was identified as a moderately 
effective treatment (Davis et al. 1989; Di Bisceglie et al. 1989). IFN has general antiviral, 
antiproliferative, and immunomodulatory activity, and it operates to treat HCV through at least 
two known mechanisms (neither of which acts directly on HCV). First, it induces IFN-stimulated 
genes, causing a general antiviral state to occur within the cell. Second, it causes memory T-cell 
to proliferate and prevents their apoptosis, and it causes the stimulation and maturation of natural 
killer and dendritic cells (Feld & Hoofnagle 2005). Unfortunately, IFN produces moderate to 
severe side effects, including influenza-like symptoms, gastrointestinal disturbances, 
neuropsychiatric symptoms, and hematologic abnormalities (Fried 2002). Poor adherence due to 
side effects, as well as the non-specific antiviral activity of the treatment, lead to a poor response 
to IFN-based treatment of only 16-20% rate of SVR (Di Bisceglie & Hoofnagle 2002). Also of 
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note, IFN is substantially less effective for infections by HCV genotype 1, the most commonly 
found genotype in the US, compared with other genotypes (Jackowiak et al. 2014).  
In the late 1990s, it was discovered that the addition of ribavirin to IFN based treatments 
substantially improved treatment outcomes (Davis et al. 1998; Poynard et al. 1998), leading to 
SVR rates of 35-40% (Feld & Hoofnagle 2005). Like IFN, ribavirin is a non-specific antiviral 
agent that directly inhibits viral replication. It is believed that ribavirin acts as a viral mutagen 
which increases the number of mutations and causes “error catastrophes” that lead to non-viable 
viral mutants (Feld & Hoofnagle 2005). 
In the early 2000s, researchers found that the use of IFN conjugated to polyethylene glycol 
(PEG-IFN) led to additional improvements in treatment success (Manns et al. 2001), with SVR 
rates over 50% (Feld & Hoofnagle 2005). PEG-IFN has an improved pharmacokinetic profile 
and fewer side effects (Feld & Hoofnagle 2005). Unfortunately, due to the lack of efficient cell 
culture systems and limited in vitro models, PEG-IFN remained the best available treatment for 
over a decade, leaving the nearly half of treated individuals who did not achieve SVR with no 
alternatives. 
Treatment of HCV: recent developments  
After 2005, with the discovery of useful HCV cell culture systems, research accelerated for 
HCV-specific treatments. In 2011, the first two drugs of a new class, known as direct acting 
antivirals (DAA), were approved. The first two approved DAAs, boceprevir and telaprevir, were 
developed to be used in combination with PEG-IFN and ribavirin (Poordad et al. 2011; Jacobson 
et al. 2011). Both of these drugs are protease inhibitors, inhibiting the action of the NS3 and 
NS4A viral proteases (Welsch et al. 2012). Because of the difficulty of treating HCV genotype 1 
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and the variability of NS3 across genotypes, these drugs were specifically approved for that 
genotype (Kiser & Flexner 2013). When used in combination with PEG-IFN and ribavirin, these 
drugs led to SVR rates as high as 75% (Poordad et al. 2011; Jacobson et al. 2013). Though SVR 
rates were improved substantially, treatment duration remained long (as long as 48 weeks), and 
the side effect profile was similar to prior treatments.  
In 2013, the blockbuster drug sofosbuvir was approved for the treatment of HCV (Gilead 
Sciences 2013). Sofosbuvir inhibits the HCV RNA-dependent RNA-polymerase, NS5B, which is 
highly conserved, and thus the drug is effective for all HCV genotypes (Lawitz et al. 2013). The 
first approved treatments with sofosbuvir included PEGIFN and ribavirin, and achieved SVR 
rates of over 90% with only 12 weeks of treatment for most HCV genotypes (Jacobson et al. 
2013; Lawitz et al. 2013). Though the treatment success rate was excellent, the need for PEGIFN 
remained a problem. Shortly thereafter, it was discovered that all-oral, interferon-free regimens 
of sofosbuvir along with second-generation NS3/NS4A protease inhibitors (e.g. simepravir) and 
NS5A inhibitors, such as daclatasvir and ledipasvir, resulted in SVR rates up to 99% and 
minimal side effects with 12 weeks of treatment (Feld et al. 2015; Sulkowski et al. 2014; Lawitz 
et al. 2014), with highly effective options available for all major genotypes, for patients with 
previously failed treatment, for patients with advanced liver disease, and for patients with HIV 
coinfection (American Association for the Study of Liver Diseases & Infectious Diseases Society 
of America 2017). Additional non-sofosbuvir containing regimens with similar mechanisms of 
action have since been approved (American Association for the Study of Liver Diseases & 
Infectious Diseases Society of America 2017). 
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Current challenges and remaining questions with HCV 
Modern DAA therapy is extremely effective and has completely changed the landscape of 
HCV treatment (Burstow et al. 2017). However, there are several remaining challenges and open 
questions with regards to HCV treatment. Perhaps first among them regards access to treatment. 
The list price for sofosbuvir, $1,000 per pill ($84,000 for a course of treatment) (University of 
Washington 2017), is prohibitively expensive for many people with HCV (Rosenthal & Graham 
2016). Even though the price paid by insurers in the United States is typically heavily 
discounted, with an average discount of 46% off of the list price (Rosenthal & Graham 2016), 
DAA treatment continues to be restricted by many Medicaid programs. As of October 2017, 30 
states restrict DAAs to patients with at least moderate liver fibrosis (12 states restrict to those 
with severe fibrosis), and 40 states restrict access to patients based on substance use (Ooka et al. 
2017), restrictions that are particularly problematic given the ‘treatment as prevention’ paradigm 
(Trooskin et al. 2015). As of September 2016, 5 states plus Washington, DC restrict treatment 
among people living with HIV and HCV to those who meet certain HIV treatment goals, such as 
achieving HIV suppression. These restrictions persist despite guidelines that suggest that nearly 
all people with HCV be treated (American Association for the Study of Liver Diseases & 
Infectious Diseases Society of America 2017). The treatment landscape is rapidly evolving, 
however, as more drugs come to market to increase competition and reduce costs (Nisen 2017), 
and as legal challenges force insurance companies to drop coverage restrictions (National AIDS 
Treatment Advocacy Project 2017). Nevertheless, it has been estimated that, even with current 
discounts, treating all patients with HCV in the US would comprise more than 50% of 
pharmaceutical expenditures in the country (Iyengar et al. 2016). Given these high costs and the 
limited access to treatment, understanding which patient populations would benefit from DAA 
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regimens and whether or not current Medicaid restrictions are optimizing survival benefits is 
essential for maximizing access to those most in need. 
There are many additional open questions with regards to HCV and its treatment, including 
the possibility of drug-drug interactions, the effectiveness of DAAs in key populations, and the 
effect of HCV on survival among people with certain common comorbidities. Some of these are 
discussed in detail in section 2C: HIV-HCV Coinfection. 
1.2 Human immunodeficiency virus 
Virology of the human immunodeficiency virus 
Human immunodeficiency virus (HIV), the causative agent of acquired immunodeficiency 
syndrome (AIDS), is a retrovirus of the genus lentivirus (Turner & Summers 1999). After 
transmission via contact with infected bodily fluids, the virus binds to the CD4 receptor and 
either the CCR5 or CXCR4 coreceptors of host cells, which are primarily found on T cells, but 
also monocytes, macrophages, dendritic cells, astrocytes, and epithelial cells (Maartens et al. 
2014).  
The virion contains several elements necessary for replication, including reverse 
transcriptase, protease, ribonuclease, and integrase (Turner & Summers 1999). Once inside the 
host cell, the viral reverse transcriptase transcribes the viral RNA into double-stranded DNA 
(Sierra et al. 2005). The viral integrase then integrates the DNA into the host genome, where it is 
transcribed by host cell processes in order to produce viral proteins and new copies of viral RNA 
(Sierra et al. 2005). Finally, the viral protease cleaves the polyproteins and packages them, along 
with viral RNA, into new virions, which exit and infect new cells (Sierra et al. 2005). Of note, 
some actions of the viral protease take place after the virion has budded from the host cell. 
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The HIV genome codes for several structural, functional, and accessory proteins. The Gag 
polyprotein is cleaved by the viral protease into the four nucleocapsid proteins – MA, CA, NC, 
and p6. The Pol polyprotein is cleaved into the functional proteins – protease, reverse 
transcriptase, RNase H, and integrase. Additionally, the HIV genome codes for Env, the 
envelope protein, and the accessory proteins Tat, Rev, Nef, Vif, Vpr, and Vpu (Turner & 
Summers 1999; Sierra et al. 2005). 
The HIV virus has two subtypes – HIV-1 and HIV-2 (Maartens et al. 2014). HIV-2 is 
predominantly found in West Africa, and is notable for being less transmissible, having a slower 
disease progression, and being less susceptible to certain classes of antiretroviral medications. 
HIV-1 is the type found in the vast majority of cases globally and will thus be the focus of the 
rest of this work. There are four HIV-1 subgroups, each corresponding to distinct zoonotic 
transmission events – M, N, O, and P. The majority of cases worldwide are group M; N, O, and 
P are only found in West Africa (Maartens et al. 2014). Each subgroup’s genome differs from the 
others’ by at least 30%, while subtypes within the subgroups differ by 15-20% (Levy 2009). Like 
HCV, HIV exhibits a very high rate of mutation, and many strains can coexist within an 
individual. This is largely due to efficient replication - 109 virions are typically produced within a 
person with HIV every day (Ho et al. 1995) - and the high error rate of HIV reverse transcriptase 
(Stebbing & Moyle 2003). The large degree of heterogeneity has important consequences for 
immune system evasion and treatment resistance (Turner & Summers 1999). 
Pathogenesis of HIV 
The primary mechanism by which HIV causes morbidity and mortality is by destruction of 
CD4 T-cells (Levy 2009; Lucas & Nelson 2015). HIV primarily destroys T-cells via two 
mechanisms – apoptosis of infected, activated cells, and pyroptosis of bystander non-infected 
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cells (Lucas & Nelson 2015). The CD4 cells of the gastrointestinal tract are the first to be 
destroyed, and these usually do not recover even after successful HIV therapy (Levy 2009; Lucas 
& Nelson 2015). The progressive exhaustion of CD4 cells leaves the host vulnerable to 
opportunistic infections, which ultimately lead to severe morbidity and death (Maartens et al. 
2014). Besides CD4 cell destruction, the destruction of astrocytes and renal epithelial cells also 
directly lead to neurocognitive disorder and nephropathy (Maartens et al. 2014).  
The host immune system mounts a potent response to HIV infection. The innate immune 
response is mediated by natural killer cells which identify and destroy cells that do not display 
major histocompatibility complex due to being infected by the virus (Levy 2009; Maartens et al. 
2014). The cellular immune response, which begins within hours or days of infection, involves 
CD8 T-cells killing HIV-infected cells (Maartens et al. 2014). Lastly, the humoral immune 
response involving HIV neutralizing antibodies arises within weeks  of infection (Maartens et al. 
2014). Because of the high mutation rate of HIV, the immune response quickly selects for 
immune resistant strains, and is ultimately unable to completely clear the virus (Maartens et al. 
2014). 
The strong and lasting immune response to HIV often causes persistent immune activation 
and inflammation via several mechanisms (Maartens et al. 2014; Lucas & Nelson 2015). First, 
HIV triggers Toll-like receptors that induce pro-inflammatory cytokine production. Second, due 
to the depletion of CD4 cells from the gut, microbial translocation often occurs, leading to an 
immune response to the translocated bacteria. Third, CD4 cell destruction by pyroptosis is highly 
inflammatory, as the process releases inflammatory chemokines and cytokines (Lucas & Nelson 
2015). 
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Natural history of HIV infection 
HIV is transmitted via exposure to infected bodily fluids such as blood or semen. Common 
routes of exposure are mother to child transmission, condomless sexual intercourse, injection 
drug use, blood transfusion, accidental inoculation, or organ transplants (Maartens et al. 2014; 
Lucas & Nelson 2015). The risk of infection after exposure is directly correlated with the viral 
load of the person with HIV (Maartens et al. 2014), which has important implications for 
treatment as prevention. 
The initial, acute infection causes symptoms in approximately 50% of cases, and includes an 
illness characterized by fever,  lymphadenopathy (swollen glands), pharyngitis (sore throat), GI 
upset, and other flu-like symptoms (Lucas & Nelson 2015) (the proportion of people with acute 
HIV experiencing symptoms is likely much higher, but only a fraction of such individuals seek 
care for their symptoms). This acute phase is characterized by an extremely high viral load, 
which increases the risk of transmission 20-fold (Hollingsworth et al. 2008). The immune 
response is able to slow down the viral replication, but is not able to eliminate the virus 
(Maartens et al. 2014). The next phase is characterized by a drop in viral load to a ‘setpoint,’ 
followed by a partial recovery of CD4 cells (Maartens et al. 2014; Lucas & Nelson 2015). At this 
stage, the virus can persist for years in a latent state in resting memory T-cells where the virus 
has been integrated into the host genome (Maartens et al. 2014), with a median incubation period 
of approximately 10 years without treatment (Bacchetti & Moss 1989). This ‘reservoir’ of 
infected cells is a major impediment of HIV cure efforts. 
Without treatment, the supply of CD4 cells is gradually exhausted (Maartens et al. 2014; 
Lucas & Nelson 2015). The immune system becomes depleted to the point of dysfunction, at 
which point the patient is said to have AIDS. AIDS is defined as a CD4 cell count of less than 
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200 cells per mm3 or the presence of an AIDS-defining illness, such as Pneumocystis pneumonia, 
cytomegalovirus retinitis, or certain cancers (US Department of Health and Human Services 
2017). Before effective treatments were available and early in the HIV epidemic, people living 
with HIV (PLWH) had a median survival time of 1 year after diagnosis with an AIDS-defining 
illness (Lee et al. 2001). Just prior to the discovery of combination antiretroviral therapy, this 
median survival time had improved to nearly 2 years (Lee et al. 2001).   
Besides the gradual destruction of the immune system, HIV also causes chronic immune 
activation (see Pathogenesis of HIV). This chronic inflammatory state exists in many patients 
even after successful HIV treatment, and is associated with mortality and several chronic 
diseases, including cardiovascular disease, cancer, neurological disease, liver disease, chronic 
obstructive pulmonary disease, neurocognitive disorders, and osteopenia/osteoporosis (Lucas & 
Nelson 2015). 
The most important prognostic factor for HIV infection is viral load (Mellors et al. 1996), 
and as such the goal of treatment is to reduce the viral load to undetectable levels (See Treatment 
of HIV). Other factors can also lead to a worse prognosis, including (but not limited to): older 
age, lower nadir CD4 cell count, higher viral setpoint, coinfection with herpesviruses or viral 
hepatitis, and increased immune activation (Lucas & Nelson 2015). 
Since the introduction and widespread adoption of effective combination antiretroviral 
therapy (ART) in Western countries, the natural history of HIV has changed dramatically. HIV is 
now managed as a chronic disease, and much of the focus of HIV care is now on managing HIV-
related comorbidities (Deeks et al. 2013). The outlook for PLWH has also greatly improved. For 
instance, between 1993 and 1995, prior to the introduction of ART, the risk of mortality 12 
months after beginning treatment for HIV was 15.8% in a large Canadian cohort (Lima et al. 
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2007). Between 2002 and 2004, well into the ART era, the risk in that same cohort had decreased 
to 6.1% (Lima et al. 2007). Additionally, PLWH can now achieve lifespans beginning to 
approach those of the general population (Samji et al. 2013; Nakagawa et al. 2013; Marcus et al. 
2016). Between 1996 and 1997, in the early ART era, a 20-year-old with HIV was expected to 
live an additional 19 years; by 2011, that figure had increased to 53 years (Marcus et al. 2016). 
AIDS as a cause of death decreased substantially pre- and post- ART as well, from 78% of 
deaths in between 1988 and 1995 to 15% between 2005 and 2010 (Weber et al. 2013). This 
decrease in AIDS as a cause of death has corresponded to an increase in the proportion of non-
AIDS causes of death, rising from 17% between 1988 and 1995 to 71% between 2005 and 2010 
(Weber et al. 2013). Further implications of HIV treatment are discussed in the section Current 
challenges and remaining questions of HIV. 
Epidemiology of HIV  
The World Health Organization estimates that 36.7 million people across the world were 
living with HIV in 2015 (World Health Organization 2017). The majority of these people (25.5 
million) are in Africa. That year, 2 million individuals became newly infected with HIV, of 
whom 1.4 million were in Africa. Finally, HIV caused 1.1 million deaths in 2015, including 800 
thousand in Africa (World Health Organization 2017).  
According to the Centers for Disease Control and Prevention, there were 1.2 million PLWH 
in the United States 2014, of whom 13% are unaware of their HIV status (Centers for Disease 
Control and Prevention 2017b). Most diagnosed PLWH in the US are middle-aged; individuals 
aged 40-59 years make up nearly 50% of people living with HIV. Non-Hispanic blacks 
accounted for 42% of diagnosed people living with HIV in the US, and 24% of diagnosed 
PLWH in the US were female. The region with the highest burden of HIV is the South, which 
 17 
 
contains 44% of diagnosed HIV cases in the US, followed by the Northeast (25%), West (20%), 
and Midwest (12%) (Centers for Disease Control and Prevention 2015a). 
In 2015, 40 thousand people in the US were newly infected with HIV (Centers for Disease 
Control and Prevention 2015a). The majority (67%) of new cases were men who have sex with 
men (MSM), and most of those were among non-Hispanic Blacks. Women made up 19% of new 
diagnoses. Among women, 86% of cases were acquired sexually, while 13% were attributed to 
injection drug use. Overall, 9% of new cases were at least partially attributed to injection drug 
use. Non-Hispanic Blacks accounted for 45% of all new diagnoses, while Hispanics accounted 
for 24%. Individuals aged 20-39 made up 61% of new diagnoses (Centers for Disease Control 
and Prevention 2015a). In 2014, 12 thousand PLWH died in the United States, with 7 thousand 
of those deaths attributed to HIV (Xu et al. 2016).  
The HIV epidemic in the United States has been in rapid transition in the last decade as HIV 
prevention and treatment have improved. Between 2005 and 2014, there has been an 18% 
decline in HIV incidence among White MSM, a 40% decline among women, a 35% decline 
among heterosexuals, and a 63% decline among PWID. Unfortunately, not all groups shared in 
these improvements. Non-Hispanic Black and Hispanic MSM have experienced increases in 
incidence of over 20% in that time period. Overall, between 2005 and 2014, the incidence of 
HIV declined by 19% (Centers for Disease Control and Prevention 2015c). 
HIV treatment: historical perspective 
HIV treatment has several goals. The first goal is to suppress HIV RNA replication, as 
reflected by the plasma RNA “viral load”. The second is to restore the functionality of the 
immune system to the greatest extent possible. The third is to reduce morbidity and prolong life. 
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The last, and most recent, goal of treatment is to prevent HIV transmission (Panel on 
Antiretroviral Guidelines for Adults and Adolescents 2018). 
For the first six years of the HIV epidemic, there were no approved or known effective 
treatments for the deadly disease (Vella et al. 2012). HIV care providers focused on managing 
crises, dealing with opportunistic infections, and providing palliative care (Chu & Selwyn 2011). 
In 1987, a major breakthrough occurred with the discovery of the first HIV antiretroviral therapy, 
a nucleoside reverse transcriptase inhibitor (NRTI) called azidothymidine (abbreviated AZT and 
later renamed zidovudine, ZDV) (Fischl et al. 1987). With treatment, 98% of patients survived 
for 24 weeks, and only 23% of these patients developed an opportunistic infection (Fischl et al. 
1987). Unfortunately, the benefit appeared to be short-lived, as the virus quickly develops 
resistance to single-agent therapy and thus immune system functional improvements are lost 
(Fischl et al. 1987). Nevertheless, additional NRTIs were quickly developed, though all faced 
similar shortcomings (Vella et al. 2012). 
It was soon discovered that, due to the high rate at which HIV mutates, monotherapy with 
any one antiretroviral selected for resistant strains of the virus (Shirasaka et al. 1995; Richman 
2001). To combat this resistance, new classes of drugs were developed to be used in combination 
with NRTIs. The first new drugs developed were the protease inhibitors (PI), the first of which 
was saquinavir (Vella et al. 2012). Shortly thereafter, nevirapine, the first of the non-nucleoside 
reverse transcriptase inhibitors (NNRTI), was approved (Vella et al. 2012). 
Despite the new classes of drugs, mono- and dual- therapy still did not provide adequate 
results (Vella et al. 2012). The most important breakthrough in HIV treatment occurred in 1997, 
when it was first demonstrated that three-drug therapy led to substantially better survival and 
immune function than prior treatment regimens (Hammer et al. 1997). The use of a potent 
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combination of three antiretroviral drugs is now referred to as combination antiretroviral therapy 
(ART). Future trials found that ART led to extremely durable HIV suppression, with one early 
trial demonstrating effectiveness beyond three years (Gulick et al. 2000). 
ART caused a paradigm shift in HIV care. In 1995, just prior to the discovery of ART, the 
all-cause mortality rate among people with HIV was 29.4 per 100 person-years. In 1997, after 
ART was introduced, that rate declined to 8.8 per 100 person-years (Palella et al. 1998). Since 
then, major improvements have been made to ART, such as treatment regimens with easier 
dosing and better side effect profiles, including the introduction of multiple single tablet, fixed-
dose, once-daily regimens (Vella et al. 2012). New drug classes have also been developed. The 
first entry inhibitor (EI), enfuvirtide, was approved in 2003 as a salvage therapy for patients who 
had developed resistance to other classes of antiretrovirals (Lalezari et al. 2003). In 2007, the 
first integrase inhibitor (II), raltegravir, was approved and was shown to have similar efficacy as 
existing drugs (Lennox et al. 2009).  
With early ART regimens, the toxicity of the drugs and the possibility of developing 
resistance led to clinicians delaying initiation of ART until their patients showed substantial 
immune system decline, typically when their CD4+ T-Cell count dropped below 200 cells per 
mm3 (Vella et al. 2012). A debate quickly ensued about when to initiate treatment, especially as 
treatments became less toxic. Some ideas included starting patients on ART when their CD4+ 
dropped below the usual threshold, but then stopping when their immune system recovered, a so-
called ‘strategic interruption’ (Vella et al. 2012). Unfortunately, this strategy was shown to lead 
to substantially worse outcomes than simple starting patients on treatment at existing thresholds 
and staying on treatment (The Strategies for Management of Antiretroviral Therapy (SMART) 
Study Group 2006). In 2009, the When to Start Consortium found that starting at or above 350 
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CD4 cells per mm3 led to better treatment outcomes than further delaying treatment (When To 
Start Consortium 2009). By 2015, the INSIGHT study showed that starting patients immediately 
after entry into care, regardless of CD4 count, provided the best patient outcomes (The INSIGHT 
START Study Group 2015), and this is the current guideline for treatment initiation in the United 
States (Panel on Antiretroviral Guidelines for Adults and Adolescents 2018). 
In addition to providing benefit to the patients themselves, early ART initiation has been 
shown to prevent transmission to others, as viral suppression is the key determinant of infectivity 
(Panel on Antiretroviral Guidelines for Adults and Adolescents 2018). In 2011, the HPTN 052 
trial was stopped three years early when it was found that immediate ART initiation led to a 93% 
reduction in HIV transmission in serodiscordant couples (Cohen et al. 2016). These results have 
led to the paradigm of ‘treatment as prevention,’ which is now a cornerstone of HIV control 
efforts and is being integrated into debates about treatment for other diseases. 
HIV treatment: classes of drugs and current guidelines 
Current guidelines recommend treatment initiation regardless of CD4 cell count, and provide 
several options for initial ART regimens (Panel on Antiretroviral Guidelines for Adults and 
Adolescents 2018). There are four main classes of antiretroviral drugs (ARV) that are used in 
recommended initial ART regimens. Typically, these involve two nucleoside/nucleotide reverse 
transcriptase inhibitors and either an integrase inhibitor, boosted protease inhibitor, or non-
nucleoside reverse transcriptase inhibitor (Panel on Antiretroviral Guidelines for Adults and 
Adolescents 2018). While other classes of ARVs exist, such as fusion inhibitors and entry 
inhibitors, these are not included in any recommended treatment regimens (Panel on 
Antiretroviral Guidelines for Adults and Adolescents 2018). 
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The first class of ARVs is the nucleoside/nucleotide reverse transcriptase inhibitors (NRTI). 
NRTIs are analogues of naturally-occurring deoxynucleotides that are used in DNA synthesis 
(Moyle 2000). Reverse transcriptase cannot distinguish between the NRTIs and 
deoxynucleotides, and as such the NRTIs compete for incorporation into the DNA strand (Moyle 
2000). NRTIs are “chain-terminator” molecules that lack an important 3’-hydroxyl group 
necessary for DNA elongation, so after they are integrated into the DNA strand, the next 
deoxynucleotide cannot bond to the DNA chain, halting DNA synthesis (Moyle 2000). Early 
NRTIs had severe side effect profiles, including neuropathy, myopathy, cardiomyopathy, 
pancreatitis, hepatitis, lactic acidosis, nephrological toxicity, bone marrow toxicity, and skin 
toxicity – all thought to be the effect of mitochondrial toxicity (Brinkman et al. 1998). 
Fortunately modern NRTIs have far fewer side effects and are better tolerated by patients (Vella 
et al. 2012). Commonly used NRTIs include abacavir (ABC), lamivudine (3TC), tenofovir (TAF 
or TDF), and emtricitabine (FTC) (Panel on Antiretroviral Guidelines for Adults and 
Adolescents 2018). 
The second class of ARVs used in ART are the protease inhibitors (PI). PIs work by 
inhibiting the action of the viral protease. By binding to the site where protein cleavage occurs, 
PIs prevent HIV proteins from being produced, leading to virions that are unfit or inactive 
(Richman 2001). PIs share a common side effect of inhibiting the CYP450 metabolic system, 
and thus can be involved in serious drug-drug interactions (Richman 2001). The side effects of 
early PIs were often pronounced, including insulin resistance, dyslipidemia, and body fat 
redistribution (Richman 2001). When PIs are used, they are almost always ‘boosted’ with a 
pharmacokinetic enhancing agent (e.g. cobicistat or ritonavir) to prolong their half-lives in the 
body (Panel on Antiretroviral Guidelines for Adults and Adolescents 2018). The most commonly 
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used protease inhibitors are atazanavir and darunavir (Panel on Antiretroviral Guidelines for 
Adults and Adolescents 2018). 
A third class of ARVs is the non-nucleoside reverse transcriptase inhibitors (NNRTIs). Like 
the NRTIs, these drugs target the reverse transcription step in the viral replication process. Their 
mechanism, however, is quite different. Rather than mimicking components of viral DNA, 
NNRTIs bind to the HIV reverse transcriptase and inhibit it from polymerizing DNA (Sluis-
Cremer & Tachedjian 2008). NNRTIs tend to induce the CYP450 system, and thus may cause 
drug-drug interactions (Richman 2001). The most common adverse effects from NNRTIs are 
skin rashes (Panel on Antiretroviral Guidelines for Adults and Adolescents 2018) and, in the case 
of efavirenz, neuropsychiatric complications (Apostolova et al. 2015). Efavirenz is the only 
NNRTI currently recommended for first-line ART initiation, and it is only recommended as part 
of an ‘alternative’ regimen (Panel on Antiretroviral Guidelines for Adults and Adolescents 
2018). 
The last, and most recently discovered, class of ARVs is the integrase inhibitors (INI). INIs 
bind to and inhibit the action of HIV integrase, which is necessary for integrating the HIV DNA 
into the host cell genome (Mouscadet & Tchertanov 2009). INIs typically have fewer and milder 
side effect profiles compared with other ARVs (Lennox et al. 2009; Panel on Antiretroviral 
Guidelines for Adults and Adolescents 2018). The currently recommended INIs for initial ART 
are dolutegravir, elvitegravir, and raltegravir (Panel on Antiretroviral Guidelines for Adults and 
Adolescents 2018). 
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Current challenges and remaining questions of HIV 
Perhaps the greatest current challenge with HIV is the lack of curative treatment or an 
effective vaccine. While there are many promising avenues being explored in that arena, it is 
important to tackle the challenges that are most pressing for PLWH and care providers today. 
The next greatest challenge is identifying PLWH and engaging them in care. In 2014, of the 1.1 
million people with HIV over 13 years old in the US, 15% were not aware of their status 
(Centers for Disease Control and Prevention 2017c), corresponding to 166,000 undiagnosed 
cases. Perhaps more strikingly, only 57% of PLWH in the US were engaged in continuous HIV 
medical care, and, 58% were virally suppressed (Centers for Disease Control and Prevention 
2017c). Because viral suppression is key for patient survival and the prevention of HIV 
transmission, getting patients engaged in care should be one of the top priorities for this 
population. 
With the great gains in HIV treatment and care that have been made in the last decade have 
come new considerations for HIV patients and providers. PLWH are now experiencing life 
expectancies rivaling those of the general population (Samji et al. 2013; Nakagawa et al. 2013). 
However, the residual inflammation, suboptimal CD4 cell counts, and hypercoagulable state 
causes chronic diseases to occur at higher frequency (Justice 2010; High et al. 2012) and younger 
ages (Desquilbet et al. 2007; High et al. 2012) than in the general population. Though the reason 
for the high rates of these conditions is not fully understood, it is believed to include immune 
dysfunction and senescence, microbial translocation, chronic inflammation, toxicity from ART, 
oxidative stress, comorbid diseases such as hepatitis C, and high rates of alcohol, tobacco, and 
drug use (Desquilbet et al. 2007; Justice 2010; High et al. 2012). Recently, there have been 
notable increases in cardiovascular disease, malignancies (not limited to those associated with 
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infections), osteopenia and osteoporosis, liver disease, renal disease, and cognitive decline in this 
population (High et al. 2012), perhaps reflecting a closer alignment to the conditions impacting 
the general population. In fact, the most common causes of death among PLWH in the US are 
non-AIDS-related, and are instead primarily related to hepatic complications, cardiovascular 
disease, and non-AIDS-defining cancers (Smith et al. 2014). 
HIV care providers are now faced with a complex problem. While they still must provide 
care and treatment for their patients’ HIV infection, they must also often guide and direct care 
for their patients’ multiple comorbid chronic conditions and manage their polypharmacy (Chu & 
Selwyn 2011). As such, it is important to elucidate the most severe conditions facing these 
patients and to identify what patient-level treatments and policy-level interventions may best 
reduce morbidity and mortality among people with HIV. Additional research is needed to 
determine how to properly prioritize the conditions to target for prevention and treatment 
interventions at both the patient and policy levels, and to aid providers in obtaining the best 
possible evidence to provide the best possible care for their patients. 
1.3 HIV/HCV Coinfection 
Diseases that travel together 
Due to shared transmission routes, HCV is a common coinfection of HIV. Both viruses can 
be transmitted via contact with infected blood (Sulkowski 2008). The most efficient means of 
blood to blood transmission is through percutaneous exposure, and therefore injection drug use 
(IDU) is the primary driver of HIV/HCV coinfection (Sulkowski 2008; Taylor et al. 2012). 
Typically, those with IDU as a primary risk factor acquire HCV prior to HIV, as HCV is much 
more likely to be acquired from any given exposure; for instance, in a study of disease 
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transmission from accidental needle-stick injuries, HCV was ten times more likely to be 
transmitted than HIV (Kim et al. 2009).  
Besides IDU, sexual transmission of HCV has had an increasing role in HIV/HCV 
coinfection (Danta et al. 2007; Taylor et al. 2012; Breskin et al. 2015). The reason for the 
increase in sexual transmission is thought to be due to increases in  the prevalence and frequency 
of condomless sex and ‘serosorting,’ or choosing perceived HIV sero-concordant sexual 
partners, since the widespread adoption of effective ART (Taylor et al. 2012). This theory is 
consistent with reports of high rates of sexually transmitted infections in men who have sex with 
men with both HIV and HCV (Danta et al. 2007; Breskin et al. 2015). Though HCV does not 
usually transmit efficiently through sexual contact (Sulkowski 2008), individuals with HIV are 
more likely to shed the virus through semen. (Taylor et al. 2012), and thus those with sexual 
practices as a primary risk factor typically acquire HIV prior to HCV (Taylor et al. 2012). 
Epidemiology of HIV-HCV coinfection 
Globally, 6.2% of PLWH are thought to be coinfected with HCV, corresponding to 2.3 
million cases (Platt et al. 2016). The odds of HCV infection among PLWH are 6 times the odds 
among those without HIV (Platt et al. 2016). Among people who inject drugs (PWID), the 
picture is much different. The estimated prevalence of HCV among PWID with HIV worldwide 
is 82.4%, and injectors with HIV have 36 times the odds of HCV infection than PWID without 
HIV (Platt et al. 2016). 
In the United States, HCV infection is much more common among PLWH, largely due to the 
higher proportion of PLWH with injection drug use as their primary risk factor for infection. 
Here, 25% of PLWH are coinfected with HCV, meaning approximately 300,000 people have 
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both diseases (Centers for Disease Control and Prevention 2017a). Similar to the picture 
globally, the prevalence of HCV is much higher among PWID with HIV, of whom 75% are 
thought to be coinfected (Centers for Disease Control and Prevention 2017a). Due to the high 
prevalence of HCV coinfection among PLWH in the United States, the CDC currently 
recommends that all PLWH be tested for HCV upon entry into care, regardless of primary 
transmission risk factor (Centers for Disease Control and Prevention 2015b). Notably, the 
guidance is less clear regarding the screening of individuals already engaged in care (Freiman et 
al. 2014). 
Coinfection and mortality 
Prior to the introduction of effective ART, HCV coinfection did not appear to impact 
mortality among people with HIV in the US (Staples et al. 1999; Klein et al. 2003). The high 
mortality associated with HIV at the time likely precluded PLWH and HCV (PLWH+HCV) 
from experiencing the adverse, prolonged effects of HCV. After ART was introduced, the effect 
of HCV coinfection on mortality among PLWH has remained unresolved. A meta-analysis of 
studies conducted early in the ART era estimated that the rate of death among PLWH+HCV was 
1.4 times the rate of people with HIV alone (Chen et al. 2009). More recently, results from the 
Swiss HIV Cohort and Antiretroviral Therapy Cohort Collaboration estimated that HCV 
coinfection increases the rate of death among PLWH by a factor of 2 to 3 (Kovari et al. 2015; 
May et al. 2015). However, other studies have found that HCV has no effect on mortality in 
PLWH (Sulkowski et al. 2002; Scherzer et al. 2017). Of note, no studies have been conducted 
estimating the role of HCV on mortality under current HIV treatment guidelines (See Current 
challenges and remaining questions with HIV-HCV coinfection). 
 27 
 
 In particular, HCV has been shown to lead to substantial increases in death from liver-
related causes among PLWH. In a study during the early ART era, it was estimated that HCV 
coinfection increased the rate of liver-related mortality by a factor of twelve in PLWH 
(Rockstroh et al. 2005). Indeed, liver-related disease, including hepatocellular carcinoma, is the 
leading non AIDS-related cause of death among PLWH in the Western world, and much of it is 
attributed to viral hepatitides (Weber et al. 2013; Smith et al. 2014). 
How HIV affects HCV 
HIV has been shown to lead to a substantially worse prognosis for HCV infection. 
PLWH+HCV are much less likely to clear their acute HCV infection, and therefore are more 
likely to progress to chronic disease, compared with people with HCV only (Sulkowski 2008). 
PLWH+HCV also tend to carry a higher HCV viral load (Sulkowski 2008) and can shed virus 
through their semen, thus facilitating sexual transmission (Taylor et al. 2012). 
PLWH+HCV often experience faster fibrosis progression compared with people with HCV 
only (Graham et al. 2001). In the early ART era, PLWH+HCV progressed by 0.18 fibrosis units 
per year, compared with 0.14 in people with HCV only, corresponding to a twelve-year faster 
progression to cirrhosis in these patients (Benhamou et al. 1999). Notably, PLWH+HCV have 
been found to have liver fibrosis measurements similar to those of people with HCV only who 
were nearly 10 years older, suggesting a substantially faster rate of fibrosis progression (Kirk et 
al. 2013). A meta-analysis conducted in 2001 found that PLWH+HCV had a risk of 
decompensated liver disease that was six times higher than that in people with HCV only, and a 
risk of cirrhosis that was twice as high (Graham et al. 2001). A second meta-analysis conducted 
in 2008 found a similar increase in the risk of cirrhosis, despite advances in and increased uptake 
of HIV therapy (Thein et al. 2008).  
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The mechanism by which HIV accelerates the progression of HCV infection is not fully 
understood but is likely due to several distinct mechanisms. First, it is known that HIV directly 
promotes fibrosis through hepatocyte apoptosis and activation of hepatic stellate cells (Kim et al. 
2009; Liberto et al. 2015). Second, HIV directly dysregulates the immune system through the 
depletion of CD4 cells, which may allow for higher HCV viral loads (Kim et al. 2009). Third, 
the chronic inflammatory state caused by HIV infection may accelerate fibrosis (Kim et al. 2009; 
Liberto et al. 2015). Fourth, the depletion of gastrointestinal lymphoid tissue by HIV may lead to 
disruption of the epithelium and microbial translocation (Kim et al. 2009). In particular, 
lipopolysaccharides from gut bacteria may enter the bloodstream and promote inflammation. 
Fifth, certain adverse side effects of HIV therapy, including insulin resistance, dyslipidemia, and 
hepatic steatosis, are known risk factors for fibrosis (Kim et al. 2009).  
Effective HIV treatment has been shown to partially attenuate the fast HCV progression due 
to HIV. PLWH+HCV on ART with detectable HIV viral load or suppressed CD4 cell counts had 
faster fibrosis progression than people with undetectable HIV viral load or normal CD4 cell 
counts (Bräu et al. 2006). Additionally, PLWH+HCV receiving ART have been shown to have a 
risk of liver-related mortality one tenth that of untreated PLWH+HCV (Qurishi et al. 2003), and 
ART has been shown to reduce the rate of hepatic decomposition by 30% (Anderson et al. 2014). 
Despite the improved fibrosis progression rates from effective HIV treatment, PLWH+HCV on 
ART still have a rate of cirrhosis that is 1.7 times that of people with HCV only (in the same 
meta-analysis, untreated PLWH+HCV had 2.5 times the rate of cirrhosis of people with HCV 
only) (Thein et al. 2008). Another study found that virally suppressed PLWH+HCV had a rate of 
hepatic decomposition 1.4 times that of people with HCV only  (Re et al. 2014). Though HCV 
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infection may lead to an increased risk of hepatoxicity from ART, this increased risk is far 
outweighed by the benefit of HIV control and decreased fibrosis progression (Sulkowski 2008). 
HIV has a major impact on the success rate of PEG-INF-based treatment for HCV. The 
success rate of these treatments were extremely low in PLWH+HCV, with only 14% success 
among patients with genotype 1 and 73% success among people with other genotypes (Chung et 
al. 2004). Notably, very few PLWH+HCV were considered eligible for treatment due to poor 
immune function and other comorbidities (Rauch et al. 2005). Fortunately, modern DAA based 
HCV treatment appears to be as effective in PLWH+HCV as in people with HCV only, with 
SVR rates over 90% across patient populations (Molina et al. 2015; Wyles et al. 2015; Naggie et 
al. 2015; Sogni et al. 2016; Montes et al. 2017).  
How HCV affects HIV 
The effect of HCV coinfection on the progression of HIV is less clear, and the evidence thus 
far is equivocal. While some studies have found no effect of HCV on HIV progression to AIDS 
or response to ART (Staples et al. 1999; Sulkowski et al. 2002; Rockstroh et al. 2005), others 
have found that HCV leads to double the risk of AIDS-related mortality and hospitalization 
(Greub et al. 2000; Klein et al. 2003).  
Modern HCV treatments may have important adverse drug-drug interactions with some ART 
regimens and non-HIV-related medications. The NS5B inhibitors, including sofosbuvir, have 
very few serious drug-drug interactions (El-Sherif et al. 2015; Panel on Antiretroviral Guidelines 
for Adults and Adolescents 2018). In general, the most serious drug-drug interactions are found 
in drugs metabolized by CYP3A, and as such these drugs should not be administered together 
(Panel on Antiretroviral Guidelines for Adults and Adolescents 2018). Common examples of 
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CYP3A-inducing ARVs are efavirenz, etravirine, and nevirapine, while CYP3A-substrate DAAs 
include daclatasvir, elbasvir, grazoprevir, paritaprevir, and simepravir. An additional important 
drug-drug interaction is between ledipasvir, a substrate of p-glycoprotein, and tenofovir 
disoproxil fumarate. Co-administration of these drugs may lead to renal injury, especially when 
used with a boosted PI (Panel on Antiretroviral Guidelines for Adults and Adolescents 2018). 
Despite the possibility of drug-drug interactions, the large number of ART and DAA choices 
provide HCV and HIV treatment options for nearly all coinfected patients, though ART regimens 
and dosing may need to be adjusted if HCV treatment is to be initiated, and monitoring for 
adverse interactions is warranted (Panel on Antiretroviral Guidelines for Adults and Adolescents 
2018). Because of the more immediate effect of HIV on adverse outcomes, treating HIV is 
considered most urgent, and it is recommended that ART be initiated prior to HCV treatment 
(Panel on Antiretroviral Guidelines for Adults and Adolescents 2018). 
Current challenges and remaining questions with HIV-HCV coinfection 
There are many open questions and challenges remaining with regard to HIV/HCV 
coinfection. First, the effect of HCV on mortality among PLWH under current ART regimens 
and guidelines is unknown, as was highlighted in a recent review article (Klein et al. 2016). The 
results from our systematic review of the effect of HCV on mortality among PLWH during the 
ART era are presented in Table 1. Out of a total of 2,174 search results, title and abstract review 
narrowed the number of relevant studies to 22. Many of these studies suffer from design and 
methodological flaws that call their results into question. Of note, only one study conducted in 
the US completed follow-up after 2009 (May et al. 2015), and none of the studies captured the 
period of modern HIV treatment guidelines which recommend initiation of ART for all patients 
regardless of CD4 cell count (Panel on Antiretroviral Guidelines for Adults and Adolescents 
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2018). Additionally, only five studies restricted their samples to patients on ART (Backus et al. 
2005; Greub et al. 2000; May et al. 2015; Rancinan et al. 2002; Weis et al. 2006), and none 
properly dealt with time-varying ART initiation or included ART as a potential effect measure 
modifier. Among the high-quality studies that appear most applicable to the population of people 
with HIV in the US, there is no clear consensus as to the effect of HCV on mortality. Five 
studies found that people with HIV and HCV have 1.4 to 2.4 times the rate of mortality 
compared with people with HIV only (Greub et al. 2000; May et al. 2015; Rockstroh et al. 2005; 
Weis et al. 2006; Thornton et al. 2017), while two studies found no effect of HCV on mortality 
among people with HIV (Sulkowski et al. 2002; Scherzer et al. 2017). A 2009 meta-analysis 
estimated that PLWH+HCV had 1.4 times the risk of mortality of PLWH alone (Chen et al. 
2009). That study, however, combined estimates corresponding to varying lengths of follow-up, 
and therefore the results are difficult to interpret. Given the lack of consensus among studies, the 
scarcity of high-quality studies generalizable to the US population of PLWH, and the fact the no 
studies have been conducted under modern ART guidelines, there is a clear need for more 
research to determine the effect of HCV on mortality among PLWH. 
A second open question with HIV-HCV coinfection is the effect of sustained virologic 
response following HCV treatment on mortality among PLWH+HCV. To date, there is minimal 
evidence of the effect of successful HCV treatment on mortality in the DAA era, and there is no 
evidence specifically for PLWH+HCV (Jakobsen et al. 2017). Two studies have evaluated how 
DAA treatment impacts mortality in the short term among people with HCV only, and they 
found that those treated with DAAs had a mortality rate less than half the rate of those who were 
untreated over one year (Backus et al. 2018) and 18 months (Butt et al. 2017). Unfortunately, 
these studies specifically excluded PLWH, and the short time-span covered is likely not long 
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enough to fully uncover the slowly progressing effects of HCV infection. Because those studies 
specifically excluded PLWH, they cannot be directly compared with our results, as risk factors 
for and causes of mortality differ between PLWH and the general population. Table 2 presents 
the results of a brief review of the literature investigating the effect of SVR on mortality in 
coinfected individuals from pre-DAA era studies. Using a broad search string, only 6 of 183 
results were relevant. Of these six studies, three were conducted by the same research group 
using the same cohort (Berenguer et al. 2009; Berenguer et al. 2012; Berenguer et al. 2014), and 
five were conducted in Spain (Berenguer et al. 2009; Berenguer et al. 2012; Berenguer et al. 
2014; Labarga et al. 2015; Mira et al. 2013). All six studies suffer from design and 
methodological flaws. First, all of these studies compared coinfected individuals who had 
achieved SVR to those who did not respond to treatment or who were not treated. Because 
response to the older PEG-IFN-based treatments used in these studies is poor among people with 
HIV and HCV, factors related to general overall health and immune function are likely 
predictors of both treatment initiation, response, and death, and are difficult or impossible to 
measure and control for in analysis. Second, since five of the studies only included people who 
had been given treatment, the results may not be well generalizable to the overall population of 
PLWH+HCV in the US, as most people with HIV and HCV were not eligible for PEG-INF 
treatment (Rauch et al. 2005). The study that included patients based on coinfection status rather 
than treatment status (Leone et al. 2016) did not properly account for time-varying confounding  
and thus the results are possibly biased (Robins 1986). Notably, none of the studies investigated 
the joint effect of HIV and HCV treatment on mortality. Overall, despite the appearance of a 
large effect of SVR on mortality, the available evidence is weak, potentially biased, and limited: 
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further studies are needed in the DAA era in order to properly assess the effect DAA treatment 
will have on mortality among PLWH+HCV. 
One other challenge with respect to HIV/HCV coinfection is that the effect of DAA therapy 
on SVR is not well-studied in real-world coinfected populations and cohorts. While many 
randomized trials have been conducted to evaluate the efficacy of DAAs in PLWH+HCV, their 
restrictive inclusion criteria make them non-generalizable to the actual population of coinfected 
individuals. A study of the representativeness of coinfected trial populations found that fewer 
than half of the members of a Canadian cohort of PLWH+HCV would have been eligible for 
even the least restricted trial, and in almost every other trial fewer than 10% of the cohort would 
have been eligible (Saeed et al. 2016). The most common reason for exclusion was due to 
subjects not following the specific ART regimens required by the trial, followed by exclusion 
due to active drug use (Saeed et al. 2016). Even if the exclusions for ART regimens were not in 
place, only 25% of the cohort members would have met the inclusion criteria for the majority of 
the trials (Saeed et al. 2016). The exclusion due to injection drug use is particularly troubling, as 
PWID are most likely to spread their infection to others and therefore, from a public health 
perspective, they may be a key population to target for HCV control efforts. Though evidence of 
the effectiveness of DAAs in real-world populations and cohorts of PLWH+HCV is beginning to 
accumulate and has shown SVR rates consistently greater than 90% (Hawkins et al. 2016; Sogni 
et al. 2016; Milazzo et al. 2017; Montes et al. 2017), further studies are needed to understand 
their effectiveness in other realistic coinfected populations, such as among PWID. 
It is clear that additional research is needed to elucidate the role HCV plays among PLWH. 
Without an understanding of how HCV infection and treatment impact mortality in this 
population, it is impossible to properly assess the impact and cost-effectiveness of policies aimed 
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at providing DAAs and potentially curing HCV, and providers are left without the information 
necessary to prioritize treatments among their patients.
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Table 1.1: Prior studies estimating the effect of HCV coinfection on mortality among people living with HIV in the ART era 
Study Years Source Population N 
Effect Measure  
(95% CI) 
Baseline 
ART 
Bias2 
Anderson et al. 2004 1997 - 2001 Atlanta Veterans Affairs Medical Center 305 HCV+ / 665 HCV- HR: 2.46 (1.26; 4.2) 73% T, C, G 
Backus et al. 2005 1997 - 2003 US Department of Veterans Affairs  4,668 HCV+ / 7,548 HCV- HR: 1.56 (1.42; 1.70) 100% G 
Bonacini et al. 2004 1992 - 2001 University of Southern California HIV/Hepatitis Clinic 256 HCV+ / 126 HCV- RR3: 0.78 (0.56; 1.08) 48% C, O 
Branch et al. 2012 1998 - 2009 Studies of the Ocular Complications of AIDS cohort 337 HCV+ / 1,597 HCV- HR: 1.50 (1.20; 1.90) 84% G 
Chen et al. 2016 ? - 2012 TREAT Asia HIV Observational Database 794 HCV+ / 4421 HCV- HR: 1.81 (1.21; 2.72) 15% M, G 
El-Serag et al. 2005 1996 - 2001 US Department of Veterans Affairs 5,320 HCV+ / 12,761 HCV- HR: 0.78 (0.70; 0.88) U C, G 
Erqou et al. 2014 2001 - 2008 ERCHIVES Study (US Veterans with HCV) 5251 HCV+ /2788 HCV- HR: 1.58 (1.36; 1.84) U C, G 
Fuster et al. 2014 2001 - 2009 Longitudinal Interrelationships of Virus and Ethanol 200 HCV+ / 197 HCV- HR: 2.55 (1.50; 4.33) 62% T, C, G 
Greub et al. 2000 1996 - 2000 Swiss HIV Cohort Study 1,157 HCV+ / 1,954 HCV- HR: 1.70 (1.26; 2.30) 100% 
 
Hung et al. 2005 1994 - 2002 National Taiwan University Hospital 53 HCV+ / 387 HCV- HR: 0.78 (0.43; 1.43) 85% T, G 
Klein et al. 2003 1996 - 1999 Immunodeficiency Clinic - Montreal Chest Institute 83 HCV+ / 456 HCV- HR: 3.37 (1.58; 7.17) U L, C, G 
May et al. 2015 2000 - 2012 Antiretroviral Therapy Cohort Collaboration 4,630 HCV+ / 28,073 HCV- HR: 2.04 (1.68; 2.76) 100% 
 
Mayor et al. 2006 1998 - 2003 Puerto Rican Retrovirus Research Center cohort 193 HCV+ / 163 HCV- HR: 1.17 (0.79; 1.72) 45% C, M 
Monga et al. 2001 1994 - 1998 Houston Veterans Affairs Medical Center 166 HCV+ / 263 HCV- RR: 1.67 (0.90; 3.10) U C, G, O 
Rancinan et al. 2002 1995 - 1999 Aquitaine HIV Cohort 576 HCV+ / 419 HCV- HR: 1.24 (0.78; 1.98) 100% M, C 
Rezaianzadeh et al. 2012 2001 - 2011 Behavioral consultation center in Shiraz, Iran 1,044 HCV+ / 294 HCV- HR: 2.12 (1.10; 4.52) 90% G 
Rockstroh et al. 2005 1995 - 2004 EuroSIDA cohort 1,960 HCV+ / 3,997 HCV- IRR: 1.41 (1.13; 1.76) 48% 
 
Scherzer et al. 2017 2000 - 2007 Fat Redistribution and Metabolic Change in HIV 193 HCV+ / 720 HCV- OR: 0.90 (0.51; 1.59) 88% 
 
Sulkowski et al. 2002 1995 - 2001 Johns Hopkins HIV cohort 873 HCV+ / 1,082 HCV- HR: 1.05 (0.85; 1.30) 74% 
 
Tedaldi et al. 2003 1996 - 2002 HIV Outpatient Study 267 HCV+ / 556 HCV- HR: 0.91 (0.55; 1.51) 84% L, C 
Thornton et al. 2017 2004-2011 UK Collaborative HIV Cohort Study 1,404 HCV+ / 22,739 HCV- IRR: 1.42 (1.15-1.76) 56%  
Weis et al. 2006 1995 - 2004 Danish HIV Cohort Study 443 HCV+ / 2,183 HCV- IRR: 2.40 (1.90; 3.00) 100% 
 
PubMed search string: ((Hepatitis C) OR HCV) AND (HIV OR (Human Immunodeficiency Virus)) AND (Survival OR Mortality OR Death). HR: Hazard ratio; IRR: Incidence rate ratio; 
RR: Risk ratio; OR: Odds ratio; U: Unknown 
1C: Regression control; R: Restriction; N: No control 
2C: Uncontrolled confounding; G: Poor generalizability to US HIV-infected population; T: Improper methods for time-varying confounding; L: Loss to follow-up; M: Missing data; 
O: Other 
3Not directly reported, estimated from crude risks
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Table 1.2: Prior studies estimating the effect of HCV sustained virologic response on mortality among people living with HIV and 
HCV in the ART era 
Study Years Study Population N 
Effect Measure 
(95% CI) 
Baseline 
ART 
Bias1 
Berenguer et al. 2009 2000 - 2005 Spanish AIDS Study Group 218 SVR / 493 no SVR IRR2: 0.15 (0.01; 0.76) 84% C, G 
Berenguer et al. 2012 2000 - 2008 Spanish AIDS Study Group 626 SVR / 973 no SVR IRR2: 0.14 (0.04; 0.30) 79% C, G 
Berenguer et al. 2014 2000 - 2008 Spanish AIDS Study Group 274 SVR / 421 no SVR HR: 0.22 (0.08; 0.60) 81% C, G 
Labarga et al. 2015 2004 - 2012 Madrid Hospital Clinic 138 SVR / 389 no SVR HR: 0.12 (0.03; 0.54) 92% C, G 
Leone et al. 2016 1997 - 2012 MASTER HIV Cohort (Italy) 102 SVR / 238 no SVR HR: 0.85 (0.16; 4.76) Unknown T, C 
Mira et al. 2013 2001-2011 10 Hospitals in Spain 43 SVR / 123 no SVR HR: 0.13 (0.02; 0.93) 96% C, G 
PubMed search string: ((Hepatitis C) OR HCV) AND (HIV OR (Human Immunodeficiency Virus)) AND ((Sustained Virologic Response) OR SVR OR Cure) AND 
(Survival OR Mortality OR Death) 
SVR: Sustained virologic response; IRR: Incidence rate ratio; H: Hazard ratio 
1C: Uncontrolled confounding; G: Poor generalizability to US HIV-infected population; T: Improper methods for time-varying confounding 
2Not directly reported, estimated from reported crude rates
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CHAPTER 2: STATEMENT OF SPECIFIC AIMS 
2.1 Specific Aims and Justification 
To further elucidate the role of HCV infection and DAA treatment on mortality among 
PLWH, at both the individual and population levels, this work has the following aims: 
Aim 1  
Estimate the effect of chronic hepatitis C infection and its treatment on 10-year all-cause 
mortality among PLWH in the Multicenter AIDS Cohort Study and Women’s Interagency HIV 
Study had they initiated ART upon study entry.  
Justification and approach: While HCV is known to substantially impact long-term all-cause 
mortality in the general population, its effect among PLWH remains unclear. Further, due to the 
fairly recent development of effective treatment for HCV, no studies have assessed the impact of 
treating HCV with DAA therapies on all-cause mortality in this population. Additionally, no 
studies of HCV or DAA treatment on mortality have been conducted in the era of modern HIV 
treatment guidelines. In this aim, we will use the parametric g-formula to assess the effect on 10-
year all-cause mortality of a joint exposure consisting of HCV infection at baseline and ART 
initiation at study entry, compared with no HCV infection at baseline and ART initiation at study 
entry. Additionally, we will estimate the effect of treating HCV with DAAs among 
PLWH+HCV, had they initiated ART upon entry into the study. Because the current standard of 
care for HIV is to begin ART regardless of CD4 cell count, estimating these effects among 
patients had they initiated ART at study entry will provide results that are more useful for future 
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policy decisions, as most patients not receiving treatment for their HIV would likely not receive 
treatment for HCV.  
Aim 2 
Estimate the effects on 10-year all-cause mortality among PLWH+HCV, as well as the 
population intervention effects among PLWH in general, of having all PLWH in the MACS and 
WIHS initiate ART at study entry and treating 1) all PLWH+HCV, 2) PLWH+HCV selected 
based on their hepatic fibrosis and viral suppression status, and 3) randomly selected proportions 
of PLWH+HCV, with proportions equal to the proportions treated under the policies in (2).  
Justification and approach: Existing Medicaid treatment criteria for DAAs often require 
patients to meet certain clinical conditions, including progressing to severe liver fibrosis or 
cirrhosis and achieving HIV suppression. It is currently not known whether or not those policies 
are optimal for treating PLWH+HCV. In this aim, using the parametric g-formula, we will assess 
the effect of treating HCV with DAAs in subsets of PLWH+HCV in the WIHS/MACS, and we 
will compare policies in which treatment is provided based on clinical criteria to policies in 
which similar proportions of PLWH+HCV are treated at random. Because HIV care providers 
and policy-makers now have to consider the many comorbidities of HIV that may arise among 
PLWH long-term, in addition to standard effect estimates restricted to PLWH+HCV, we will 
also estimate population intervention effects in the population of PLWH more generally which 
depend on the prevalence of HCV and can thus be compared with similar estimates for other 
HIV comorbidities. 
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2.2 Rationale 
Hepatitis C (HCV) is a common co-infection of HIV. Of the approximately 40 million 
PLWH worldwide, an estimated 4-5 million are also have HCV (Alter 2006). This proportion is 
even higher in the United States, where an estimated 25% of the population of PLWH is 
coinfected with HCV (Centers for Disease Control and Prevention 2017a). Since the widespread 
adoption of combination antiretroviral therapy (ART) in the United States, the prognosis for 
PLWH has drastically improved, with life expectancies now approaching those of the people 
without HIV (Nakagawa et al. 2013).  
Unfortunately, PLWH and HCV (PLWH+HCV) have experienced more modest gains. The 
rate of all-cause mortality among PLWH+HCV is estimated to be between 1.7 and 2.5 times the 
rate among PLWH only (Anderson et al. 2004; Greub et al. 2000), though other studies have 
found no effect of HCV on all-cause mortality among PLWH (Sulkowski et al. 2002; Scherzer et 
al. 2017). In addition, PLWH+HCV have increased morbidity due to both their HIV and HCV 
infections (Greub et al. 2000; Koziel & Peters 2007; Sulkowski & Thomas 2003; Graham et al. 
2001; Bambha et al. 2012). 
Prior to 2013, treatment for HCV infection involved PEGylated interferon (United States 
Centers for Disease Control and Prevention 2010). For PLWH+HCV, treatment lasted 48 weeks, 
and sustained virologic response (SVR) rates were poor (Koziel & Peters 2007). The extremely 
low effectiveness of these treatments can be attributed to poor efficacy and low compliance 
because of the common and severe side effects of the medications (Mulhall & Younossi 2005). 
Fortunately, in 2013, a new class of HCV medications known as direct acting antivirals (DAA) 
were introduced. These treatments are not only more effective, but they also had substantially 
fewer side effects and only require a 12 week course of treatment (Afdhal et al. 2014; Jacobson 
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et al. 2013). The SVR rate with DAA therapy can be over 97% (Afdhal et al. 2014), with similar 
effectiveness among PLWH+HCV (Sogni et al. 2016; Hawkins et al. 2016; Milazzo et al. 2017).  
DAAs come with a significant cost, however, with the current list price of Sofosbuvir being 
$84,000 (University of Washington 2017). These treatments are therefore well-suited for 
viewing through the lens of precision medicine, in which treatments are targeted to populations 
expected to achieve the greatest benefit. Currently, many state Medicaid programs limit DAA 
treatment to those who meet certain clinical criteria, such as those who abstained from illicit 
drugs and alcohol, who have achieved HIV suppression, or who have progressed to severe 
fibrosis or cirrhosis (Ooka et al. 2017), despite guidelines suggesting that nearly all people with 
HCV should be treated regardless of clinical factors (American Association for the Study of 
Liver Diseases & Infectious Diseases Society of America 2017). To date, no studies have been 
conducted to assess the effect of HCV infection and DAA treatment policies on all-cause 
mortality among PLWH who receive ART regardless of CD4 cell count, as is recommended by 
current HIV treatment guidelines (Panel on Antiretroviral Guidelines for Adults and Adolescents 
2018).  
Randomized controlled trials evaluating the effect of HCV interventions on mortality in this 
population are infeasible due to the long period between HCV infection and clinical 
manifestations, as well as because the known effectiveness of modern HCV treatment precludes 
equipoise. Therefore, to fill these important gaps in the literature, this work uses existing cohort 
data from the combined Multicenter AIDS Cohort Study (Kaslow et al. 1987) and Women’s 
Interagency HIV Study (Barkan et al. 1998; Adimora et al. 2018) along with causal inference 
methodology (Hernán & Robins 2017) to estimate the causal impact on all-cause mortality of 
HCV infection and various treatment policies under current HIV treatment guidelines. In 
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addition to average treatment effects, this work will also estimate population intervention effects 
(Westreich 2017) that contrast the observed mortality in the population of PLWH had all 
individuals initiated ART immediately with that which would be observed if all PLWH initiated 
ART immediately and certain subgroups of PLWH+HCV were treated for their HCV.  
By taking a ‘patients to policy’ approach (Westreich 2017), the results of this work will 
provide important evidence for both clinicians and policymakers. Given the many comorbidities 
that the aging population of PLWH experience, it is necessary to understand the conditions that 
have the greatest impact on patient and population health. By estimating standard exposure and 
treatment effects as well as population intervention effects, these results will aid in determining 
how to prioritize HCV treatment against treatments for other HIV comorbidities and will provide 
valuable evidence for guiding policies with regards to HCV treatment. 
2.3 Quantities to be estimated 
As both aims of this work involve the estimation of disease, treatment, and intervention 
effects, no statistical hypothesis tests will be conducted. The following quantities, in the form of 
risk differences and risk ratios, will be estimated in this work (each quantity will be estimated 
after first applying a hypothetical intervention to have all study participants initiate ART at 
baseline): 
Aim 1  
1) The effect of baseline chronic HCV on 10-year all-cause mortality among PLWH in the 
MACS and the WIHS. 
2) The effect of baseline chronic HCV on 10-year all-cause mortality among PLWH+HCV 
in the MACS and the WIHS. 
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3) The effect of DAA treatment at study entry on 10-year all-cause mortality among 
PLWH+HCV in the MACS and the WIHS. 
Aim 2 
1) The effect of treating all PLWH+HCV with DAAs at study entry on 10-year all-cause 
mortality in the MACS and the WIHS. 
2) The effect of treating PLWH+HCV with DAAs after they progress to severe liver fibrosis 
or cirrhosis on 10-year all-cause mortality in the MACS and the WIHS. 
3) The effect of treating PLWH+HCV with DAAs after they achieve HIV suppression on 
10-year all-cause mortality in the MACS and the WIHS. 
4) The effect of treating PLWH+HCV with DAAs after they progress to severe liver fibrosis 
or cirrhosis and achieve HIV suppression on 10-year all-cause mortality in the MACS 
and the WIHS. 
5) The effect of treating randomly selected PLWH+HCV with DAAs at baseline, with 
proportions selected equal to the proportions treated in 2-4, on 10-year all-cause mortality 
in the MACS and the WIHS. 
6) The population intervention effects of each of the above policies, estimated in the entire 
population of PLWH in the MACS and the WIHS. 
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CHAPTER 3: METHODS 
3.1 Description of data sources 
The Multicenter AIDS Cohort Study 
The Multicenter Aids Cohort Study (MACS) is an ongoing study of men who have sex with 
men (MSM) with and without HIV (Kaslow et al. 1987). The MACS began as in 1984 with the 
goals of describing the natural history of AIDS, determining the biological and behavioral factors 
that caused AIDS, and collecting biological specimens for further research (Kaslow et al. 1987). 
After HIV was discovered to be the causative agent of AIDS in 1983 (Barre-Sinoussi et al. 1983; 
Gallo et al. 1983), the goals of the MACS changed (Kaslow et al. 1987). First, the MACS seeks 
to identify and evaluate HIV seropositive men in the study, which included determining 
correlates of seropositivity and describing the natural history of HIV. Second, the study aims to 
identify and evaluate HIV seroconverters, in particular by determining the factors associated 
with seroconversion, characterizing the early phases of HIV infection, and determining the 
relationship between clinical status, viremia, and host immune response. Third, the study seeks 
to characterize those who did not seroconvert to identify protective factors against infection and 
determine whether or not HIV infection was possible without seroconversion. Lastly, the MACS 
aims to design additional studies of HIV prevention and therapy. Since its inception, many 
additional aims and substudies have been added to the MACS protocols. 
The MACS has study sites in four locations across the United States: Baltimore, 
MD/Washington, DC (Johns Hopkins University); Pittsburgh, PA / Columbus, OH (University 
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of Pittsburgh); Chicago, IL (Northwestern University); and Los Angeles, CA (University of 
California – Los Angeles). Any MSM without a diagnosis of AIDS is eligible to participate 
(Kaslow et al. 1987). Participants are recruited through a variety of mechanisms, including media 
publicity (including publicity in the gay press), personal connections of gay activists and study 
participants, promotional events and offerings (e.g. raffles, free medical screening), and clinical 
contacts with medical practices and studies focusing on MSM (Kaslow et al. 1987). The success 
of each recruitment effort has differed by study site. In Baltimore, most participants had 
responded to gay and metropolitan newspaper stories or had been recruited by leaders of the gay 
community. In Chicago, the greatest success came from recruiting participants from clinics for 
MSM and from an existing hepatitis B vaccine study. In Los Angeles, most participants came 
from an existing AIDS cohort, referrals from health professionals, and announcements in the 
media. Finally, in Pittsburgh, investigators found most participants through recruitment at gay 
bars and bathhouses. 
The initial wave of recruitment occurred between 1984 and 1985 and included 4,954 
participants. A second wave recruited 668 additional participants between 1987 and 1990 with 
the goal of including more black individuals. The third wave occurred between 2001 and 2003 in 
which 1,350 participants were recruited, with an aim of including more black and Hispanic 
subjects. Finally, a fourth wave of recruitment began in 2010 with the goal of replacing 
participants who were lost to follow-up or died. As of October 2013, a total of 7,087 men had 
been recruited into the study, contributing 61,357 HIV positive person-visits (Multicenter AIDS 
Cohort Study Group 2017). 
MACS study visits occur at baseline and every six months thereafter (Kaslow et al. 1987). 
The baseline visits have several components, and subsequent visits include a subset of these 
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components. First, study investigators conduct a face-to-face interview and administer a 
questionnaire to determine identifying information, demographic data, past medical history, 
current medical history, risk factors, drug use, and sexual practices. Next, a physician, 
physician’s assistant, or nurse practitioner performs a complete, standard physical exam on the 
participant. Lastly, samples are collected for lab tests, for instance (but not limited to) complete 
blood counts, HIV immunoassays, and lymphocyte phenotyping (for information on specific lab 
tests and collected information, see Variable measurement and operationalization). 
The MACS investigators make great efforts to prevent loss to follow-up (Dudley et al. 1995). 
Community advisory boards are included in the study planning and design in order to ensure 
acceptability with the MSM community. Meeting location and hours are chosen in order to best 
accommodate study participants. At each study visit, the investigators collect several pieces of 
information that could be used to locate the participants. These include driver’s license and 
social security numbers, the names and addresses of people who would know how to contact the 
participant, and the name and contact information for the participant’s health care providers. At 
the end of each study visit, an appointment is scheduled for the next study visit. Between 2-4 
weeks prior to a study visit, a reminder letter is sent to the participant, which is followed by a 
telephone call two weeks later. If contact cannot be made, investigators continue calling the 
participant for an additional 45 days or until contact is made. If contact is still not made, and 
extended search is conducted of named contacts, death certificates and obituaries, AIDS 
registries, death indices, departments of motor vehicles, consumer information services, and tax 
and voter rolls. If a participant moves away from a study site, they are able to have study visits at 
the nearest study site to their new location, and if they are too far away or a full visit is not 
possible, participants can have laboratory samples collected by their own physician and can be 
 46 
 
interviewed by telephone and mailed questionnaires. As of October 2015, 67% of the members 
of the cohort with HIV who were known to be alive remained in active follow-up (Center for the 
Analysis and Management of MACS Data 2017). 
The Women’s Interagency HIV Study 
 The Women’s Interagency HIV Study (WIHS) began in 1994 to address the lack of 
knowledge about HIV among women (Barkan et al. 1998; Adimora et al. 2018). Still ongoing, 
the WIHS had several initial aims. First, the study aims to describe the spectrum and natural 
history of HIV among women. Second, the WIHS has the goal of investigating the relationship 
between virologic and immunologic factors with HIV disease progression in women. Finally, the 
study seeks to investigate the risk factors that may be related to HIV disease progression, 
including infectious, treatment-related, endocrine, nutritional, health care utilization, 
socioeconomic, and behavioral risk factors. As understanding of HIV improved, additional aims 
and substudies have been added to the WIHS. 
The WIHS began with six study sites – Bronx, NY/Manhattan, NY; Washington, DC; San 
Francisco, CA/Bay Area, CA; Los Angeles, CA/Southern California/Hawaii; and Brooklyn, NY. 
Later, four additional sites were added – Chapel Hill, NC; Atlanta, GA; Miami, FL; and 
Birmingham, AL. In order to be eligible for participation in the WIHS, subjects have to be older 
than 13 years of age, provide informed consent, , be willing to be tested for HIV, be able to 
complete an interview in English or Spanish, be able to travel to and from the clinic site, and be 
willing and able to provide blood for laboratory analyses (Barkan et al. 1998). People with and 
without HIV are frequency matched on demographics and key risk factors including age, 
race/ethnicity, highest education level attained, injection drug use, and total number of sexual 
partners. Recruitment occurs through several avenues. First, participants are recruited from HIV 
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primary care clinics, hospital-based programs, and HIV research programs. Second, investigators 
attend community outreach events and posted notices at community gathering sites and women’s 
support groups. Third, potential participants are identified at HIV testing sites and drug 
rehabilitation programs. Finally, participants are able to provide referrals for other potential 
subjects. In order to encourage participation, remuneration in the form of gift packs, access to 
bathing facilities, laundry supplies, meals, transportation, and access to dental care may be 
provided. 
The first wave of recruitment occurred between 1994 and 1995, in which 2,623 participants 
were enlisted for the study (Women’s Interagency HIV Study Group 2017). Additional 
recruitment waves occurred between 2001 and 2002 (1,143 additional subjects), 2011 and 2012 
(371 additional subjects), and 2013 and 2015 (845 additional subjects). As of September 2015, a 
total of 3,702 participants with HIV had enrolled in the WIHS, contributing 64,931 HIV positive 
person-visits (Women’s Interagency HIV Study Group 2017).  
WIHS study visits are similar to those of the MACS. Study visits occur at baseline and every 
six months (Barkan et al. 1998). The baseline visit includes several components, of which a 
subset is included in follow-up visits. First, study investigators administer a structured interview 
to determine sociodemographic information; medical, health, obstetric, gynecologic, and 
contraceptive history; substance abuse; sexual behavior; health care utilization; and psychosocial 
information. Second, participants go through a comprehensive physical and gynecologic exam 
that includes measurement of vital signs; a test of cognitive function; an evaluation of Karnofsky 
score; an examination of external and internal genitalia; a cervical vaginal lavage; and 
colposcopy, biopsy, and dysplasia treatment as indicated. Finally, laboratory specimens are 
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collected (for information on select laboratory measurements, see Variable measurement and 
operationalization). 
Like the MACS, the WIHS has detailed, extensive protocols to minimize loss to follow-up 
(Hessol et al. 2001). Community advisory boards are included in the study design phase in order 
to ensure acceptability among participants. The study utilizes bilingual, female interviewers and 
staff in order to make the participants feel comfortable, safe and respected. Transportation 
assistance is offered for women who have difficulty attending study visits, and women who 
move are able to attend visits at their closest WIHS site. Also, abbreviated interviews are offered 
to participants who were too ill to attend a study visit or who were incarcerated. In order to 
encourage participants to attend follow-up visits, monetary compensation is offered. In order to 
locate women if they are lost, prior to study visit appointments, study investigators send letters 
and make phone calls to confirm the visits and remind the participants to attend. Additionally, 
after each visit, participants are asked to fill out a form that provided information on contacts 
who would know how to reach the subject. If a woman missed a study visit or cannot be located, 
the investigators used extended searches to find her including visits to clinics and locations 
where the women were recruited, searches of medical databases and death registries, and checks 
of county jails and prisons. As of September 2016, of the cohort participants with HIV who were 
known to be alive, 70% from the first recruitment wave, 79% from the second recruitment wave, 
92% from the third recruitment wave, and 96% from the fourth recruitment wave remained in 
active follow-up (WIHS Data Management and Analysis Center 2017). 
Study inclusion/exclusion criteria 
 The cohort used for this work has relatively minor inclusion/exclusion criteria. First, only 
participants without a clinical diagnosis of AIDS are included, as these subjects are at high risk 
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for mortality and are not likely to be candidates for HCV treatment. Second, only participants 
with no prevalent ART use at baseline are included in to avoid the possibility of selection bias 
and left truncation bias due to conditioning on survival on ART until entry into the study. 
Finally, only visits that occurred between October 1, 1994 and September 30, 2015 are 
(corresponding to WIHS visits 1 through 42 and MACS visits 22 through 63), as these are the 
dates in which both the WIHS and the MACS were simultaneously operating. 
3.2 Variable measurement and operationalization 
HIV 
In both the MACS and the WIHS, all participants are screened at baseline using enzyme-
linked immunosorbent assays (ELISA). For those who screen positive, the diagnosis is 
confirmed with Western Blot. Those who screen negative are retested at subsequent visits until 
seroconversion. 
HCV 
Routine HCV testing was not part of the original MACS protocol. Prospective HCV testing 
in the MACS began in 2001 (Seaberg et al. 2014). Participants enrolled after 2001 were screened 
for HCV Ab at baseline. For those reactive to HCV Ab, further tests for HCV RNA were 
performed. For participants who enrolled prior to 2001, stored blood specimens from within two 
years of the baseline visit were retrospectively tested for HCV Ab. Those reactive to HCV Ab 
were tested for HCV RNA using samples from their most recent study visit at the time of 
screening. Those who tested positive for HCV Ab but negative for HCV RNA at this last study 
visit had their baseline samples tested for HCV RNA. HCV Ab was tested with 3rd generation 
Enzyme Immunoassays (ADVIA Centaur HCV assay, Siemens Healthcare Diagnostics, 
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Tarrytown, NY, USA), and HCV RNA was quantified with quantitative real-time polymerase 
chain reaction assays (COBAS AmpliPrep COBAS TaqMan HCV assay, Roche Molecular 
Systems, Pleasanton, CA, USA). Baseline HCV status was determined for 99.3% of MACS 
participants under this protocol (Seaberg et al. 2014). 
Women in the WIHS were screened for HCV Ab at baseline. Those who screened positive 
were further tested for HCV RNA. HCV Ab testing in the WIHS was conducted using 2nd or 3rd 
generation Enzyme Immunoassays (Ortho-Diagnostic Systems, Rochester, NY, USA), and HCV 
RNA was tested for with branched DNA methods (Quantiplex 2.0 branched chain DNA-
enhanced label amplification assay, Chiron, Emeryville, CA, USA) and real-time polymerase 
chain reaction assays (COBAS Amplicor HCV Detection Kit, Roche Diagnostic Systems, 
Pleasonton, CA). 
Baseline HCV status was classified into three levels for this work (Seaberg et al. 2014). 
Those negative for HCV Ab were considered to have never had HCV (HCV-). Those positive for 
HCV Ab but negative for HCV RNA were considered to have successfully treated HCV or 
spontaneously cleared HCV (SVR). Those who were positive for HCV RNA were considered to 
have chronic HCV infection (HCV+). In this work, comparisons were between the HCV+ group 
and the combined HCV- and SVR groups. 
Antiretroviral therapy 
At each study visit, participants are asked to bring lists of any medications and pill bottles for 
any prescription drugs they used since their last visit. If no documentation is provided, the 
participant is asked to name any medications they can from memory, and pictures of commonly 
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used antiretroviral medications are provided. If a previously reported medication is not 
mentioned, the interviewer specifically asks about that medication. 
The definition of antiretroviral therapy (ART) used in this work was guided by the November 
2014 US Department of Health and Human Services guidelines (Panel on Antiretroviral 
Guidelines for Adults and Adolescents 2014). ART was defined as regimens consisting of three 
or more antiretroviral drugs including at least one protease inhibitor, entry inhibitor, integrase 
inhibitor, or non-nucleotide reverse transcriptase inhibitor. 
Once a participant reported initiating ART, they were considered on ART for the remainder 
of the study (the intent-to-treat assumption). The intent-to-treat assumption was previously found 
to correctly classify the ART status of 94% of person-time in the MACS and WIHS (Cole et al. 
2003). 
In order to isolate more recent ART regimens, ART was split into two variables based 
initiation date. ART initiated prior to October 1, 2001 (the first visit following the approval of 
tenofovir, a component of many modern ART regimens (Panel on Antiretroviral Guidelines for 
Adults and Adolescents 2018)) was considered early ART, while any ART initiated after that 
date was considered modern ART. All interventions considered in this work assumed 
participants initiate specifically modern ART upon entry into the study. 
Loss to follow-up 
Study participants are considered lost to follow-up at their second consecutive missed study 
visit and are censored at the moment where they are defined as lost to follow-up. 
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Death 
 Study coordinators obtained date and cause of death either directly from the National Death 
Index (https://www.cdc.gov/nchs/ndi/index.htm) or through hard copies of death certificates 
obtained by the study investigators. Participants who were not lost to follow-up and died within 6 
months of their 𝑘th study visit were considered to have died between their 𝑘th and 𝑘+1th study 
visits. 
Potential confounders 
Baseline and time-varying confounders for each aim were identified using a causal diagram 
(Greenland et al. 1999) constructed prior to data analysis (Figure 3.1). Baseline and follow-up 
CD4 cell count is evaluated in each study using flow cytometric procedures (Giorgi et al. 1990). 
Continuous CD4 cell count was included in the models with five-knot restricted cubic splines, 
with knots at the 5th, 27.5th, 50th, 72.5th, and 95th percentiles (Harrell 1986). 
Baseline and follow-up HIV viral load measurement procedures varied over time in each 
study as the accuracy of measurements improved. In the MACS, viral load was initially 
measured using sensitive bDNA signal amplification assays (Chiron, Emoryville, CA, USA), 
with a lower limit of detection of 500 copies/ml. Next, viral loads were measured with Roche 
Amplicor RNA kits (Hoffman-Laroche, Nutley, NJ, USA), with lower limits of detection of 400 
copies/ml. The MACS currently uses Ultrasensitive RNA polymerase chain reaction assays 
(Hoffman-LaRoche, Nutley, NJ, USA), with lower limits of detection of 50 copies/ml. The first 
test to be used in the WIHS was the nucleic acid sequence-based amplification assay (Organon-
Teknika, Durham, NC, USA), with a lower limit of detection of 4000 copies/ml. The WIHS 
currently uses the COBAS AmpliPrep/COBAS TaqMan test (Roche, Pleasonton, CA, USA), 
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with lower limit of detection of 20 copies/ml. Baseline HIV viral load was included in the 
models as a single continuous variable, and time-varying HIV Viral load was included as a 
dichotomous variable representing detectable or undetectable viral load.  
Chronic hepatitis B infection was defined as a positive test at baseline for HBV surface 
antigen (HBsAg). In both studies, HBsAg is tested at baseline using enzyme immunoassays 
(Abbot Laboratories, Abbot Park, IL, USA). 
Age, sex, race/ethnicity, injection drug use (IDU), alcohol use, and smoking are determined 
from self-administered questionnaires and interview at baseline and follow-up visits. Age was 
included in the models with five-knot restricted cubic splines with knots at the 5th, 27.5th, 50th, 
72.5th, and 95th percentiles. Sex was represented with an indicator variable for female sex. 
Race/ethnicity was categorized as non-Hispanic White, non-Hispanic Black, Hispanic, and 
Other. IDU and smoking were dichotomized as current versus prior/never. Alcohol use was 
dichotomized as current heavy alcohol use versus no current heavy alcohol use, with heavy 
alcohol use being defined as consuming more than 7 drinks per week for women and more than 
14 drinks per week for men (United States Department of Health and Human Services 2015). 
BMI is assessed at each study visit, and BMI was categorized as obese (BMI greater than 30 
kg/m2) versus non-obese.  
Fibrosis is measured with the non-invasive FIB-4 index (Sterling et al. 2006) and AST to 
Platelet Ratio Index (APRI) (Lin et al. 2011), defined as  
𝐹𝐼𝐵4 =
𝐴𝑔𝑒 ∗ 𝐴𝑆𝑇
𝑃𝑙𝑎𝑡𝑒𝑙𝑒𝑡𝑠 ∗ 𝐴𝐿𝑇
1
2
 
and 
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𝐴𝑃𝑅𝐼 =
(𝐴𝑆𝑇/𝑈𝐿 )
𝑃𝑙𝑎𝑡𝑒𝑙𝑒𝑡𝑠
∗ 100 
, respectively. 
where AST is aspartate aminotransferase and ALT is alanine aminotransferase, both measured in 
units/liter, UL is the upper limit of normal for the AST test measured in the same units as AST, 
age is measured in years, and platelets are measured in units of 109 per liter (Sterling et al. 2006). 
Fibrosis was categorized into 3 groups: FIB-4 ≥ 3.25 or AST to Platelet Ratio Index (APRI) ≥ 1 
was classified as severe fibrosis/cirrhosis, while FIB-4 < 1.45 and APRI < 0.7 (together) was 
classified as no significant fibrosis. Other combinations were classified as moderate fibrosis. The 
APRI cutoffs are based on a meta-analysis (Lin et al. 2011) that suggested these perform better at 
classifying severe fibrosis/cirrhosis and no significant fibrosis than the commonly used cutoffs of 
2 and 0.5, respectively. Severe fibrosis/cirrhosis was assumed to be non-reversible.
  
 
5
5
 
Figure 3.1: Causal diagram used to select confounders 
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3.3 Notation 
The following notation will be used throughout this section. Individuals will be indexed by 𝑖 ∈
{1,2,3, … , 𝑛}, and time (in visits) will be indexed by 𝑡 ∈ {0,1,2,3, … , 𝜏}. Uppercase letters will 
denote random variables, and lowercase letters and numbers will represent their potential 
realizations. An overbar (e.g. ?̅?𝑖𝑡) denotes history, for example ?̅?𝑖𝑡 = {𝐴𝑖0, 𝐴𝑖1, 𝐴𝑖2, … , 𝐴𝑖𝑡}, 
?̅?𝑖𝑡 = {𝑈𝑖0, 𝑈𝑖1, … , 𝑈𝑖𝑡}, and ?̅?𝑖𝑡 = {𝑊𝑖0,𝑊𝑖1, … ,𝑊𝑖𝑡}. Let ?̅?𝑖 = ?̅?𝑖𝜏. Superscripts, e.g. 𝑌𝑖
𝑎, on 
random variables represent potential outcomes, in this case meaning the level of 𝑌 that subject 𝑖 
would have experienced had, possibly counter to fact, they received treatment level 𝑎. 
Additionally, 𝑓𝑋(𝑥) denotes a probability mass function or probability density function for the 
random variable 𝑋 evaluated at 𝑥. From here forward, observations will be assumed independent 
and identically distributed, and subscripts distinguishing individuals will be dropped. 
3.4 The generalized parametric computation algorithm formula 
The parametric generalized computation algorithm formula (Robins 1986) will be used in 
both aims of this work. Hereafter, the use of the parametric generalized computation algorithm 
formula for the estimation of causal effects will be referred to as g-computation, and the formula 
itself will be referred to as the g-formula. In this section, the goal is to motivate the need for g-
computation (or other causal inference methods) and demonstrate how it can be used to estimate 
causal effects.  
Consider a study is to estimate the causal effect of a dichotomous exposure (or treatment) 𝐴 
measured at times 0,1, … , 𝜏, with exposure at time 𝑡 denoted 𝐴𝑡, on an outcome 𝑌 measured at 
the end of the study. Measured covariates at time 𝑡 are denoted with 𝑊𝑡, and unmeasured 
covariates with 𝑈𝑡. Assume that 𝑈𝑡 temporally precedes 𝑊𝑡, which temporally precedes 𝐴𝑡. For 
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simplicity, the discussion that follows will be restricted to static exposure regimes, meaning 
regimes that consist of setting a subject’s exposure history to a certain value regardless of 
exposure or covariate history, e.g. ?̅? = {𝑎0, 𝑎1, … , 𝑎𝜏}, though similar results are available for 
non-static (dynamic) exposure regimes (Young et al. 2011). The set of all possible static 
exposure regimes is denoted 𝒜, and the set of all possible covariate histories is 𝒲. Common 
examples of static regimes for a binary exposure are always exposed {1,1, … ,1} or never exposed 
{0,0, … ,0}. Using counterfactual notation, the average causal effect (ACE) comparing two 
exposure regimes is defined as 𝐴𝐶𝐸 = 𝐸(𝑌?̅? − 𝑌?̅?
∗
) = 𝐸(𝑌?̅?) − 𝐸(𝑌?̅?
∗
), for ?̅? ≠ ?̅?∗, which can 
be interpreted as the difference in the expected value of 𝑌 had the entire population followed 
regime ?̅? compared with the expected value of 𝑌 had the entire population followed regime ?̅?∗.  
The ACE, which compares the expected values of two unobserved variables, is distinct from the 
usual associational effect, 𝐸(𝑌|?̅? = ?̅?) − 𝐸(𝑌|?̅? = ?̅?∗), which compares the expected outcomes 
among the subsets of individuals who followed regimes ?̅? and ?̅?∗.  
To identify the ACE nonparametrically, four conditions are sufficient to link the observed 
data to the potential outcomes (Robins 1986): 
1) Consistency 
𝑌 = ∑ 𝐼(?̅? = ?̅?)𝑌?̅?
?̅?∈𝒜
 
where 𝐼(𝑥) is the indicator function that takes the value 1 if 𝑥 is true and 0 otherwise. 
The potential outcome for a subject under their observed exposure history is equal to their 
observed outcome. Threats to consistency typically come from two sources: interference between 
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subjects and relevant variation in the versions of exposure (Cole & Frangakis 2009; 
VanderWeele 2009).  
2) Conditional exchangeability  
𝑌?̅? ⫫ 𝐴𝑡|{?̅?𝑡−1, ?̅?𝑡}, ∀ ?̅? ∈ ?̃? 
where ?̃? are the exposure regimes to be compared. Each potential outcome is statistically 
independent of the observed exposure at a given time conditional on exposure history and the 
history of a set of covariates 𝑊. Threats to conditional exchangeability typically arise from 
uncontrolled confounding and selection bias (Hernán & Robins 2017). 
3) Positivity 
If 𝑓?̅?𝑡−1,?̅?𝑡(?̅?𝑡−1, ?̅?𝑡) > 0, then 𝑓𝐴𝑡|?̅?𝑡−1,?̅?𝑡(𝑎𝑡|?̅?𝑡−1, ?̅?𝑡) > 0, ∀ ?̅? ∈ ?̃? 
At every time 𝑡, there are individuals following each exposure history to be compared in every 
stratum defined by observed combinations of exposure history and covariate history. Violations 
of positivity can be either random (by chance nobody with a certain exposure level is observed in 
a strata of past treatment and covariates) or deterministic (it is not possible for someone with 
certain past exposure and covariates to have a certain exposure level, for example men cannot be 
exposed to hysterectomy) (Westreich & Cole 2010). 
4) No measurement error (Edwards et al. 2015) 
Under these four conditions, 𝐸(𝑌?̅?) can be identified nonparametrically from the observed 
data as follows: 
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𝐸(𝑌?̅?) 
= ∑ 𝐸(𝑌?̅?|𝑊0 = 𝑤0)𝑓𝑊0(𝑤0)
𝑤0∈𝒲0
(𝑙𝑎𝑤 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦) 
= ∑ 𝐸(𝑌?̅?|𝐴0 = 𝑎0,𝑊0 = 𝑤0)𝑓𝑊0(𝑤0)
𝑤0∈𝒲0
 (𝑒𝑥𝑐ℎ𝑎𝑛𝑔𝑒𝑎𝑏𝑖𝑙𝑖𝑡𝑦) 
= ∑ ∑ 𝐸(𝑌?̅?|𝐴0 = 𝑎0,𝑊1 = 𝑤1,𝑊0 = 𝑤0)𝑓𝑊1|𝑊0,𝐴0(𝑤1|𝑎0, 𝑤0)𝑓𝑊0(𝑤0)
𝑤1∈𝒲1𝑤0∈𝒲0
 (𝑙𝑎𝑤 𝑜𝑓 𝑡𝑜𝑡𝑎𝑙 𝑝𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦) 
= ∑ ∑ 𝐸(𝑌?̅?|𝐴1 = 𝑎1, 𝐴0 = 𝑎0,𝑊1 = 𝑤1,𝑊0 = 𝑤0)𝑓𝑊1|𝑊0,𝐴0(𝑤1|𝑎0, 𝑤0)𝑓𝑊0(𝑤0)
𝑤1∈𝒲1𝑤0∈𝒲0
 (𝑒𝑥𝑐ℎ𝑎𝑛𝑔𝑒𝑎𝑏𝑖𝑙𝑖𝑡𝑦) 
… (𝑖𝑡𝑒𝑟𝑎𝑡𝑒 𝑢𝑛𝑡𝑖𝑙 𝑡𝑖𝑚𝑒 𝜏)  
= ∑ 𝐸(𝑌?̅?|?̅? = ?̅?, ?̅? = ?̅?)∏𝑓𝑊𝑡|?̅?𝑡−1,?̅?𝑡−1(𝑤𝑡|?̅?𝑡−1, ?̅?𝑡−1)
𝜏
𝑡=0?̅?∈𝒲
 
= ∑ 𝐸(𝑌|?̅? = ?̅?, ?̅? = ?̅?)∏𝑓𝑊𝑡|?̅?𝑡−1,?̅?𝑡−1(𝑤𝑡|?̅?𝑡−1, ?̅?𝑡−1)
𝜏
𝑡=0?̅?∈𝒲
 (𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 𝑎𝑛𝑑 𝑐𝑜𝑛𝑠𝑖𝑠𝑡𝑒𝑛𝑐𝑦) 
In summary, 
𝐸(𝑌?̅?) = ∑ 𝐸(𝑌|?̅? = ?̅?, ?̅? = ?̅?)∏𝑓𝑊𝑡|?̅?𝑡−1,?̅?𝑡−1(𝑤𝑡|?̅?𝑡−1, ?̅?𝑡−1)
𝜏
𝑡=0?̅?∈𝒲
                                                                          (1) 
Equation (1) is the non-parametric g-formula (Robins 1986), which only includes 
expectations and distributions of observed variables. If the covariates are continuous, the sum 
becomes an integral. Intuitively, the g-formula is an extension of standardization. Consider the 
single time-period case. There, (1) becomes 
𝐸(𝑌𝑎) = ∑ 𝐸(𝑌|𝐴 = 𝑎,𝑊 = 𝑤)𝑓𝑊(𝑤)
𝑤∈𝒲 
 
which is exactly the formula for direct standardization. 
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In the setting of a well-designed and properly executed randomized controlled trial with no 
loss to follow-up and perfect compliance, it is reasonable to expect conditions (1) - (3) to be met 
by design. In non-experimental settings or in less ideal experiments, however, the conditions 
cannot as easily be assumed to hold, and care must be taken to evaluate whether each condition 
is reasonable. G-computation is particularly useful for analyzing observational studies in settings 
where randomized controlled trials are either infeasible or unethical. 
The causal diagram (Greenland et al. 1999) in Figure 3.2 represents a two time-period study 
like the one above, and will be used to motivate the need for methods beyond ‘standard’ 
statistical methods to estimate the causal effects of time-varying exposure. According to the 
diagram, to d-separate 𝐴0 from 𝑌, it is sufficient to control for 𝑊0. Similarly, to d-separate 𝐴1 
from 𝑌, it is sufficient to control for 𝑊1, 𝐴0 and 𝑊0. 𝑊1, however, is on the causal pathway 𝐴0 →
𝑊1 → 𝑌, so controlling for 𝑊1 will block an open causal pathway for the exposure of interest, 
leading to bias. Additionally, controlling for 𝑊1 opens the non-causal pathways 𝐴0 → 𝑊1 ←
𝑈1 → 𝑌 and 𝐴0 → 𝑊1 ← 𝑈1 ← 𝑈0 → 𝑌, which may cause additional bias. It is therefore clear 
that standard statistical methods, such as multivariable regression analysis, will lead to biased 
effect estimates in scenarios in which there is time-varying confounding affected by prior 
exposure. As shown above, however, g-computation is capable of estimating the effects in such 
scenarios without bias. 
Because of the high-dimensionality (large number of variables and time-points) of the data in 
typical applications, it is often not possible to nonparametrically identify causal effects. Instead, 
each component of the g-formula can be estimated using parametric or semiparametric models 
(Robins 1986). The use of parametric or semiparametric models adds a fifth identification 
condition: 
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5) Properly specified models 
In this work, to assess model specification, the modelled and observed natural course were 
compared on their survival curves, the proportion of people censored and lost to follow-up, the 
proportion of person-time on ART, the proportion of subjects with chronic HCV at baseline, the 
proportion of person-time with suppressed viral load, the average CD4 cell count at last visit, and 
the proportion of person-time with each time-varying covariate category. If the models differed 
substantially from the observed natural course, a two-step procedure was used to improve model 
fit. First, interaction terms were added to the models in the following order until the values are 
aligned: ART/HCV, ART/Time, HCV/Time, HCV/ART/Time, ART/covariates, 
HCV/covariates, covariates/covariates. Second, to improve parsimony, spline terms were 
removed and variable categories collapsed until the models displayed misalignment. 
One undesirable property of parametric g-computation is the g-null paradox (Robins & 
Wasserman 1997). The g-null paradox states that, if the sharp null hypothesis holds, meaning 
𝑌?̅? = 𝑌?̅?
∗
for every ?̅?, ?̅?∗, then, under certain assumptions, model misspecification is guaranteed 
if typical parametric models are used (e.g. linear and logistic regression) without additional 
precautions. Because the exposures/treatments in this work (HCV, ART) almost certainly have 
an effect on the outcome (death), the sharp null hypothesis is not likely to hold and the g-null 
paradox should not be a major concern.
  
 
6
2
 
Figure 3.2: Causal diagram motivating the g-computation algorithm formula 
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G-computation and survival analysis 
To use g-computation, it is necessary to estimate two separate quantities: the conditional 
probability of the outcome conditional on exposure and covariate history, and the probability 
mass or density function of the covariates conditional on past exposure and covariate histories. 
Well-established methods have been developed to estimate the former quantity in the presence of 
censoring (loss to follow-up and unequal follow-up time between subjects), such as the product-
limit estimator (Kaplan & Meier 1958).  
Risk estimation in this context falls under the rubric of survival analysis. In survival analysis, 
instead of simply being interested in the probability of the outcome, we are instead interested in 
the time to the outcome. Let the time that some individual experiences the outcome of interest be 
denoted 𝑇, and the potential time the individual would experience the outcome had they had 
exposure history ?̅? be 𝑇?̅?. A participant is administratively censored if their event time 𝑇 is 
larger than the endpoint of the study, 𝜏. Participants lost to follow-up are censored at the time the 
definition for loss to follow-up is met (not necessarily at their last missed visit). Let 𝐶𝑡 = 1 if a 
participant is censored by time 𝑡, otherwise 𝐶𝑡 = 0. The survival probability at time 𝑡 (denoted 
𝑆𝑡), the probability of not experiencing the outcome by 𝑡, is 𝑃(𝑇 > 𝑡), and the risk is 𝑅𝑡 = 1 −
𝑃(𝑇 > 𝑘). The discrete-time hazard, which is the probability of experiencing the outcome at 
time 𝑡 conditional on not having experienced the outcome prior to 𝑡, is ℎ𝑡 = 𝑃(𝑇 = 𝑡|𝑇 > 𝑡 −
1). Finally, let 𝑌𝑡 = 0 𝑖𝑓 𝑇 > 𝑡, otherwise 𝑌𝑡 = 1. With this notation, 𝑆𝑡 = 𝑃(𝑌𝑡 = 0), 𝑅𝑡 =
𝑃(𝑌𝑡 = 1) = 1 − 𝑆𝑡, and ℎ𝑡 = 𝑃(𝑌𝑡 = 1|𝑌𝑡−1 = 0). 
The product limit method was used to estimate survival probabilities: 
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𝑃?̂?(𝑌𝑡+1 = 1) = ?̂?𝑡+1 = 1 −∏(1 − 𝑃?̂?(𝑌𝑘+1 = 1|𝑌𝑘 = 0))
𝑡
𝑘=0
 
=∑[𝑃?̂?(𝑌𝑘+1 = 1|?̅?𝑘 = 0)∏𝑃?̂?(𝑌𝑚 = 0|?̅?𝑚−1 = 0)
𝑘
𝑚=0
]
𝑡
𝑘=0
                                                                                                    (2) 
In words, the estimated survival probability by time 𝑡 + 1 is the product of 1 minus the estimated 
discrete-time hazard at each time up to 𝑡 + 1. Estimating the survival probability and thus the 
risk reduces to estimating the discrete-time hazard at each time. 
Recall that individuals in the study may be censored if they are lost to follow-up or if they are 
administratively censored. To validly estimate the survival probability in the presence of such 
censoring, it is necessary to assume that censoring is noninformative or independent, which 
means 𝐶?̅? ⫫ 𝑇|?̅?𝑡−1, ?̅?𝑡−1. In words, this means that censoring history at 𝑡 is independent of 
event time conditional on covariate and exposure history. Hereafter, the potential outcomes 𝑌𝑡
?̅? 
will always include a second intervention to prevent subject-specific censoring and loss to 
follow-up, so 𝑌𝑡
?̅? = 𝑌𝑡
?̅?,𝑐?̅?=0̅. 
In this setting, g-computation can be implemented as follows. First, use survival methods to 
estimate the probability of the outcome conditional on exposure and covariate history and 
remaining uncensored. Second, standardize over the distribution of covariate history conditional 
on exposure history and remaining uncensored. To estimate the former quantity, it is sufficient to 
estimate the time-varying discrete-time hazard function, as shown above. The time-varying 
discrete-time hazard was modelled parametrically using logistic regression with parameters 
estimated with maximum likelihood. Under the assumption that the discrete-time hazard is small 
at each time-point, the parameters from the logistic model will approximate those from a 
discrete-time hazard model.  
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To estimate the probability distribution of covariate history conditional on exposure history 
and remaining uncensored, the distribution of the covariates can be factored in two steps (in the 
following formulas, conditioning on exposure history and remaining uncensored is omitted for 
brevity, though the concepts remain the same). First, 
𝑓?̅?𝑡|…(?̅?𝑡| … ) =∏𝑓𝑊𝑘|?̅?𝑘−1,…(𝑤𝑘|?̅?𝑘−1, … )
𝑡
𝑘=0
                                                                                                                     (3) 
which in words means that the probability distribution of covariate history by 𝑡 is equal to the 
product of the conditional distributions of covariates at each time point conditional on covariate 
history up to that time point. Second, 
𝑓𝑊𝑡|…(𝑤𝑡| … ) =∏𝑓𝑊𝑙,𝑡|𝑊−𝑙,𝑡,…(𝑤𝑙,𝑡|𝑤−𝑙,𝑡 , … )
𝑚
𝑙=1
                                                                                                                   (4) 
where 𝑊𝑙,𝑡 is the 𝑙th covariate at time 𝑡, and 𝑊−𝑙,𝑡 is the vector of all covariates indexed less than 
𝑙 at time 𝑡. This means that the conditional distribution of covariates at time 𝑘 is equal to the 
product of the distributions of each individual covariate conditional on the other covariates at 
time 𝑘 that are prior to that covariate. From (3) and (4), the distribution of the covariate history 
can be factored into the product of the conditional distributions of the individual covariates at 
each time conditional on prior covariate history, thus obviating the need for multivariate 
modelling. These distributions were estimated using parametric models: logistic regression for 
binary covariates and linear regression for continuous covariates, with parameters estimated by 
maximum likelihood. 
Combining the estimator from (2) with the results from (3) and (4), the g-formula in the 
survival context takes the form (adapted from Westreich et al. 2012) 
 66 
 
𝐸(𝑌𝑡+1
?̅? ) = 1 − ∑ [(∏(1 − Pr(𝑌𝑘+1 = 1|?̅?𝑘 = ?̅?𝑘 , ?̅?𝑘 = ?̅?𝑘 , ?̅?𝑘 = 𝐶?̅? = 0))
𝑡
𝑘=0
)∏𝑓(𝑊𝑘|?̅?𝑘−1 = ?̅?𝑘−1, ?̅?𝑘−1 = ?̅?𝑘−1, ?̅?𝑘 = 𝐶?̅? = 0)
𝑡
𝑘=0
]
?̅?𝑡∈𝒲𝑡
=∑ ∑ {
𝑃𝑟(𝑌𝑘+1 = 1|?̅?𝑘 = ?̅?𝑘 , ?̅?𝑘 = ?̅?𝑘, ?̅?𝑘 = 𝐶?̅? = 0) ×
∏[
𝑓(𝑤𝑚|?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚 = 𝐶?̅? = 0) ×
𝑃𝑟(𝑌𝑚 = 0|?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚−1 = 𝐶?̅?−1 = 0)
]
𝑘
𝑚=0
}
?̅?𝑡∈𝒲𝑡
𝑡
𝑘=0
                                                                                               (6) 
where 
𝑓(𝑤𝑘|?̅?𝑘−1 = ?̅?𝑘−1, ?̅?𝑘−1 = ?̅?𝑘−1, ?̅?𝑘 = 𝐶?̅? = 0)
=∏𝑓𝑊𝑙,𝑘|𝑊−𝑙,𝑘,?̅?𝑘−1,?̅?𝑘−1,?̅?𝑘,?̅?𝑘(𝑤𝑙,𝑘|𝑤−𝑙,𝑘 , ?̅?𝑘−1, ?̅?𝑘, 0,0)
𝑚
𝑙=1
 
Note that the independent censoring assumption allows for conditioning on 𝐶?̅? = 0. By 
replacing the probabilities and distributions in (5) with their respective estimates from properly 
specified models, we can obtain a valid estimate ?̂?(𝑌𝑡+1
?̅? ). Confidence intervals and standard 
errors of the estimate are obtained with the nonparametric bootstrap (Efron & Tibshirani 1986). 
The natural course  
Because all of the components of the g-formula are estimated from the data, it is advisable to 
perform tests to check for proper model specification. One such model check is to compare their 
results to the so-called natural course, which is the observed cumulative incidence function in the 
study. While alignment with the natural course is neither necessary nor sufficient for valid effect 
estimation, it does provide a degree of confidence in the model specification. To estimate the 
natural course, it is sufficient to estimate the joint distribution of the data and sum over exposure 
and covariate histories as follows (Westreich et al. 2012) 
𝐸(𝑌𝑡+1) = ∑ ∑ ∑
{
 
 
 
 
𝑃𝑟(𝑌𝑘+1 = 1|?̅?𝑘 = ?̅?𝑘 , ?̅?𝑘 = ?̅?𝑘 , ?̅?𝑘 = 𝐶?̅? = 0) ×
∏
[
 
 
 
 
𝑓(𝑤𝑚|?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚 = 𝐶?̅? = 0) ×
𝑃𝑟(𝑌𝑚 = 0|?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚−1 = 𝐶?̅?−1 = 0) ×
𝑃𝑟(𝐶𝑚 = 0|?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚 = 𝐶?̅?−1 = 0) ×
𝑓(𝐴𝑚 = 𝑎𝑚|?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚 = 𝐶?̅? = 0) ]
 
 
 
 𝑘
𝑚=0
}
 
 
 
 
?̅?𝑡∈𝒜𝑡?̅?𝑡∈𝒲𝑡
𝑡
𝑘=0
                                         (7) 
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which requires additional models for the censoring and exposure processes.  
As an aside, note that (6) and (7) allow for another interpretation of the g-formula: a 
modification to the distribution of the data in which the distributions of the exposure and 
censoring histories are replaced with a degenerate distribution taking value 1 at the exposure and 
censoring histories of interest (Robins & Hernán 2009). 
G-computation in practice  
Due to the large number of covariates and time points, it may not be possible to sum over all 
possible covariate histories needed for g-computation. Instead, Monte Carlo simulation can be 
used as follows (adapted from (Taubman et al. 2009; Westreich et al. 2012; Keil et al. 2014)): 
1) Using the entire study sample, use maximum likelihood to estimate the parameters of 
models for 
a. The density of covariates at time 𝑘 conditional on covariate history, exposure 
history, and not experiencing the outcome and remaining uncensored through 
time 𝑘 
b.  The discrete-time hazard of the outcome by visit 𝑘 + 1 conditional on covariate 
history, exposure history, and remaining uncensored through time 𝑘. 
c. If estimating the natural course additionally estimate models for the following, 
otherwise continue to (2) 
i. The probability of exposure at time 𝑘 conditional on covariate history, 
exposure history, remaining uncensored through time 𝑘, and not 
experiencing the outcome and remaining uncensored by time 𝑘. 
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ii. The probability of remaining uncensored through time 𝑘 + 1 conditional 
on covariate history, exposure history, not experiencing the outcome and 
remaining uncensored by time 𝑘. 
2) Randomly select with replacement a large sample (in this case, n=50,000) of the 
participants in the study 
3) For each subject in the sample 
a. Set time 𝑘  to 0. Assign the subjects their baseline covariates (values at 𝑘 = 0) 
from the input data and set baseline exposure to the exposure level of interest 
i. If estimating the natural course, rather than assigning exposure at this 
step, use the observed value of baseline exposure. 
b. Estimate the discrete-time hazard of the outcome by time 𝑘 + 1 conditional on 
previously assigned covariates and exposure history through time 𝑘 and 
remaining uncensored through time 𝑘 using the parameters estimated in 1b. 
i. If estimating the natural course, also estimate the probability that the 
subject was lost to follow-up at time 𝑘 + 1 conditional on previously 
assigned covariate and exposure history through time 𝑘 and remaining 
uncensored through time 𝑘 using the estimated parameters for the model 
in 1cii. Draw a Bernoulli variable with this probability. If this variable, 
which represents loss to follow-up, takes the value 1, record the subject as 
lost to follow-up, and proceed to the next subject. 
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c. Increment 𝑘 by 1. For each subject draw covariates for time 𝑘 with probabilities 
conditional on previously assigned covariate and exposure history through 𝑘 − 1 
and remaining uncensored and free of the outcome through time 𝑘 using the 
parameters estimated in step 1a. Set exposure to the value for time 𝑘 from the 
exposure regime of interest. 
i. If estimating the natural course, rather than setting exposure, draw a 
value of exposure for time 𝑘 from the estimated parameters for the model 
in 1ci conditional on previously assigned covariate and exposure history 
through 𝑘 − 1 and remaining uncensored and free of the outcome through 
time 𝑘. 
d. Repeat 3b-3c for that subject until 𝑘 = 𝑡, that is, until the end of follow-up. 
e. Use the estimated discrete-time hazards from each time point in the product-limit 
estimator to estimate the probability of survival to time 𝑡 for that subject  
i. If estimating the natural course, weight each subject by the cumulative 
probability of remaining uncensored by time 𝑡. 
4) Average the predicted survival probabilities across subjects, use 1 minus that average as 
an estimate of the risk of the outcome by 𝑡 under the assigned exposure regime. 
5) Repeat step 3-4 for each exposure regime of interest. 
a. Compare across exposure regimes of interest to estimate causal contrasts. 
6) Estimate standard errors and confidence intervals with the non-parametric bootstrap 
(Efron & Tibshirani 1986). For this work, 1000 bootstrap samples were used. 
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Intuitively, this algorithm works by creating datasets based on modified data distributions in 
which exposure takes on each exposure regime of interest with probability 1. The survival 
probability estimated in this dataset is an estimate of the potential survival probability under the 
assigned exposure regime. When the algorithm is used for the natural course, a dataset is 
generated using the unmodified data distribution. If the models are properly specified, the 
survival probabilities and features of the covariate densities from this dataset should be the same 
as in the original data. 
3.5 Inverse probability weighted estimation of marginal structural models 
The use of g-computation is one of several methods for estimating causal effects. One 
alternative, for instance, is the nonparametric inverse probability weighted estimator. For a time-
fixed exposure and binary outcome, it is straightforward to derive the nonparametric inverse 
probability weighted estimator starting from the nonparametric g-formula estimator as follows: 
?̂?(𝑌𝑎) = ∑ 𝑃?̂?(𝑌 = 1|𝐴 = 𝑎,𝑊 = 𝑤)𝑃?̂?(𝑊 = 𝑤)
𝑤∈𝒲
= ∑
∑ 𝐼(𝑌𝑖 = 1, 𝐴𝑖 = 𝑎,𝑊𝑖 = 𝑤)
𝑛
𝑖=1
∑ 𝐼(𝐴𝑖 = 𝑎,𝑊𝑖 = 𝑤)
𝑛
𝑖=1
∗
∑ 𝐼(𝑊𝑖 = 𝑤)
𝑛
𝑖=1
𝑛
𝑤∈𝒲
=
1
𝑛
∑
∑ 𝐼(𝑌𝑖 = 1, 𝐴𝑖 = 𝑎,𝑊𝑖 = 𝑤)
𝑛
𝑖=1
∑ 𝐼(𝐴𝑖 = 𝑎,𝑊𝑖 = 𝑤)
𝑛
𝑖=1 /∑ 𝐼(𝑊𝑖 = 𝑤)
𝑛
𝑖=1𝑤∈𝒲
=
1
𝑛
∑ ∑
𝑌𝑖𝐼(𝐴𝑖 = 𝑎,𝑊𝑖 = 𝑤)
Pr̂ (𝐴𝑖 = 𝑎|𝑊𝑖 = 𝑤)
𝑛
𝑖=1𝑤∈𝒲
=
1
𝑛
∑
𝑌𝑖𝐼(𝐴𝑖 = 𝑎)
Pr̂ (𝐴𝑖 = 𝑎|𝑊𝑖 = 𝑤𝑖)
𝑛
𝑖=1
 
Perhaps the most widely used method (more widely used than g-computation) for estimating 
the causal effects of time-varying exposure regimes is the estimation of marginal structural 
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models (MSM) with inverse probability weighted (IPW) estimating equations (Robins et al. 
2000).  
A MSM is a model of the form 
𝐸(𝑌𝑡
?̅?) = 𝑔(?̅?, 𝑡; 𝜃) 
which is marginal because it models the marginal distribution of the potential outcomes and is 
structural because it is a model for the potential outcomes (Robins et al. 2000). The IPW 
estimating equations estimation of MSMs involves two steps. First, construct weights for each 
individual of the form 𝑠𝑤𝑡 = 𝑠𝑤𝑡
𝐴 ∗ 𝑠𝑤𝑡
𝐶, where 
𝑠𝑤𝑡
𝐴 =
∏ 𝑃(𝐴𝑘 = 𝑎𝑘|?̅?𝑘−1 = ?̅?𝑘−1)
t
k=0
∏ 𝑃(𝐴𝑘 = 𝑎𝑘|?̅?𝑘−1 = ?̅?𝑘−1, ?̅?𝑘 = ?̅?𝑘)
𝑡
𝑘=0
 
and  
𝑠𝑤𝑡
𝐶 =
∏ 𝑃(𝐶𝑘 = 0|?̅?𝑘−1 = ?̅?𝑘−1,𝑖, 𝐶?̅?−1 = 0)
t
k=0
∏ 𝑃(𝐶𝑘 = 0|𝐶?̅?−1 = 0, ?̅?𝑘−1 = ?̅?𝑘−1,𝑖, ?̅?𝑘 = ?̅?𝑘)
𝑡
𝑘=0
 
where each of the probabilities needed for the weights can be estimated with properly specified 
parametric, semiparametric, or nonparametric models. 
Second, estimate the parameters of the model  
𝐸(𝑌𝑡|?̅? = ?̅?) = ℎ(?̅?, 𝑡; 𝛾) 
using the uncensored subjects with each subject weighted by their estimated weight 𝑠?̂?𝑡.  If the 
models for the weights are properly specified, then the estimated parameters 𝛾 are valid 
estimates of the parameters 𝜃 (Robins et al. 2000). 
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Intuitively, IPW estimation of MSMs works by creating a pseudo-population in which the 
groups subjects who had each exposure regime, as well as the censored and uncensored groups, 
are unconditionally exchangeable (Cole & Hernán 2008). The exposure weights 𝑠𝑤𝑡
𝐴 standardize 
the distribution of the covariates among each group to be the same as the distribution of the 
covariates in the entire study population. Similarly, the censoring weights 𝑠𝑤𝑡
𝐶 standardize the 
distribution of the covariates in the uncensored in a given exposure group to be the same as that 
entire group. Another way to conceptualize this is that after weighting, each uncensored 
exposure regime group represents a copy of the entire population (scaled down to the size of that 
particular uncensored exposure group) had they been set to that exposure regime and been 
prevented from being censored. Because the exposure regime groups and the censored and 
uncensored are exchangeable in the pseudo-population, association in the pseudo-population can 
be interpreted as causation, and the parameters from conditional models will estimate the 
parameters from MSMs. 
IPW estimation of MSMs can be used in the survival context as well. Such estimation can 
proceed in four steps (adapted from Westreich et al. 2010) 
1) Estimate the time-varying weights 𝑠𝑤𝑡 for each individual at each time, as described 
above. 
2) Nonparametrically estimate the discrete-time hazards for each exposure regime at each 
time 𝑘 in the uncensored population weighted by 𝑠𝑤𝑘 using the Kaplan-Meier estimator 
(Kaplan & Meier 1958)  
𝑃?̂?(𝑌𝑘+1 = 1|?̅?𝑘 = 𝐶?̅? = 0, ?̅?𝑘 = ?̅?𝑘) =
𝑑𝑘,?̅?
𝑟𝑘,?̅?
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where  
𝑑𝑘,?̅? =∑𝑠𝑤𝑖,𝑘 ∗ 𝑌𝑖,𝑘+1 ∗ 𝐼(?̅?𝑖,𝑘 = ?̅?𝑘, 𝐶?̅?,𝑘 = ?̅?𝑖,𝑘 = 0)
𝑛
𝑖=1
 
And 
𝑟𝑘,?̅? =∑𝑠𝑤𝑖,𝑘 ∗ 𝐼(?̅?𝑖,𝑘 = ?̅?𝑘, 𝐶?̅?,𝑘 = ?̅?𝑖,𝑘 = 0)
𝑛
𝑖=1
 
Note that instead of conditioning on the entire exposure history, practical applications 
often condition on only the 𝑘 most recent exposures (Westreich et al. 2010). In such a 
case, the estimator is no longer nonparametric, and the structural model must be properly 
specified for valid estimation (Breskin et al. 2018). 
3) Estimate the distribution of the potential outcomes at 𝑡 + 1 as 
𝑃?̂?(𝑌𝑡+1
?̅? = 0) = 𝑆𝑡+1
?̅? =∏(1 − 𝑃?̂?(𝑌𝑘+1 = 1|?̅?𝑘 = 𝐶?̅? = 0, ?̅?𝑘 = ?̅?𝑘))
𝑡
𝑘=0
 
4) Use the nonparametric bootstrap to estimate standard errors and confidence intervals 
(Efron & Tibshirani 1986). 
Because the models that need to be specified for IPW estimation of MSMs (structural model, 
exposure model, censoring model) are orthogonal to the models that need to be specified for g-
computation (outcome model, covariates model), obtaining similar results from both methods 
adds reassurance that the models for each method may be properly specified. Of note, IPW 
estimation of MSMs is not subject to the g-null paradox. 
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Many other methods exist for the estimation of the distribution of potential outcomes, such as 
g-estimation of structural nested models (Robins 1999), augmented inverse probability weighted 
estimators (Bang & Robins 2005), and targeted maximum likelihood estimators (van der Laan & 
Rubin 2006). Though these estimators have many desirable properties such as double robustness 
and semiparametric efficiency, they were not used in this work. 
3.6 Policy-relevant effect measures 
Commonly used effect measures, such as the risk difference and risk ratio, are not ideal for 
comparing interventions for different conditions. These measures do not take into account the 
effectiveness of the intervention, the proportion of the population to which the intervention 
would apply, nor the prevalence of the exposure in the population. Different effect measures, 
such as the population intervention effects (Hubbard & Van Der Laan 2008; Westreich 2014; 
Westreich 2017), may be better suited for such purposes. Unlike standard effect measures, which 
compare an entire population being exposed to the same population being unexposed, these 
policy-relevant effects compare the observed experience (natural course) of the population to that 
which would occur under an intervention applied to some subset of the population. Because 
these effects may take into account the effectiveness of the intervention, the proportion 
intervened upon, and the prevalence of exposure, they can be used to compare the effects of 
interventions for different conditions or different policies for treating a single condition. 
For simplicity, we present results for a baseline treatment and exposure, though these results 
can be extended for time-varying treatments and exposures. We present results definitions and 
results specific to the difference scale, though these effects can be defined on any scale of 
interest. Note that many of the relationships described here do not hold on other scales. The 
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fundamental quantity underlying these policy-relevant effects is the average effect of policy 
among the exposed (APEX), defined as: 
𝐴𝑃𝐸𝑋 = 𝐸[𝑌|𝐻 = 1] − 𝐸[𝑌𝐷=1,𝐻=1|𝐻 = 1] 
where 𝐻, 𝐷, 𝑌, and 𝑌𝐷=𝑑,𝐻=ℎ are binary random variables, with 𝐻 equal to 1 if a person was 
observed to have the exposure (i.e. hepatitis C infection at baseline), 𝐷 equal to 1 if a person 
received treatment (i.e. DAA), 𝑌 equal to 1 if a person experienced the event (i.e. death by 10 
years), and 𝑌𝐷=𝑑,𝐻=ℎ equal to 1 if the person would have experienced the outcome of interest if, 
possibly counter to fact, they had received treatment level 𝑑 and had exposure level ℎ. We 
assume that treatment has no effect on people who are not exposed, so 𝑌𝐷=1,𝐻=0 = 𝑌𝐷=0,𝐻=0. 
Hereafter we will refer to the potential outcome under no exposure, regardless of treatment, as 
𝑌𝐻=0. The APEX thus contrasts the observed outcomes among people with exposure to the 
outcome that would be expected if all people with the exposure received treatment.  
When the treatment is 100% effective, works instantaneously (or nearly so), completely 
eliminates the effect of exposure, and has no side effects, treatment becomes the same as erasing 
exposure (𝑌𝐷=1,𝐻=1 = 𝑌𝐻=0). The APEX can then be expressed as: 
𝐴𝑃𝐸𝑋 = 𝐸[𝑌|𝐻 = 1] − 𝐸[𝑌𝐻=0|𝐻 = 1] 
If treatment is unsuccessful, we assume treatment has no impact on the outcome among the 
exposed (it has no effect on the exposure and has no side effects), and thus 𝑌𝐷=1,𝐻=1 can take on 
one of two forms, either 𝑌𝐷=1,𝐻=1 = 𝑌𝐻=0 (treatment was successful) or 𝑌𝐷=1,𝐻=1 = 𝑌𝐷=0,𝐻=1 
(treatment was unsuccessful). We define 𝑅 = 𝐼[𝑌𝐷=1,𝐻=1 = 𝑌𝐻=0] as an indicator of successful 
treatment, where 𝐼 is the indicator function. Assuming that treatment success is independent of 
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the values of 𝑌𝐷=1,𝐻=1 and 𝑌𝐻=0 (though not {𝑌𝐷=1,𝐻=1, 𝑌𝐻=0}) among the exposed (e.g. 
treatment success is essentially random), the APEX is then: 
𝐴𝑃𝐸𝑋 = 𝐸[𝑌|𝐻 = 1] − 𝐸[𝑌𝐷=1,𝐻=1 = 1|𝐻 = 1] 
= 𝐸[𝑌|𝐻 = 1] − 𝐸[𝑅 × 𝑌𝐻=0 + (1 − 𝑅) × 𝑌𝐷=0,𝐻=1|𝐻 = 1] 
= 𝐸[𝑌|𝐻 = 1] − (𝐸[𝑌𝐻=0|𝐻 = 1) × 𝑃𝑟(𝑅 = 1|𝐻 = 1) + 𝐸[𝑌𝐷=0,𝐻=1|𝐻 = 1] × (1 − 𝑃𝑟(𝑅 = 1|𝐻 = 1)) 
In the present study, we assume that no individuals received treatment at baseline (as nearly all 
of the study period predates the introduction of DAAs), so by causal consistency: 
𝐸[𝑌|𝐻 = 1] = 𝐸[𝑌𝐷=0,𝐻=1|𝐷 = 0,𝐻 = 1] × Pr(𝐷 = 0|𝐻 = 1) + 𝐸[𝑌𝐷=1,𝐻=1|𝐷 = 1,𝐻 = 1] × Pr(𝐷 = 1|𝐻 = 1) 
= [𝑌𝐷=0,𝐻=1|𝐷 = 0,𝐻 = 1] 
= [𝑌𝐷=0,𝐻=1|𝐻 = 1] 
We then have: 
𝐴𝑃𝐸𝑋 = (𝐸[𝑌|𝐻 = 1] − 𝐸[𝑌𝐻=0|𝐻 = 1]) × 𝑃𝑟(𝑅 = 1|𝐻 = 1) 
In words, this means that the APEX is equal to the APEX under perfectly effective treatment 
times the probability that treatment is effective among the exposed. 
In contrast to the APEX, which is only estimated among those with exposure, the population 
attributable risk difference is estimated among the entire population of interest (Westreich 2017). 
The population attributable risk difference compares the risk in the entire population to the risk if 
all of the exposed were treated with a treatment that is 100% effective. The population 
attributable risk difference can be defined as: 
𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝐴𝑡𝑡𝑟𝑖𝑏𝑢𝑡𝑎𝑏𝑙𝑒 𝑅𝑖𝑠𝑘 𝐷𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 
= 𝐸[𝑌] − (𝐸[𝑌𝐷=1,𝐻=1|𝐻 = 1] × Pr(𝐻 = 1) + 𝐸[𝑌|𝐻 = 0) × Pr(𝐻 = 0)) 
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= 𝐸[𝑌] − (𝐸[𝑌𝐻=0|𝐻 = 1] × 𝑃𝑟(𝐻 = 1) + 𝐸[𝑌|𝐻 = 0] × 𝑃𝑟(𝐻 = 0)) 
= (𝐸[𝑌|𝐻 = 1] × 𝑃𝑟(𝐻 = 1) + 𝐸[𝑌|𝐻 = 0] × 𝑃𝑟(𝐻 = 0))
− (𝐸[𝑌𝐻=0|𝐻 = 1] × 𝑃𝑟(𝐻 = 1) + 𝐸[𝑌|𝐻 = 0] × 𝑃𝑟(𝐻 = 0)) 
= 𝑃𝑟(𝐻 = 1) × (𝐸[𝑌|𝐻 = 1] − 𝐸[𝑌𝐻=0|𝐻 = 1])  
= 𝑃𝑟(𝐻 = 1) × 𝐴𝑃𝐸𝑋 
Often, interest lies in the effect of policies under which people receive treatment based on 
their covariate values, referred to as the dynamic effect of policy in the exposed (DPEX). The 
DPEX compares the risk of the outcome among the exposed to the risk had certain exposed 
individuals been treated based on the values of their covariates. For a baseline exposure and 
treatment, the DPEX is: 
𝐷𝑃𝐸𝑋 
= 𝐸[𝑌|𝐻 = 1] − (∑(𝐸[𝑌𝐷=1,𝐻=1|𝐺 = 𝑔,𝐻 = 1]) × Pr(𝐺 = 𝑔|𝐻 = 1)
𝑔∈𝒢
+∑(𝐸[𝑌|𝐺 = 𝑔,𝐻 = 1]) × Pr(𝐺 = 𝑔|𝐻 = 1)
𝑔∉𝒢
) 
= 𝐸[𝑌|𝐻 = 1] − (∑(𝐸[𝑌𝐻=0|𝐺 = 𝑔,𝐻 = 1] × Pr(𝑅 = 1|𝐺 = 𝑔,𝐻 = 1)
𝑔∈𝒢
+ E(Y|G = g, H = 1) × (1 − Pr(R = 1|G = g, H = 1)) × Pr (𝐺 = 𝑔|𝐻 = 1)
+∑(𝐸[𝑌|𝐺 = 𝑔,𝐻 = 1]) × Pr(𝐺 = 𝑔|𝐻 = 1)
𝑔∉𝒢
) 
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=∑𝐸[𝑌|𝐺 = 𝑔,𝐻 = 1] × Pr (𝐺 = 𝑔|𝐻 = 1)
𝑔∈𝒢
−∑(𝐸[𝑌𝐻=0|𝐺 = 𝑔,𝐻 = 1] × Pr (𝑅 = 1|𝐺 = 𝑔,𝐻
𝑔∈𝒢
= 1) + E(Y|G = g, H = 1) × (1 − Pr(𝑅 = 1|𝐺 = 𝑔,𝐻 = 1)) × Pr (𝐺 = 𝑔|𝐻 = 1) 
=∑Pr (𝐺 = 𝑔|𝐻 = 1) ×
𝑔∈𝒢
Pr(𝑅 = 1|𝐺 = 𝑔,𝐻 = 1) × (𝐸[𝑌|𝐺 = 𝑔,𝐻 = 1] −  𝐸[𝑌𝐻=0|𝐺 = 𝑔,𝐻 = 1]) 
=∑Pr (𝐺 = 𝑔|𝐻 = 1) ×
𝑔∈𝒢
𝐴𝑃𝐸𝑋𝑔 
where subgroups are defined by 𝑔, 𝒢 is the set of subgroups that receive treatment under the 
given policy, 𝐴𝑃𝐸𝑋𝑔 is the APEX in subgroup 𝑔.  
Similar to the population intervention effect, the dynamic intervention risk difference 
compares the risk in the entire population of interest to the risk in the entire population if certain 
exposed individuals were treated based on the values of their covariates (Westreich 2017). For 
instance, the difference in the 10-year risk of mortality observed in the entire population of 
PLWH and the risk in that population if all of those coinfected with HCV with severe 
fibrosis/cirrhosis are treated with DAAs is an example of a dynamic intervention risk difference. 
The dynamic intervention risk difference is: 
𝐷𝑦𝑛𝑎𝑚𝑖𝑐 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝑟𝑖𝑠𝑘 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 
= 𝐸[𝑌] − (𝐸[𝑌|𝐻 = 0] × Pr(𝐻 = 0)
+ (∑(𝐸[𝑌𝐷=1,𝐻=1|𝐺 = 𝑔,𝐻 = 1]) × Pr(𝐺 = 𝑔|𝐻 = 1)
𝑔∈𝒢
+∑(𝐸[𝑌|𝐺 = 𝑔,𝐻 = 1]) × Pr(𝐺 = 𝑔|𝐻 = 1)
𝑔∉𝒢
) × Pr(𝐻 = 1)) 
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= Pr(𝐻 = 1) × (𝐸[𝑌|𝐻 = 1]
− (∑𝐸[𝑌𝐷=1,𝐻=1|𝐺 = 𝑔,𝐻 = 1] × Pr(𝐺 = 𝑔|𝐻 = 1)
𝑔∈𝒢
+∑𝐸[𝑌|𝐺 = 𝑔,𝐻 = 1] × Pr(𝐺 = 𝑔|𝐻 = 1)
𝑔∉𝒢
)) 
= Pr(𝐻 = 1) × 𝐷𝑃𝐸𝑋 
Finally, one may be interested in the effect of treating randomly selected exposed individuals 
at baseline. Such effects are referred to as the generalized effect of policy in the exposed (GPEX), 
defined as: 
𝐺𝑃𝐸𝑋 
= 𝐸[𝑌|𝐻 = 1] − (𝑝 × 𝐸[𝑌𝐷=1,𝐻=1|𝐻 = 1] + (1 − 𝑝) × 𝐸[𝑌|𝐻 = 1]) 
= 𝐸[𝑌|𝐻 = 1] − (𝑝 × 𝐸[𝑌𝐻=0|𝐻 = 1] + (1 − 𝑝) × 𝐸[𝑌|𝐻 = 1]) 
= 𝑝 × (𝐸[𝑌|𝐻 = 1] − (𝐸[𝑌𝐻=0|𝐻 = 1] × Pr (𝑅 = 1|𝐻 = 1) + 𝐸[𝑌|𝐻 = 1] × (1 − Pr (R = 1|H = 1))  
= 𝑝 × Pr(𝑅 = 1|𝐻 = 1) × (𝐸[𝑌|𝐻 = 1] − 𝐸[𝑌𝐻=0|𝐻 = 1]) 
= 𝑝 × APEX 
where 𝑝 is the proportion of the exposed who are treated. 
Again, a population intervention analog of the GPEX exists, and is known as the generalized 
intervention risk difference (Westreich 2017). The generalized intervention risk difference 
compares the risk in the entire population to the risk if randomly selected exposed individuals 
receive treatment. The generalized intervention risk difference is: 
𝐺𝑒𝑛𝑒𝑟𝑎𝑙𝑖𝑧𝑒𝑑 𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝑟𝑖𝑠𝑘 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 
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= 𝐸[𝑌] − (𝐸[𝑌|𝐻 = 0] × Pr[𝐻 = 0] + (𝑝 × 𝐸[𝑌𝐷=1,𝐻=1|𝐻 = 1] + (1 − 𝑝) × 𝐸[𝑌|𝐻 = 1]) × Pr(𝐻 = 1)) 
= Pr(𝐻 = 1) × (𝐸[𝑌|𝐻 = 1] − (𝑝 × 𝐸[𝑌𝐷=1|𝐻 = 1] + (1 − 𝑝) × 𝐸[𝑌|𝐻 = 1])) 
= Pr(𝐻 = 1) × 𝐺𝑃𝐸𝑋  
 Estimation of these effects can be accomplished with modifications to the g-computation 
estimation procedure, as follows: 
1) Using the entire study sample, use maximum likelihood to estimate the parameters of 
models for 
a. The density of time-varying covariates at time 𝑘 conditional on covariate history, 
exposure history, and not experiencing the outcome and remaining uncensored 
through time 𝑘 
b.  The discrete-time hazard of the outcome by visit 𝑘 + 1 conditional on covariate 
history, exposure history, and remaining uncensored through time 𝑘. 
2) Randomly select with replacement a large sample (in this case, n=50,000) of the 
participants in the study with exposure at baseline 
3) For each subject in the sample 
a. Set time 𝑘  to 0. Assign the subjects their baseline covariates (values at 𝑘 = 0) 
from the input data and set baseline exposure to the exposure level of interest if 
the conditions for intervention are met 
b. Estimate the discrete-time hazard of the outcome by time 𝑘 + 1 conditional on 
previously assigned covariates and exposure history through time 𝑘 and 
remaining uncensored through time 𝑘 using the parameters estimated in 1b. 
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c. Increment 𝑘 by 1 For each subject draw covariates for time 𝑘 with probabilities 
conditional on previously assigned covariate and exposure history through 𝑘 − 1 
and remaining uncensored and free of the outcome through time 𝑘 using the 
parameters estimated in step 1a. Set exposure to the value for time 𝑘 from the 
exposure regime of interest if the conditions for intervention are met. 
d. Repeat 3b-3c for that subject until 𝑘 = 𝑡, that is, until the end of follow-up. 
4) Use the estimated discrete-time hazards from each time point in the product-limit 
estimator to estimate the probability of survival to time 𝑡 for that subject  
5) Average the predicted survival probabilities across subjects, use 1 minus that average as 
an estimate of the risk of the outcome by 𝑡 under the assigned exposure regime 
6) Repeat step 3-4 for each intervention of interest. 
7) Estimate the effect measure 
a. For the APEX, simply take the difference of the estimates from each intervention. 
b. For the GPEX, multiply the difference of the estimates by the proportion treated. 
c. For the population intervention analogs of the effects, multiply the APEX, GPEX, 
or DPEX by the prevalence of exposure in the population. 
8) Estimate standard errors and confidence intervals with the non-parametric bootstrap 
(Efron & Tibshirani 1986).  
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a. When using the bootstrap for the generalized effects, randomly assign treatment 
within the simulation and skip step 6b. This captures the variability due to the 
random treatment selection process. 
It may be useful to cast these policy-relevant effects as a public health analog of precision 
medicine (Collins & Varmus 2015). Rather than tailoring individual treatments to patients based 
on their individual characteristics to maximize the benefit to the patient, these effects tailor 
policy-level interventions to target those members of the population who are most likely to 
benefit from the policy. Such targeted interventions may improve the effectiveness, both in terms 
of outcomes and cost, compared with interventions that are targeted to an entire population. 
Incorporating cost-effectiveness measures into the estimation of these effects is a natural next 
step to connect the fields of epidemiology and health policy, and will connect research from 
‘bench to bedside, and from bedside to policy.’ 
3.7 Estimating hepatitis C infection and treatment effects from observational data 
Under certain assumptions, the effects of HCV infection and DAA treatment can be 
estimated separately without data on DAA usage. Consider Figure 3.2. For the effect of HCV 
infection, the variable 𝐻𝐶𝑉 𝐴𝑐𝑞𝑢𝑖𝑠𝑖𝑡𝑖𝑜𝑛 is the exposure of interest. For this exposure, fibrosis 
lies on the causal pathway between exposure and outcome, and therefore should not be 
accounted for in the analysis as it is a mediator of the effect of HCV infection on mortality. 
For the effect of HCV treatment, the exposure is 𝐻𝐶𝑉0. Here, accounting for fibrosis blocks 
confounding pathways, and therefore should be accounted for in the analysis. Intuitively, this 
holds baseline fibrosis constant, so that an individual’s liver damage is not immediately reversed 
after HCV treatment, as would happen with actual DAA treatment. In contrast, when fibrosis is 
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not accounted for, toggling baseline HCV status also toggles baseline fibrosis, thus emulating 
what would happen if subjects acquired or never acquired HCV. Assuming HCV primarily 
impacts mortality through pathways that involve liver damage, and that curing HCV with DAAs 
has no effect besides halting HCV’s effect on liver damage, this method allows for the estimation 
of the effect of treatment without actually having data on patients treated with DAAs. Stated 
differently, under the assumption that an individual without HCV with a given degree of liver 
fibrosis at baseline has the same risk of mortality as a similar individual after successful 
treatment of their HCV infection (conditional on confounders), the survival experience of HCV-
uninfected PLWH can serve as a proxy for the experience PLWH+HCV would have had if they 
were treated with DAAs. Technically, PLWH without HCV infection are assumed to be 
conditionally exchangeable (Hernán & Robins 2017) with treated PLWH+HCV given baseline 
fibrosis and confounders. Additionally, it is assumed that someone with a given set of baseline 
characteristics has the same risk of mortality whether they never had HCV or were successfully 
treated for HCV. A thorough discussion of these assumptions is provided in Chapter 6. 
 84 
 
 
 
 
CHAPTER 4: THE EFFECTS OF HEPATITIS C INFECTION AND TREATMENT ON 
ALL-CAUSE MORTALITY AMONG PEOPLE LIVING WITH HIV 
 
4.1 Introduction 
With modern antiretroviral therapy (ART), life expectancies for people living with HIV 
(PLWH) are approaching those of HIV seronegative individuals (Samji et al. 2013). While 
AIDS-related causes of death continue to decline (Smith et al. 2014), liver-related complications 
have emerged as a major source of mortality, largely driven by co-infection with viral hepatitides 
(Weber et al. 2013).  
In the United States (US), an estimated 25% of PLWH are co-infected with HCV (Centers 
for Disease Control and Prevention 2017a). However, the effect of HCV on mortality among 
PLWH remains unclear. In the era of effective and less toxic ART,  studies estimated that all-
cause mortality rates are up to two-fold higher among individuals with HIV/HCV co-infection 
(Anderson et al. 2004; May et al. 2015), but others found more modest effects (Thornton et al. 
2017; Scherzer et al. 2017). Most studies investigating the role of HCV co-infection on mortality 
among PLWH were conducted prior to ART guidelines recommending treatment for all PLWH 
regardless of CD4 cell count (Panel on Antiretroviral Guidelines for Adults and Adolescents 
2018). These studies also pre-date direct acting antiviral (DAA) medications, which are capable 
of reliably producing sustained HCV virologic response (SVR) in more than 97% of individuals 
(Afdhal et al. 2014), irrespective of HIV status (Milazzo et al. 2017).  
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Though DAA treatment is considered curative, it may not fully reverse the effects of HCV 
infection, and thus infection and treatment effects may differ (Westreich 2014). Although data 
are accumulating that DAAs reduce complications of HCV infection (van der Meer & Berenguer 
2016; Ioannou et al. 2017) and improve survival (Butt et al. 2017; Backus et al. 2018), treatment 
does not immediately reverse liver fibrosis. Therefore, mortality risk may remain elevated in 
successfully treated individuals. 
Without estimates of the long-term impacts of HCV co-infection and DAA treatment on 
mortality in those initiating modern ART, it is difficult for clinicians and policy-makers to 
properly prioritize HCV care among PLWH. We thus separately estimated the long-term effects 
of HCV infection and DAA treatment on all-cause mortality among PLWH under modern 
guidelines suggesting ART initiation regardless of CD4 cell count. Because DAAs are a recent 
development, there is insufficient person-time to directly estimate their effects on long-term 
mortality. We thus used a novel application of the parametric g-formula (Robins 1986) in which 
HCV-uninfected PLWH serve as proxies for DAA-treated PLWH+HCV with the same degree of 
liver fibrosis. 
4.2 Methods 
Study sample 
Data came from the Women’s Interagency HIV Study (WIHS) (Barkan et al. 1998; Adimora 
et al. 2018) and the Multicenter AIDS Cohort Study (MACS) (Kaslow et al. 1987). Briefly, the 
WIHS and MACS are ongoing US-based cohort studies of HIV-infected and -uninfected women 
and men who have sex with men, respectively. MACS began in 1984, with additional 
recruitment waves in 1987, 2001, and 2010 at four urban locations. WIHS began in 1994 at six 
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urban locations, with additional recruitment waves in 2001, 2011, and 2013, eventually 
expanding to 10 urban and suburban sites. In both studies, laboratory procedures, clinical 
examinations, and structured interviews are conducted at entry and every six months thereafter. 
Information collected through interview includes self-reported medication use along with 
demographic, socioeconomic, and behavioral characteristics. The laboratory procedures included 
measures of, in particular, CD4 cell count, HIV RNA, HCV Ab and RNA, and non-invasive 
markers of liver fibrosis. 
Individuals included in our cohort were HIV-infected at study entry or seroconverted during 
follow-up. Visits occurring after the opening of WIHS recruitment (October 1, 1994) were 
included. All participants were ART-naïve and without an AIDS diagnosis prior to their first 
eligible study visit. Follow-up began at the first eligible study visit after HIV diagnosis and 
continued until the first of: loss to follow-up, death, 10 years after the first eligible visit, or 
September 30, 2015. A participant was considered lost to follow-up at the time of their second 
missed study visit. Time was discretized into 6-month intervals, corresponding to the 
approximate interval between planned study visits. 
Definitions  
In both studies, HCV Ab was assessed at baseline by enzyme immunoassay. Specimens with 
reactive Ab results underwent HCV RNA testing by real-time polymerase chain reaction assays. 
Those with detectable HCV RNA were considered to have chronic HCV (HCV+). 
The definition of ART was guided by the November 2014 US Department of Health and 
Human Services guidelines (Panel on Antiretroviral Guidelines for Adults and Adolescents 
2014). Once a participant reported initiating ART, they were assumed to remain on it for the 
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duration of the study (the intent-to-treat assumption). ART was split into two variables based on 
time of initiation. ART initiated prior to October 1, 2001 (when tenofovir, a key component of 
many modern ART regimens (Panel on Antiretroviral Guidelines for Adults and Adolescents 
2018), was approved) was considered early ART, while ART initiated after that date was 
considered modern ART.  
Ascertainment of death 
Both studies perform death registry searches to obtain information on the mortality of 
participants. Date and cause of death are obtained either directly from the National Death Index 
(https://www.cdc.gov/nchs/ndi/index.htm) or through copies of death certificates obtained by 
study investigators.  
Confounders  
Confounders were chosen using a causal diagram (Greenland et al. 1999) constructed prior to 
data analysis. Time-fixed confounders included age, sex, race and ethnicity, injection drug use 
(IDU), heavy alcohol use, and smoking status. Time-varying confounders included CD4 cell 
count and HIV RNA. For the effect of DAA treatment (but not HCV infection, see the statistical 
analysis section), hepatic fibrosis was also included as a time-fixed confounder after 
categorization into 3 levels: FIB-4 (Sterling et al. 2006) ≥ 3.25 or AST to Platelet Ratio Index 
(APRI) (Lin et al. 2011) ≥ 1 was classified as cirrhosis, while FIB-4 < 1.45 and APRI < 0.7 
(together) was classified as no significant fibrosis. Other combinations were classified as non-
cirrhotic fibrosis. We chose APRI cutoffs based on a meta-analysis (Lin et al. 2011) that 
suggested the improved performance of these cutoffs for classification of cirrhosis and no 
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significant fibrosis than the commonly used cutoffs of 2 and 0.5, respectively. Further details on 
variable measurement and operationalization are in Chapter 3. 
Statistical analysis 
The parametric g-computation algorithm formula (hereafter referred to as the g-formula) 
(Robins 1986) was used to estimate the causal effects in this study. We estimated the effects on 
10-year all-cause mortality of: 1) chronic HCV infection among all PLWH, 2) chronic HCV 
infection among PLWH+HCV, and 3) DAA treatment among PLWH+HCV. Pooled logistic 
regression was used to model the discrete-time hazard of mortality conditional on ART, HCV 
status, and confounders. Pooled logistic and linear regressions were used to model the 
conditional distributions of the time-varying confounders. Using these models, the time-varying 
confounder histories and survival curves were simulated for an enlarged resampled set of the 
observed population under each HCV scenario (Westreich et al. 2012; Murray et al. 2017). Each 
effect was estimated after first setting each person to initiate modern ART at study entry. 
Confidence intervals were estimated using the nonparametric bootstrap with 1000 samples. Full 
details of the g-formula estimation procedure are in the Chapter 3. 
Multiple imputation was used to handle missing data (Allison 2001) (the amount missing for 
each variable is presented in Table 4.1, and ranged from none to 30% missing (baseline 
fibrosis)). We assumed a multivariate normal imputation model, which is robust to non-
normality in many settings (Allison 2001). Missing time-varying covariates were carried forward 
from the most recent measurement. The ‘Boot MI’ algorithm was used to incorporate multiple 
imputation into the bootstrap (Schomaker & Heumann 2018), with 20 imputed datasets per 
bootstrap sample. 
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To assess the fit of parametric models, the natural course was simulated in one imputed 
dataset and the distributions of key variables were compared to those observed in the data.  
Though most of the period covered in this study predates DAAs, it is still possible to estimate 
the effect of DAAs using data available from the MACS and WIHS. These effects were 
estimated under the assumption that an individual without HCV with a given degree of liver 
fibrosis at baseline has the same risk of mortality as a similar individual after successful 
treatment of their HCV infection (conditional on confounders). Intuitively, the survival 
experience of HCV-uninfected PLWH served as a proxy for the experience PLWH+HCV would 
have had if they were treated with DAAs. Technically, PLWH without HCV infection were 
assumed to be conditionally exchangeable (Hernán & Robins 2017) with treated PLWH+HCV 
given baseline fibrosis and confounders.  
Therefore, baseline fibrosis was included as a confounder to estimate the effect of DAA 
treatment. In contrast, fibrosis was not included when estimating the effect of HCV infection, 
because fibrosis is the primary mechanism through which HCV causes mortality. Rather than 
assuming all PLWH+HCV would achieve SVR with DAAs, a beta-Bernoulli random variable 
was used to determine DAA treatment success, with average treatment effectiveness of 0.96 and 
95% of the distribution falling between 0.93 and 0.98 (Naggie et al. 2015). 
Sensitivity analyses 
First, the effect of HCV infection was estimated with a marginal structural model fit with 
inverse probability weighted estimating equations (Robins et al. 2000). The models needed for 
this method are distinct from those needed for the g-formula, so concordance between the results 
 90 
 
provides confidence in the model specifications. Further details of the MSM are provided in the 
Chapter 3 and Appendix A. 
Second, subjects may have been enrolled long after HCV acquisition and time of HCV 
acquisition is unknown in this study. As such, subjects with prolonged infection have more 
advanced liver fibrosis on average than those with recently acquired infections, and there is also 
a possibility of selection bias. To provide an estimate less impacted by such biases, we estimated 
the effect of HCV infection restricted to participants without significant fibrosis, as these 
individuals are more likely to have recently acquired HCV.  
Third, to address possible confounding by hepatitis B virus (HBV) co-infection, we 
conducted each of the analyses restricted to those negative for HBsAg at baseline. We used 
restriction (rather than standardization or adjustment) due to the small number of HBV/HCV co-
infected individuals in the study population leading to issues of non-positivity (Westreich & Cole 
2010). 
4.3 Results 
Study sample 
Overall, 3,056 people were eligible for the study, of whom 543 (18%) had HCV at baseline. 
The study population was 58% female (85% of those with HCV were female). The median 
follow-up time was 7.5 years (interquartile range: 2, 10). PLWH+HCV had more advanced liver 
fibrosis by FIB-4 and APRI and lower median CD4 cell counts; they were also more likely to 
inject drugs, use alcohol heavily, and smoke at baseline than those without HCV. ART was 
initiated by 63% of study participants during follow-up. Of those initiating ART, 32% did so 
after October 1, 2001 (constituting modern ART). Additional characteristics of the study 
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population are presented in Table 4.1 (the characteristics of the populations from the MACS and 
WIHS are presented separately in Table 5.1), and the modelled and observed natural course are 
presented in Table A.1 and Figure A.1. 
Estimated effects of HCV infection and DAA treatment 
All of the estimated effects occur after intervening to have all PLWH initiate modern ART at 
study entry. The 10-year risk difference (RD) for all-cause mortality comparing all PLWH 
having HCV to none having HCV was 4.3% (95% confidence interval [CI]: 0.4%, 8.9%), and the 
risk ratio (RR) was 1.4 (95% CI: 1.0, 1.9) (Table 4.2; Figure 4.1). We also estimated the effect of 
HCV infection specifically among PLWH+HCV (in contrast to among all PLWH as above). The 
10-year RD comparing all-cause mortality among PLWH with observed HCV to that expected 
had they not had HCV was 5.3% (95% CI: 0.6%, 10.5%) and the RR was 1.4 (95% CI: 1.0; 1.8) 
(Table 4.2; Figure 4.2).  
The 10-year RD for all-cause mortality comparing all PLWH+HCV being treated with DAAs 
to none being treated was -3.8% (95% CI: -9.2%, 0.9%), corresponding to a RR of 0.8 (95% CI: 
0.6, 1.1) (Table 4.2; Figure 4.3).  
Sensitivity Analyses 
The estimated effect of HCV infection from the marginal structural model was similar to that 
from the g-formula, but the CI was wider (RD: 4.1%; 95% CI: -7.4%, 25.0% compared to 4.3%; 
95% CI: 0.4%, 8.9%). After restricting to those without significant fibrosis, the estimated effects 
of HCV infection among all PLWH and among PLWH+HCV were attenuated (RD: 3.7% and 
4.1%, compared with 4.3% and 5.3%, respectively). When restricted to those without HBV co-
infection, the effects of HCV infection among all PLWH and among PLWH+HCV, as well as 
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the effect of DAA treatment, were stronger (RD: 4.9%, 6.1%, and -4.5%, compared with 4.3%, 
5.3%, and -3.8%, respectively) (Table A.2). 
4.4 Discussion 
In the modern ART era, it is imperative to identify interventions that alleviate the sources of 
mortality that most impact PLWH. Using causal inference methods, we estimated the effects of 
HCV infection and DAA treatment on mortality risk among PLWH after initiating modern ART 
according to current guidelines. Our results suggest that successful interventions to prevent and 
treat HCV would likely yield mortality benefits in this population. Our estimated RD for HCV 
co-infection among all PLWH corresponds to a number needed to harm (NNH, defined as 
1
|𝑅𝐷|
) 
of 23, meaning that if 23 PLWH initiated ART at study entry and had HCV, we would expect 
one additional death over 10-years compared with none of them having HCV. Our estimated risk 
difference for DAA treatment corresponds to a number needed to treat (NNT) of 26, so we 
would expect one fewer death over 10 years if 26 PLWH+HCV initiated ART at study entry and 
were treated with DAAs compared with only initiating ART. The estimated beneficial effect of 
DAA treatment among PLWH+HCV was smaller than the harmful effect of HCV infection in 
the same population, likely due to the time necessary for liver fibrosis to revert after SVR. 
Our results provide evidence of the effect of HCV infection and DAA treatment among 
PLWH. We estimated effects after ART initiation at study enrollment, providing evidence that is 
useful for clinicians and policy-makers to properly prioritize HCV prevention and DAA 
treatment after patients enter care for HIV. By using data from large, long-running observational 
cohorts, we could estimate effects on 10-year all-cause mortality, a time-frame that captures the 
slow, progressive nature of HCV. These cohorts also had data on liver fibrosis which, along with 
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modern causal inference methodology, allowed us to separately estimate the effects of HCV 
infection and a well-defined DAA treatment intervention (Westreich 2014). 
The risk ratio attributable to HCV infection that we estimated is similar to the pooled risk 
ratio of 1.35 reported by a 2009 meta-analysis (Chen et al. 2009). Despite the numerical 
similarity, our results carry a different interpretation. Most notably, all prior studies accounted 
for ART use either with regression adjustment or by restricting their study populations to those 
who had initiated ART, thus providing estimates that are conditional on observed ART. Our 
estimates can instead be interpreted as the effect of HCV infection after an intervention had been 
applied so that all study participants initiate modern ART upon study enrollment, regardless of 
what ART use was actually observed. 
Our estimated effect of HCV treatment is smaller than previous estimates among PLWH 
from the pegylated interferon (PEG-IFN) era, where hazard ratios for mortality comparing those 
who achieved SVR on PEG-IFN plus ribavirin to those who did not achieve SVR or were not 
treated ranged from 0.12 (Labarga et al. 2015) to 0.22 (Berenguer et al. 2014). As PEG-IFN is 
more toxic than DAAs among PLWH+HCV (Koziel & Peters 2007), those who were 
successfully treated with a PEG-IFN plus ribavirin regimen were likely selected for treatment 
based upon ability to tolerate the drugs, and thus were likely healthier than those who would 
have been successfully treated with DAAs as well as those for whom PEG-IFN plus ribavirin 
treatment was not attempted or was not successful. Therefore, these prior results are likely 
overestimates for the effect of DAAs. Our estimated DAA treatment effect is also smaller than 
the hazard ratios of 0.43 and 0.44 reported in short-term studies in the general population of the 
effect of DAA treatment (Butt et al. 2017) and the effect of SVR after DAA treatment (Backus et 
al. 2018), respectively. Because those studies specifically excluded PLWH, they cannot be 
 94 
 
directly compared with our results, as risk factors for and causes of mortality differ between 
PLWH and the general population. 
Our inferences are subject to limitations. First, there are likely confounders not accounted for 
in our analyses. For instance, for HCV treatment, we assumed that those without HCV could 
serve as proxies for those who were treated for HCV. However, HCV uninfected individuals 
with moderate-to-severe fibrosis (or cirrhosis) likely had underlying factors causing their liver 
damage. Some of these were measured and controlled for in the analysis, but others likely 
remain, meaning the proxies may have had a higher mortality risk than co-infected individuals 
who achieved SVR. Therefore, we likely provide a conservative estimate of the effect of HCV 
treatment. After restricting to PLWH without HBV co-infection, HCV infection and DAA 
treatment had somewhat stronger estimated effects on mortality. However, the similarity of the 
estimates, along with the rarity of HBV in our study and the fact that the distribution of HBV 
was similar between those with and without HCV, imply that meaningful confounding by HBV 
is unlikely. Second, we did not account for the possibility of fibrosis reversion after successful 
DAA treatment (van der Meer & Berenguer 2016). Reversion should reduce mortality after HCV 
treatment, further suggesting that our estimated treatment effect is conservative. We likewise did 
not account for reinfection after successful treatment or for incident infections after baseline. 
Third, our estimates may be biased if the models for mortality or the time-varying confounders 
are misspecified. Though we used several methods to assess the fit of the outcome and 
confounder models, the possibility of model misspecification remains. Due to the large amount 
of missing data, our results may also be particularly sensitive to misspecification of the 
imputation models. Lastly, our study sample is historical, as it combines studies of men and 
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women beginning in the mid-1990’s. As such, our results may not be immediately applicable to 
the current population of PLWH in the US (Lesko et al. 2016). 
Likely violations of our assumptions would suggest that our results are underestimates of the 
true effect of DAA treatment among people with HIV. Given our effect estimates for HCV 
infection and treatment, we believe HIV care providers should make strong efforts to prevent and 
treat HCV in their patients, and that policy-makers and insurers should expand access to DAAs 
and prioritize HCV interventions for PLWH. As person-time accrues in the DAA era, future 
studies should directly estimate the effect of DAAs on long-term mortality among PLWH+HCV.
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Table 4.1: Study population at baseline, Women’s Interagency HIV Study and Multicenter AIDS Cohort Study, 1994-2015 
  Total   HCV+   HCV-   Missing HCV 
 N=3056  N=543  N=2411  N=102 
  n %   n %   n %   n % 
Age (Median, IQR) 38 (32; 44)  40 (35; 44)  37 (31; 43)  40 (33; 49) 
            
Race            
White (Non-Hispanic) 1113 36.4  109 20.1  980 40.7  24 23.5 
African American 1339 43.8  321 59.1  957 39.7  61 59.8 
Hispanic 529 17.3  107 19.7  409 17.0  13 12.7 
Other 74 2.4  6 1.1  64 2.7  4 3.9 
Missing 1   0   1   0  
            
Female Sex 1777 58.1  460 84.7  1231 51.1  86 84.3 
            
CD4 count (median, IQR) 417 (258; 607)  379 (217; 586)  422 (271; 606)  471 (333; 685) 
Missing 169   16   139   14  
            
Detectible HIV Viral Loada 2393 95.1  487 95.5  1829 95.0  77 93.9 
Missing 539   33   486   20  
            
IDU            
Never 2313 76.5  102 19.0  2156 90.4  55 53.9 
Former 491 16.2  300 55.8  162 6.8  29 28.4 
Current 220 7.3  136 25.3  66 2.8  18 17.6 
Missing 32   5   27   0  
            
Heavy Alcohol Useb 377 12.7  102 19.4  252 10.7  23 23.0 
Missing 77   18   57   2  
            
Smoking            
  
 
9
7 
 
Abbreviations: HCV, hepatitis C virus; IQR, interquartile range; IDU, injection drug use; HBsAg, hepatitis B surface antigen; ART, antiretroviral 
therapy 
aLower limit of detection varied over time, and ranged from 500 copies/ml to 20 copies/ml 
bDefined as more than 7 drinks per week for women and more than 14 drinks per week for men (United States Department of Health and Human 
Services 2015) 
cCirrhosis defined as FIB-4 ≥ 3.25 or AST to Platelet Ratio Index APRI ≥ 1; no significant fibrosis defined as FIB-4 < 1.45 and APRI < 0.7; other 
combinations were classified as non-cirrhotic fibrosis.
Never 918 30.4  58 10.8  837 35.2  23 22.8 
Former 693 23.0  77 14.4  601 25.2  15 14.9 
Current 1406 46.6  400 74.8  943 39.6  63 62.4 
Missing 39   8   30   1  
            
BMI > 30 kg/m2 617 22.2  105 20.8  482 22.1  30 32.6 
Missing 273   37   226   10  
            
HBsAg Positive 130 4.4  17 3.2  109 4.6  4 7.0 
Missing 103   4   54   45  
            
Fibrosis Statusc            
No significant fibrosis 1621 76.2  225 49.0  1362 84.6  34 56.7 
Non-cirrhotic fibrosis 304 14.3  127 27.7  162 10.1  15 25.0 
Cirrhosis 203 9.5  107 23.3  85 5.3  11 18.3 
Missing 928   84   802   42  
            
ART            
Initiated pre-October 2001 1296 42.4  229 42.2  1034 42.9  33 32.4 
Initiated post-October 2001 613 20.1   52 9.6   537 22.3   24 23.5 
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Table 4.2: Effects of HCV infection and DAA treatment on 10-year all-cause mortality had all subjects initiated ART at baseline, 
Women’s Interagency HIV Study and Multicenter AIDS Cohort Study, 1994-2015 
Effect Population Exposure/Treatment   Riska (95% CI)   Risk Differencea (95% CI)   Risk Ratio (95% CI) 
HCV Infection All PLWH HCV+  14.69 (8.10, 24.36)  4.34 (0.42, 8.92%)  1.42 (1.04, 1.86) 
  HCV-  10.35 (6.04, 17.60)  Ref  Ref 
         
HCV Infection Only PLWH+HCV HCV+  18.56 (10.67, 30.34)  5.29 (0.57, 10.47)  1.40 (1.04, 1.81) 
  HCV-  13.27 (8.36, 22.08)  Ref  Ref 
         
HCV Treatment Only PLWH+HCV All HCV treated  14.88 (9.17, 24.39)  -3.80 (-9.22%, 0.89)  0.80 (0.61, 1.06) 
  No HCV treated  18.68 (10.81, 30.54)   Ref   Ref 
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; HCV, hepatitis C virus 
aExpressed as percent 
  
  
 
9
9 
Figure 4.1: The effect of HCV infection on 10-year all-cause mortality among PLWH, Women’s Interagency HIV Study and 
Multicenter AIDS Cohort Study, 1994-2015.  
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Figure 4.2: The effect of HCV infection on 10-year all-cause mortality among PLWH and HIV, Women’s Interagency HIV Study and 
Multicenter AIDS Cohort Study, 1994-2015.  
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Figure 4.3: The effect of DAA treatment on 10-year all-cause mortality among PLWH and HIV, Women’s Interagency HIV Study and 
Multicenter AIDS Cohort Study, 1994-2015.  
 
Solid line is the risk no HCV treated with DAAs, dashed line is all HCV treated with DAAs
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CHAPTER 5: THE POPULATION INTERVENTION EFFECTS OF HEPATITIS C 
TREATMENT POLICIES ON ALL-CAUSE MORTALITY AMONG PEOPLE LIVING 
WITH HIV 
 
5.1 Background 
The prognosis for persons living with HIV (PLWH) has markedly improved with 
antiretroviral therapy (ART) (Samji et al. 2013). Given the many comorbidities now associated 
with HIV, understanding the impact of interventions for each condition is essential for allocating 
patient, clinician, and public resources. Among causes of death that predominate in the ART-era, 
liver-related complications have emerged as a major culprit, with mortality largely attributable to 
hepatitis C virus (HCV) co-infection (Weber et al. 2013). Fortunately, the advent of direct acting 
antiviral (DAA) treatments has changed the landscape for people with HIV-HCV co-infection 
dramatically; sustained HCV virologic response (SVR) is achievable in >97% of individuals 
(Afdhal et al. 2014) irrespective of HIV status (Milazzo et al. 2017).  
These treatments, however, come at a high financial cost to the healthcare system. To limit 
expenditures, payers have restricted DAA treatment to those who meet certain criteria. As of 
October 2017, 30 Medicaid programs restricted DAA treatment based on liver fibrosis, with 12 
limiting access to only those beneficiaries at or nearing cirrhosis (National Viral Hepatitis 
Roundtable & Harvard Law School Center for Health Law and Policy Innovation 2017). 
Additionally, 40 programs required patients to be free of alcohol or illicit drugs (National Viral 
Hepatitis Roundtable & Harvard Law School Center for Health Law and Policy Innovation 
2017). Achievement of HIV clinical benchmarks for persons with HIV-HCV co-infection, such 
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as achieving CD4 count targets or HIV suppression, has been used as a restriction for DAA 
treatment in 5 states plus Washington, DC (Ooka et al. 2017). These restrictions persist despite 
treatment guidelines recommending DAA treatment for nearly all patients with HCV regardless 
of such factors (American Association for the Study of Liver Diseases & Infectious Diseases 
Society of America 2017). Because these policies are rapidly evolving as the cost of DAAs falls 
(Kapadia et al. 2017), evidence is needed to properly evaluate how such restrictions impact 
mortality – especially for people with HIV-HCV co-infection whose risk for progression of liver 
disease exceeds that of HCV monoinfected individuals (Kirk et al. 2013).  
The goal of our analysis was to evaluate the impact of DAA restrictions on 10-year, all-cause 
mortality among PLWH at two levels. First, we estimated the effects of various restrictive DAA 
treatment policies on mortality among HIV-HCV co-infected persons to determine how much 
mortality could be averted by expanding access to DAAs. Second, we estimated the population-
level impact of these criteria on mortality among the entire population of PLWH. These 
estimates take into account the prevalence of HCV among PLWH, and thus will aid in 
comparing HCV treatment with interventions for other comorbidities among PLWH. Together, 
these results will provide important information that may be used by policymakers when setting 
future HIV and HCV policies. 
5.2 Methods 
Study Sample  
Our data came from two ongoing, US-based cohorts of HIV-infected and -uninfected women 
(Women’s Interagency HIV Study ,WIHS) (Barkan et al. 1998; Adimora et al. 2018) and men 
who have sex with men (Multicenter AIDS Cohort Study, MACS) (Kaslow et al. 1987). MACS 
began enrollment in 1984, with additional recruitment waves in 1987, 2001, and 2010 at four US 
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cities. WIHS opened in 1994 in six US cities and added additional participants in 2001, 2011, 
and 2013; it now represents 10 urban and suburban locations. In both cohorts, participants attend 
visits every 6 months for laboratory testing and specimen storage, clinical examinations, and 
interviews. Information collected at these visits includes medication use; sociodemographic and 
behavioral characteristics; CD4 cell count and HIV RNA; and HCV antibody and RNA. 
Additionally, scores assessing liver fibrosis (FIB-4 (Sterling et al. 2006) and AST to platelet ratio 
index (APRI) (Lin et al. 2011)) are calculated for all cohort members. 
Eligibility for this analysis required documentation of HIV infection at cohort entry or HIV 
seroconversion during follow-up (with inclusion beginning at the visit corresponding to HIV 
diagnosis). Only visits after the start of WIHS recruitment (October 1, 1994) were included. All 
participants were required to be ART-naïve and free of an AIDS diagnosis at their first eligible 
visit. Follow-up lasted until the first of: loss to follow-up (the date of a participant’s second 
missed study visit), death, 10 years after the first eligible visit, or September 30, 2015. 
Definitions 
The presence of antibody (Ab) against HCV was tested at baseline in both studies by enzyme 
immunoassay. Reactive specimens underwent HCV RNA testing by nucleic acid amplification; 
those with detectable HCV RNA were considered to have active, chronic HCV infection. 
Participants who lacked HCV RNA tests but had reactive HCV Ab were considered missing 
HCV. 
The definition of ART was guided by the November 2014 US Department of Health and 
Human Services guidelines (Panel on Antiretroviral Guidelines for Adults and Adolescents 
2014). Any three-drug regimen including at least one protease inhibitor, entry inhibitor, integrase 
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inhibitor, or non-nucleoside reverse transcriptase inhibitor was considered ART. Once a 
participant initiated ART, they were assumed to remain on it for the remainder of follow-up (in a 
previous analysis, this assumption correctly classified 94% of person-time in MACS and WIHS 
(Cole et al. 2003)). ART initiated after October 1, 2001 (the first visit following the approval of 
tenofovir, a component of many current ART regimens (Panel on Antiretroviral Guidelines for 
Adults and Adolescents 2018)) was considered “modern ART.” Each effect in this study was 
estimated after applying a hypothetical intervention to have all participants initiate modern ART 
at entry, as HIV treatment guidelines recommend that all PLWH receive ART (Panel on 
Antiretroviral Guidelines for Adults and Adolescents 2018). 
Date and cause of death are obtained either directly through periodic searches of the National 
Death Index or through copies of death certificates obtained by study investigators. 
Confounders 
Confounders for the ART-on-mortality and HCV-on-mortality relationships were chosen 
using a causal diagram (Greenland et al. 1999) constructed prior to analysis. Baseline 
confounders were age, sex, race and ethnicity, CD4 cell count, HIV RNA, injection drug use 
(IDU), heavy alcohol use (defined as >7 drinks per week for women and >14 drinks per week for 
men (United States Department of Health and Human Services 2015)), smoking, obesity, and 
liver fibrosis. Time-varying confounders for the ART-on-mortality relationship included CD4 
cell count, HIV RNA, IDU, heavy alcohol use, smoking, obesity, and liver fibrosis. Fibrosis was 
categorized into 3 levels: FIB-4 ≥ 3.25 or APRI ≥ 1 was classified as severe fibrosis/cirrhosis, 
while FIB-4 < 1.45 and APRI < 0.7 (together) was classified as no significant fibrosis. Other 
combinations were considered moderate fibrosis. The APRI cutoffs were guided by a meta-
analysis (Lin et al. 2011) that suggested these perform better than commonly used cutoffs of 2 
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and 0.5, respectively. Details on variable measurement and operationalization are in the Chapter 
3. 
Statistical analysis 
We compared the difference between the risk of 10-year, all-cause mortality among HIV-
HCV co-infected persons and the risk under different DAA access policies, including treating i) 
all HIV-HCV co-infected persons, ii) HIV-HCV co-infected persons who meet certain pre-
conditions (achieving HIV suppression, progressing to severe fibrosis or cirrhosis, or both), and 
iii) treating the same proportion of HIV-HCV co-infected persons as in (ii) chosen randomly 
without clinical restrictions. Additionally, we estimated the population intervention analogs of 
the above three effects (Hubbard & Van Der Laan 2008; Westreich 2014; Westreich 2017). Such 
population-level effects compare mortality among all PLWH to mortality in that population had 
HIV-HCV co-infected persons been treated according to each of the previously described 
criteria. All of these effects are defined in detail in Chapter 3.  
The above effects cannot be directly estimated with existing data, as insufficient person-time 
has accrued in the DAA era to estimate long-term effects. Instead, we used data collected prior to 
the DAA era along with strong assumptions to estimate the effects in this study. Each effect was 
estimated by assuming that an HCV-uninfected person has the same risk of mortality as an HCV-
infected person after successful treatment of their HCV infection, assuming they both have 
similar degrees of liver fibrosis and are of similar age, race and ethnicity, sex, smoking status, 
etc. Technically, those without HCV infection were assumed to be conditionally exchangeable 
(Hernán & Robins 2017) with successfully treated co-infected individuals given baseline fibrosis 
and confounders. 
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We estimated these values using the parametric g-computation algorithm formula (hereafter 
referred to as the g-formula) (Robins 1986). The g-formula simulates the impact of interventions 
in cohort data by conducting microsimulations within a single cohort (Westreich et al. 2012; Keil 
et al. 2014). We used regressions pooled over time to model the distributions of mortality and the 
time-varying confounders. Using these models, we simulated the time-varying confounder 
histories and survival curves under each HCV intervention. We assumed that DAAs had an 
average effectiveness of 96% (Naggie et al. 2015). Confidence limits were estimated using the 
nonparametric bootstrap percentile method with 1000 samples (Efron & Tibshirani 1986). Full 
details of the g-formula estimation procedure are in the Chapter 3. 
We used multiple imputation to handle missing data with a multivariate normal imputation 
model (Allison 2001). The proportion missing for each variable ranged from 0% to 30% (for 
fibrosis, specifically). Missing time-varying covariates were carried forward from the most 
recent measurement. We incorporated multiple imputation into the bootstrap with the ‘Boot MI’ 
algorithm (Schomaker & Heumann 2018), with 20 imputed datasets per bootstrap sample.  
5.3 Results 
Study sample  
A total of 3,056 PLWH were included in the study (1,777 women, 1,279 men). The 
prevalence of HCV was 18% (27% among women; 7% among men). Follow-up lasted a median 
of 7.5 years (interquartile range: 2, 10). Those with HIV-HCV co-infection were generally older; 
more likely to be female; had lower CD4 cell counts; were more likely to use injection drugs, 
drink heavily, or smoke; and had worse fibrosis at baseline (Table 5.1). ART was prescribed to 
63% of participants, 32% of whom initiated a modern ART regimen. The observed and modelled 
distributions of key variables were similar (Figure B.1, Table B.1). 
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Estimated effects of DAA access criteria 
The risk difference (RD) comparing 10-year all-cause mortality risk among co-infected 
persons who were not treated for HCV to what would be expected if all were treated with DAAs 
was -3.7% (95% confidence interval (CI): -9.1%, 0.6%) (Table 5.2). 
If only those co-infected persons with undetectable HIV RNA received DAAs, mortality risk 
would be reduced by -1.9% (95% CI: -5.2%, 0.5%). Under this criterion, 90% (95% CI: 84%, 
93%) of co-infected persons would be treated with DAAs. The effect of treating the same 
proportion of co-infected persons at baseline without regard for HIV viral suppression (that is, 
the effect of choosing 90% of co-infected persons at baseline to receive treatment) was an 
expected mortality risk reduction of -3.3% (95% CI: -8.2%, 0.5%) (Table 5.2 and Figure 5.1).  
Only providing DAAs to co-infected persons with severe fibrosis/cirrhosis would be 
expected to reduce the risk of mortality by -1.6% (95% CI: -4.7%, 0.8%), and 60% (95% CI: 
45%, 70%) of co-infected persons would receive treatment. If the same proportion of co-infected 
persons were randomly selected for treatment at baseline, mortality risk would be reduced by -
2.2% (95%: -5.6%, 0.3%) (Table 5.2 and Figure 5.1). 
 Finally, by only treating co-infected persons with severe fibrosis/cirrhosis and undetectable 
HIV viral load, the risk of mortality would be expected to decline by -1.1% (95% CI: -2.8%, 
0.6%), and 51% (95% CI: 38%, 59%) of co-infected persons would be treated. By treating the 
same proportion of co-infected persons at baseline without these restrictions, mortality would be 
expected to decline by -1.9% (95% CI: -4.7%, 0.3%). (Table 5.2 and Figure 5.1). The timing of 
DAA treatments under each set of treatment criteria are presented in Figure B.2.  
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Estimated population intervention effects of DAA access criteria 
The RD comparing the 10-year all-cause mortality risk in the entire population of PLWH to 
the risk in the entire population that would be expected if all co-infected persons received DAAs 
was -0.7% (95% CI: -1.8%, 0.1%) (Table 5.3). 
If only co-infected persons with undetectable HIV RNA received DAAs, the mortality risk 
among all PLWH would be expected to be reduced by -0.4% (95% CI: -1.0%, 0.1%). Under this 
criterion, 90% (the same proportion reported in the previous section) of co-infected persons 
received DAAs. The effect of treating the same proportion of co-infected persons randomly at 
baseline was an expected -0.6% (95% CI: -1.6%, 0.1%) decrease in mortality among all PLWH 
(Table 5.3). 
Treating only co-infected persons with severe fibrosis/cirrhosis with DAAs would lead to an 
expected -0.3% (95% CI: -0.8%, 0.2%) reduction in mortality among all PLWH, and 60% of co-
infected persons would be treated. Treating the same proportion of co-infected persons at 
baseline without fibrosis restrictions would reduce mortality among all PLWH by -0.4% (95% 
CI: -1.1%, 0.1%) (Table 5.3). 
Finally, the effect of treating only co-infected persons with severe fibrosis/cirrhosis and 
undetectable HIV RNA was an estimated -0.2% (95% CI: -0.5%, 0.1%) reduction in mortality 
risk among all PLWH, and 51% of co-infected persons would be treated. If the same proportion 
of co-infected persons were treated without these restrictions, the mortality risk among all 
PLWH would decrease by -0.4% (95% CI: -0.9%, 0.1%) (Table 5.3).  
 
 
 110 
 
5..4 Discussion 
We found that use of common eligibility criteria for treating people with HIV/HCV co-
infection with DAAs consistently yield a smaller decline in 10-year, all-cause mortality than 
treating a similar proportion of persons at random upon diagnosis of HCV infection, without any 
eligibility criteria. Treating people upon diagnosis would require providing treatments earlier 
than under the criteria we investigated and could therefore entail higher upfront costs (Figure 
B.2). However, the additional mortality benefit of earlier treatment is substantial. To state this 
another way: consider the most restrictive policy we investigated, providing treatment to those 
who achieve HIV suppression and progress to severe fibrosis or cirrhosis, which led to treatment 
of 51% of co-infected persons on average. We could achieve the same mortality benefit by 
treating only 28% of co-infected persons at diagnosis chosen randomly, nearly cutting in half the 
proportion treated. 
The worse mortality outcomes conferred by restrictive eligibility criteria are not surprising: 
these criteria were developed based on financial considerations, in contrast to evidence-based 
HCV treatment guidelines that recommend treating nearly all persons with HCV (American 
Association for the Study of Liver Diseases & Infectious Diseases Society of America 2017). By 
only treating co-infected individuals who have severe fibrosis/cirrhosis, we may be intervening 
too late in the HCV disease process. At that stage of liver damage, the increased risk of adverse 
outcomes due to liver fibrosis and cirrhosis may attenuate the benefit of DAA treatment, thus 
reducing the effect of such an intervention.  
These findings suggest that setting treatment access policies with only short-term cost-
containment in mind can cause patients unnecessary harm. Lives may have been saved if careful 
consideration had been used to set DAA treatment policies. These restrictive policies were likely 
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well-intentioned, as deferring treatment may have been in anticipation of market-driven DAA 
price reductions which would allow wider access in the future. However, such considerations are 
somewhat obviated by the large mortality reduction we estimated for treating patients at baseline 
without consideration of clinical factors. Survival could be further improved by using methods 
that have been developed to optimize treatment allocation (Athey 2017). Such methods, along 
with guidance from clinicians and care-providers, should be used when considering future 
policies to prevent unnecessary mortality. 
Our study is subject to several limitations. First, because our study mostly predates the DAA 
era, all of our effect estimates rely on the assumption that PLWH without HCV had the same 
mortality experience that similar people with HIV-HCV co-infection would have had with 
successful DAA treatment. We controlled for several risk factors for fibrosis, such as alcohol 
use, injection drug use, and obesity, but other risk factors probably remain. The presence of such 
factors would mean that our effects underestimate the true effects. On the other hand, we also 
assumed that all effects of HCV on mortality besides fibrosis are eliminated by successful DAA 
treatment and that DAAs have no side effects impacting mortality. Second, we did not model 
incident HCV infections or reinfection (and subsequent retreatment) after successful treatment. 
Third, all of our results rely on the correct model specifications. While our models were able to 
re-create the observed distributions of several key variables with fidelity, this does not guarantee 
proper model specification. Lastly, our study sample was included MSM and women in roughly 
even proportions, with data dating back to 1994. Our results therefore may not generalize to the 
current population of PLWH in the United States (Lesko et al. 2016). One particular caution is 
that the applicability of the population intervention effects is contingent on the prevalence of 
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HCV in the population of interest; care must be taken to adjust these values for potential 
differences in the HCV prevalence observed in real-world populations. 
Even with these limitations, our results provide valuable evidence that can aid policymakers 
in setting DAA policies for people living with HIV/HCV, as well as in prioritizing interventions 
to reduce mortality among PLWH in general. Because it takes years for HCV to impact 
mortality, there has been insufficient time in the DAA-era to estimate the true impact of HCV 
treatment criteria. Until more person-time accumulates in this era, estimates that rely on strong 
assumptions, like those we present, are needed to properly evaluate treatment policies. 
The population intervention effects we estimated consider not only the effect of successful 
HCV treatment, but also the proportion of PLWH who would be intervened upon. As such, these 
estimates can be compared with similar estimates for other conditions in this population and can 
thus be used to properly compare interventions for different HIV comorbidities. Similar effects 
should be estimated for other conditions impacting PLWH to optimally allocate limited public 
health resources. 
 DAA access in the US is rapidly evolving. Though many DAA restrictions requiring patients 
to meet clinical pre-conditions are being updated (Kapadia et al. 2017), as of October 2017 the 
majority of Medicaid programs still limit treatment to those with at least moderate liver fibrosis 
(National Viral Hepatitis Roundtable & Harvard Law School Center for Health Law and Policy 
Innovation 2017). Policymakers in those states may wish to consider our results when setting 
future DAA access policies. As we proceed further into the DAA era, studies should directly 
evaluate the impact of HCV treatment policies among people living with HIV-HCV co-infection 
to optimize the delivery of DAAs in this population. 
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Table 5.1: Baseline characteristics of eligible study participants stratified by source, Women’s Interagency HIV Study and Multicenter 
AIDS Cohort Study, 1994-2015 
  Women's Interagency HIV Study   Multicenter AIDS Cohort Study 
  HCV+   HCV-   HCV+   HCV- 
 n=460  n=1231  n=83  n=1180 
  N %   N %   N %   N % 
Age (Median, IQR) 40 (35; 44)  34 (29; 40)  44 (40; 50)  40 (34; 45) 
            
Race            
White (Non-Hispanic) 74 16.1%  178 14.5%  35 42.2%  802 68.0% 
African American 281 61.1%  710 57.7%  40 48.2%  247 20.9% 
Hispanic 99 21.5%  293 23.8%  8 9.6%  116 9.8% 
Other 6 1.3%  49 4.0%  0 0.0%  15 1.3% 
Missing 0   1   0   0  
            
CD4 count (median, IQR) 373 (213; 575)  410 (262; 609)  405 (250; 652)  433 (280; 605) 
Missing 13   36   3   103  
            
Detectible Viral Loada 428 95.3%  1137 94.3%  59 96.7%  692 96.2% 
Missing 11   25   22   461  
            
IDU            
Never 61 13.3%  1096 89.1%  41 52.6%  1060 91.9% 
Former 293 63.7%  106 8.6%  7 9.0%  56 4.9% 
Current 106 23.0%  28 2.3%  30 38.5%  38 3.3% 
Missing 0   1   5   26  
            
Heavy Alcohol Useb 93 20.8%  143 11.9%  9 11.7%  109 9.5% 
Missing 12   28   6   29  
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Smoking            
Never 47 10.3%  502 40.9%  11 14.3%  335 29.0% 
Former 58 12.7%  215 17.5%  19 24.7%  386 33.4% 
Current 353 77.1%  510 41.6%  47 61.0%  433 37.5% 
Missing 2   4   6   26  
            
Obese 97 22.6%  382 31.7%  8 10.5%  100 10.2% 
Missing 30   25   7   201  
            
HBsAg Positive 12 2.6%  28 2.3%  5 6.2%  81 7.1% 
Missing 2   12   2   42  
            
Fibrosis Statusc            
No significant fibrosis 211 51.2%  1004 86.0%  14 29.8%  358 81.0% 
Moderate fibrosis 112 27.2%  103 8.8%  15 31.9%  59 13.3% 
Severe fibrosis/Cirrhosis 89 21.6%  60 5.1%  18 38.3%  25 5.7% 
Missing 48   64   36   738  
            
ART            
Initiated pre-October 2001 212 46.1%  521 42.3%  17 20.5%  513 43.5% 
Initiated post-October 2001 33 7.2%   269 21.9%   19 22.9%   268 22.7% 
Abbreviations: HCV, hepatitis C virus; IQR, interquartile range; IDU, injection drug use; HBsAg, hepatitis B virus surface antigen; ART, 
antiretroviral therapy 
102 Participants had missing HCV status 
aLower limit of detection varied over time, and ranged from 500 copies/ml to 20 copies/ml 
bDefined as more than 7 drinks per week for women and more than 14 drinks per week for men (United States Department of Health and Human 
Services 2015) 
cCirrhosis defined as FIB-4 ≥ 3.25 or AST to Platelet Ratio Index APRI ≥ 1; no significant fibrosis defined as FIB-4 < 1.45 and APRI < 0.7; other 
combinations were classified as non-cirrhotic fibrosis  
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Table 5.2: Effects of DAA treatment criteria on 10-year all-cause among people living with HIV and HCV, Women’s Interagency 
HIV Study and Multicenter AIDS Cohort Study, 1994 – 2015 
Policy % Treateda Risk differenceb Treat same % at randomb Difference 
No Intervention 0 Ref Ref - 
All HCV Treated 100 -3.7 (-9.1, 0.6) - - 
Only HIV suppressed treatedc 89.6 (84.3, 93.0) -1.9 (-5.2, 0.5) -3.3 (-8.1, 0.5) -1.4 (-3.6, 0.3) 
Only severe fibrosis treated c 59.9 (44.3, 69.4) -1.6 (-4.7, 0.8) -2.2 (-5.6, 0.3) -0.6 (-1.4, 0.0) 
Only HIV suppressed and cirrhosis treated 51.0 (37.9, 59.1) -1.1 (-2.8, 0.6) -1.9 (-4.7, 0.3) -0.8 (-2.4, 0.1) 
Abbreviations: DAA, direct-acting antiviral; PLWH, people living with HIV; ART, antiretroviral therapy; HCV, hepatitis C virus 
aPercent of all people living with HIV-HCV co-infection treated with DAAs. 
bExpressed as percent, comparing stated scenario to a reference group of no one treated for HCV. 
cIncludes those who meet the criteria at baseline as well as those who progress to meet it during follow-up 
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Table 5.3: Population intervention effects of DAA treatment criteria on 10-year all-cause mortality among people living with HIV, 
Women’s Interagency HIV Study and Multicenter AIDS Cohort Study, 1994 – 2015 
Policy % Treateda Risk Differenceb Treat Same % at Randomb Difference 
No Intervention 0 Ref Ref - 
All HCV Treated 100 -0.7 (-1.8; 0.1) - - 
Only HIV suppressed treatedc 89.6 (84.3, 93.0) -0.4 (-1.0, 0.1) -0.6 (-1.6, 0.1) -0.3 (-0.7, 0.1) 
Only severe fibrosis treated c 59.9 (44.3, 69.4) -0.3 (-0.9, 0.2) -0.4 (-1.1, 0.1) -0.1 (-0.3, 0.0) 
Only HIV suppressed and cirrhosis treated 51.0 (37.9, 59.1) -0.2 (-0.5, 0.1) -0.4 (-0.9, 0.1) -0.2 (-0.4, 0.0) 
Abbreviations: DAA, direct-acting antiviral; PLWH, people living with HIV; ART, antiretroviral therapy; HCV, hepatitis C virus 
aPercent of all people living with HIV-HCV co-infection treated with DAAs. 
bExpressed as percent, comparing stated scenario to a reference group of no one treated for HCV. 
cIncludes those who meet the criteria at baseline as well as those who progress to meet it during follow-up
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Figure 5.1: Effects of DAA treatment criteria on 10-year all-cause mortality among people living 
with HIV and HCV, the Women’s Interagency HIV Study and Multicenter AIDS Cohort Study, 
1994-2015 
  
Triangle is the effect of treating those who achieve HIV viral suppression. Diamond is the effect of 
treating those progress to severe fibrosis/cirrhosis. Square is the effect of treating those who both achieve 
HIV viral suppression and progress to severe fibrosis/cirrhosis. Circles are the effects of treating the same 
proportion without regard for clinical factors. Effects falling in the green region are superior to treating 
without regard for clinical factors, and effects falling in the red region are inferior to treating without 
regard for clinical factors.
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CHAPTER 6: DISCUSSION 
 
6.1 Overview 
 
 As PLWH begin to achieve life expectancies rivalling those of HIV-uninfected individuals 
(Samji et al. 2013), non-AIDS related comorbidities are taking center stage in the provision of 
care for this population. In this work, we explored the role of one such comorbidity, HCV 
infection, and its treatment on 10-year all-cause mortality among PLWH. Additionally, we 
formally defined effect measures that may be of interest to patients, clinicians, and policy-
makers; provide conditions under which they can be estimated from observational data, even in 
the absence of actual treatment data; and provide expressions and algorithms for their estimation.  
We estimated several effect measures that may inform treatment and policy decisions, 
including the effect of HCV infection on 10-year all-cause mortality among all PLWH and 
among PLWH+HCV, the effect of DAA treatment among PLWH+HCV, and the effects of DAA 
treatment policies in which subgroups of PLWH+HCV are treated with DAAs, either chosen at 
random or based on clinical criteria used by certain Medicaid programs to determine treatment 
eligibility. All of the effects were estimated after first applying a hypothetical intervention in 
which all study participants initiate ART at baseline, making the results particular relevant in the 
era of modern ART guidelines suggesting ART initiation for all PLWH, regardless of CD4 cell 
count.  
The results from Aim 1 may be of particular interest to patients and clinicians. The effect of 
HCV infection on all-cause mortality gives an estimate of the increased risk PLWH may face if 
they have HCV coinfection, and the effect of DAA treatment provides an estimate of how 
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mortality would be impacted among PLWH+HCV if their HCV coinfection is treated. Given the 
robustness of the effect of HCV infection in a sensitivity analysis in which only those with no or 
mild fibrosis were included, this effect may also be reasonably used to inform clinicians as to the 
reduction in all-cause mortality that may be achieved if HCV is prevented in PLWH. 
The estimates in Aim 2 may be used to inform population-level interventions and policies for 
PLWH. By comparing interventions based on Medicaid reimbursement criteria to interventions 
in which the same proportion of PLWH+HCV are treated at random, we provide information that 
can be used to determine whether or not these Medicaid criteria are efficient and provide an 
estimate of how much additional benefit could be had by changing or loosening these 
restrictions. The estimated population intervention effects incorporate information on the 
prevalence of HCV coinfection and the proportion of PLWH+HCV who would be treated, so 
these estimates may be compared with similar estimates for other comorbidities, thus aiding in 
determining which interventions on which conditions would lead to the greatest benefit in this 
population. 
6.2 Study findings 
 
 In Chapter 3, we described two methods for estimating causal effects – the parametric 
generalized computation algorithm formula (the g-formula) (Robins 1986) and the estimation of 
marginal structural models using inverse probability of treatment weighted estimating equations 
(Robins et al. 2000). We then demonstrated how these methods can be used to estimate the 
average effect of a policy among the exposed (APEX), the generalized effect of a policy among 
the exposed (GPEX), and the dynamic effect of a policy among the exposed (DPEX), as well as 
corresponding population intervention effects. Under certain conditions, we showed that the 
APEX is equivalent to the average effect of exposure in the exposed (ATT), thus allowing for the 
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estimation of the APEX without data on treatment. Using this methodological framework, it is 
possible to predict the long-term impact of hypothetical or recently developed treatments using 
cohort data that precedes the introduction of these new therapies. Evidence can then be provided 
to guide treatment decisions and policies far sooner than would be possible if investigators had to 
wait for adequate person-time to accrue after treatment introduction. We further showed how the 
GPEX, DPEX, and population intervention effects can be estimated by scaling the APEX and 
provided an algorithm for estimating each of these parameters. 
In Chapter 4, we estimated the effects of HCV infection and treatment among PLWH. We 
found that HCV leads to a substantial increase in the 10-year risk of all-cause mortality in 
PLWH, and that DAA treatment is effective at reducing the 10-year risk of all-cause mortality 
among PLWH+HCV. The results were robust to sensitivity analyses for the functional forms of 
the models used in the analysis, the set of confounders accounted for in the analysis, and the 
degree of liver fibrosis among study participants. 
 Though our estimated effect of HCV infection among PLWH was similar to the pooled effect 
from a 2009 meta-analysis (Chen et al. 2009), our analysis permits a different interpretation. 
First, the meta-analysis pooled results from studies of varying duration, thus precluding a clear 
interpretation of the results. Second, studies included in the meta-analysis accounted for ART 
either through stratification or restriction. In contrast, we applied a hypothetical intervention to 
have all participants initiate ART at study entry. The meta-analysis results are thus interpreted as 
conditional on observed ART use, whereas ours are interpreted as occurring after providing ART 
to the entire population, regardless of observed use, and thus are more applicable to the current 
era in which all PLWH are recommended to be on ART, regardless of CD4 count. 
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 Our estimated effect of DAA treatment was substantially smaller in magnitude than the 
results from past studies of HCV treatment among PLWH. Nearly all previous studies were 
conducted prior to the introduction of DAAs, and instead compared PLWH+HCV who achieved 
HCV SVR with PEG-IFN to those who did not achieve SVR or did not receive treatment. As 
PEG-IFN is much more poorly tolerated than DAAs among PLWH, those who successfully 
achieved SVR using PEG-IFN are likely to differ on risk factors for mortality compared with 
those who did not achieve SVR or who did not receive treatment, so unmeasured and 
uncontrolled confounding may be a serious issue in prior studies. 
 To date, only two studies have estimated the effect of DAAs on mortality, and both found 
DAAs to have a much larger effect on mortality than our results suggest. Both of these studies 
were of short duration (under 18 months), and both excluded PLWH. As the risk of mortality 
differs substantially between PLWH and HIV-uninfected people, the results of those studies 
cannot be directly compared to our results. Additionally, those studies were likely too short in 
duration to capture the full effect of HCV, a slow, progressive disease.  
 In Chapter 5, we estimated the effects of interventions to provide DAA treatment to subsets 
of the population of PLWH+HCV chosen according to criteria used by some state Medicaid 
programs to determine treatment eligibility. We also estimated the effect of randomly treating 
proportions of PLWH+HCV at baseline, with the proportions selected to equal those who would 
receive therapy under the Medicaid criteria. In addition to standard effect estimates, we 
estimated the population intervention effects of these interventions, which account for the 
prevalence of HCV among PLWH and can thus be compared to similar estimates for 
interventions on other HIV comorbidities. To our knowledge, this was the first study to estimate 
these effects. We found that interventions in which PLWH+HCV are able to access treatment 
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only if they meet certain clinical criteria (such as progression to severe fibrosis or cirrhosis 
and/or achieving HIV suppression), were substantially less effective at reducing mortality than 
treating an identical proportion of PLWH+HCV chosen at random. Our results suggest that these 
Medicaid criteria are inefficient, and that mortality could be prevented among PLWH without 
increasing the total number of people treated with DAAs, though the number of people treated 
immediately would increase (as would upfront costs). However, our estimates show that treating 
27% of PLWH+HCV at baseline would lead to the same 10-year all-cause mortality risk as the 
most restrictive policy we investigated (i.e. treating only those co-infected individuals who 
achieve HIV suppression and progress to severe fibrosis or cirrhosis). This is almost half the 
proportion treated under the restrictive policy. As such, it may be possible to make 
improvements to DAA treatment policies without increasing present costs. These results also 
show that expanding access so that all PLWH+HCV receive DAAs would substantially reduce 
mortality. Our findings support the HCV treatment guidelines recommended by the American 
Association for the Study of Liver Diseases and the Infectious Diseases Society of America, 
which suggest DAA treatment for nearly all people living with HCV regardless of clinical factors 
(American Association for the Study of Liver Diseases & Infectious Diseases Society of 
America 2017). As such, policy-makers should consider these results when setting future HCV 
treatment policies for PLWH+HCV. 
 More generally, the results from Chapter 5 highlight the fact that policies based on cost-
containment are often suboptimal, and that lives can be saved by considering evidence when 
choosing treatment allocation strategies. Though such policies are often well-intentioned, 
particularly in anticipation of future price decreases that would allow broader access at a later 
date, when lives are at stake it is necessary to take greater care when setting policy. The fact that 
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we found that simply allocating treatment at random was more effective than allocating based on 
commonly used clinical criteria shows how poorly such policies perform in practice. 
6.3 Strengths and limitations 
 
This work resulted in a valuable contribution to the literature for both HIV and HCV. Using 
data from 1994 to 2015, this was the longest study of HIV/HCV coinfection to date. The study 
period allowed for the study of long-term outcomes, such as 10-year all-cause mortality, which is 
important given the increased lifespan of PLWH and the slow, progressive nature of HCV 
infection. This work was also the first study to look at mortality due to HCV among PLWH 
under modern ART guidelines. Because current HIV treatment guidelines advise all people with 
HIV to receive ART regardless of their CD4 cell count, the effects estimated here represent 
realistic treatment scenarios and are more immediately applicable to the current population of 
PLWH.  
The dataset and analytic approach for this work also add to its unique strength. Because the 
data include information on liver function, it was possible to estimate the effects of both HCV 
infection and its treatment, making the results pertinent for informing both prevention and 
treatment strategies. The analytic methods we used produced estimates of the effects of well-
defined interventions, and thus allowed us to separately explore the role HCV infection and 
treatment have on mortality among PLWH under modern HIV treatment guidelines. We 
additionally were able to estimate the reduction in mortality that one would expect under 
different DAA access policies in this population. Despite the population under study having not 
actually fully existed in the modern ART era nor the era of DAA treatment, the carefully 
considered assumptions applied in this work allow for the estimation of causal effects under 
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hypothetical interventions that ensure ART initiation at baseline for all study participants and 
that effectively treat HCV. 
In addition to “usual” causal effects, this work estimated policy-relevant effects which have 
yet to be explored for this topic. These estimates provide information necessary to understand the 
impact of HCV interventions and treatment policies applied to the population of PLWH as a 
whole. By estimating both traditional treatment effects and population intervention effects, these 
results aid patients, care providers, and policy-makers in properly prioritizing HCV interventions 
against interventions for other HIV comorbidities and help to determine the best way to 
implement such interventions. 
To evaluate the impact of chronic HCV infection and its treatment in the population of 
PLWH, this work used a longitudinal cohort design using existing data from two long-running, 
ongoing HIV cohort studies. Ideally, randomized controlled trials, including pragmatic trials 
(Roland & Torgerson 1998), are used to evaluate the causal effect of a treatment or intervention. 
A randomized controlled trial of HCV treatment in this population to explore its effect on all-
cause mortality would be prohibitively expensive, time-consuming, and ethically problematic 
because of the long period between HCV infection and its clinical manifestations, as well as 
because of the known efficacy of HCV therapy in this population.  
Thus, the observational cohort study design using existing data is well-suited for this topic 
for several reasons. Because the cohort study is not designed specifically to test an intervention 
in the study population, broad inclusion and exclusion criteria can be used allowing important 
subgroups to be represented. This may allow for the results to be better generalized or 
transported to relevant target populations (Lesko et al. 2017). Additionally, the cohort study 
collects rich data on many characteristics of the study subjects, allowing the same data set to be 
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used to evaluate multiple interventions. In this case, the effects of both HCV infection and 
treatment were evaluated. Further, because the study data were already available, the timing from 
analysis to results was not delayed due to the collection of new data. Lastly, as this study did 
involve collecting new data from cohort members or applying an intervention, the cost was 
minimal and there was no need for clinical equipoise. Under the causal identification 
assumptions, the results of this cohort study should mimic those of a well-conducted randomized 
controlled trial (Hernán et al. 2008).  
Unfortunately, there are “costs” that are incurred by not conducting a randomized controlled 
trial. First among them is the need to address the causal identification conditions in the analysis 
phase of the study, rather than the design phase. In order for the methods used in this work to 
produce unbiased estimates of causal effects, then consistency, conditional exchangeability, 
positivity, elimination of measurement error, and proper model specification must all hold. As 
these conditions (except positivity) cannot generally be assessed, a reasonable justification for 
assuming each of them to hold is necessary. 
In order for consistency to hold, the observed outcome for individuals must be equal to the 
outcome that they would have if an intervention set them to have their observed exposure. 
Consistency is typically violated due to interference or relevant treatment variation. In the case 
of HCV and HIV, interference is unlikely, as the exposure or treatment status of others should 
not impact the outcome of a given individual. In order to validly assume treatment variation 
irrelevance holds, it should be sufficient to assume that the effect of prior HCV is fully mediated 
by the baseline characteristics of study participants, and that successful HCV treatment or 
spontaneous clearance have no effect on mortality besides its effect on HCV. In other words, for 
those without baseline chronic HCV, given a participant’s baseline variables, it was assumed that 
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it does not matter whether the participant never had HCV, spontaneously cleared HCV, or had 
successful HCV treatment (in this cohort, the two latter situations are likely to be relatively rare, 
as people with HIV and HCV have poor clearance and successful treatment rates with older 
HCV treatments). For those with baseline chronic HCV, it was assumed that the duration of 
HCV prior to study entry does not impact mortality besides its impact on baseline variables. 
While it is reasonable to assume that the primary pathway through which HCV impacts mortality 
is through progressive liver fibrosis and that successful DAA treatment halts HCV-related 
fibrosis progression, there may be other effects of HCV that do not get eliminated by treatment, 
thus violating the assumption of consistency. 
In this work, the greatest concern for exchangeability is the fact that people with HCV may 
systematically differ from those without HCV in unknown ways. For instance, after controlling 
for baseline demographic, behavioral, and health-related variables, those with advanced liver 
fibrosis who do not drink alcohol and do not have HCV likely have another underlying health 
condition causing their fibrosis, such as non-alcoholic fatty liver disease. Though controlling for 
variables such as heavy alcohol use and obesity status may mitigate these issues, residual 
confounding is likely. Such confounding would be expected to lead to bias towards the null of 
the estimates, as the group without HCV will have higher mortality. An example of how such 
confounding may operate is displayed in the simplified causal diagram in Figure 6.1. Conditional 
exchangeability for ART is perhaps less of a concern, as the primary factors used for ART 
treatment decisions prior to the current guidelines are accounted for in this study. 
Positivity may pose a problem in this work as many confounders will be included in the 
model, leading to potentially sparse data. The models used for g-computation extrapolate over 
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the variable combinations that exhibit non-positivity, but such extrapolation must be carefully 
considered as it may not be valid to do so. 
Measurement error may enter the work in a few ways. First, information was only collected 
at six-month intervals, and thus measurement error could be introduced due to course 
measurement with respect to time. Such measurement error would lead to residual confounding 
and would be a threat to conditional exchangeability. Also, all of the laboratory measurements 
used in the work may be subject to both random error and systematic error. The data collected 
through questionnaires may be subject to recall bias and bias due to the sensitive nature of some 
of the questions, which may lead to underreporting of some variables, such as injection drug use. 
HCV status may also be subject to misclassification. Because only baseline HCV is included as 
an exposure, it is possible that some subjects clear HCV during the study, either spontaneously 
or through treatment. This is not an issue for this work, as the effect of baseline HCV can be 
interpreted as including observed clearance and treatment patterns. Some subjects may also 
acquire HCV during the study period. Such misclassification would bias the estimates toward the 
null. Finally, liver fibrosis was measured indirectly, and such measurements do not have perfect 
sensitivity or specificity for liver fibrosis, assuming liver biopsy as a reference or “gold” 
standard. 
Finally, model specification may be an issue, as the many variables that will be included in 
the models may impact the outcome in complex and unpredictable ways. By using flexible 
modelling techniques, such as the use of splines for continuous variables and including product 
terms, the models are hopefully able to approximate the true relationships. By checking the 
natural course against the observed data and using methods that require orthogonal models as a 
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sensitivity analysis, some confidence can be had that the models were correctly specified, though 
whether or not they were is ultimately unverifiable.  
Besides these identification conditions, there are several other threats to the validity of the 
results in this work. In order for multiple imputation to produce valid results in the presence of 
missing data, missingness must be at random, and the functional form of the imputation models 
must be properly specified. In order for the effects of HCV treatment to be identified from the 
observed data, the assumptions that (given measured baseline characteristics) HCV primarily 
impacts mortality through liver fibrosis progression and HCV treatment primarily impacts 
mortality by halting this progression must hold. Based on the current understanding of HCV and 
its treatment, this assumption is not unrealistic. Finally, the population used for this work is 
likely not representative of any populations of PLWH in the United States which are of direct 
clinical interest, and as such these results are not trivially transportable to any population that 
would realistically be the target of HCV interventions (Westreich et al. 2017). 
Even with these limitations and untestable assumptions, this work provides valuable 
information that adds to the literature and will ultimately contribute to the evidence base for 
updating HIV and HCV care policies and guidelines. The sensitivity analyses that were 
conducted systematically evaluated many of the threats to validity that this work may face, thus 
providing additional confidence in the results and a deeper understanding of possible sources of 
bias. The innovative study design, analytical methods, and effects to be estimated make this 
work a powerful and unique contribution to the HIV and HCV literature. 
6.4 Future directions 
 
 There are several directions that future research on HCV infection and treatment among 
PLWH could take. First, as person-time accumulates in the DAA era, studies that directly 
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estimate the effect of DAA treatment on mortality among PLWH+HCV should be conducted. If 
properly conducted, such studies will not require the same strong assumptions required for the 
results of this work to be valid, and thus may provide stronger evidence of the effect of HCV 
treatment on all-cause mortality in this population. 
 Second, the results of this study and future studies should be transported to other key 
populations of PLWH, such as the population of PLWH alive in the US, or the population of 
newly diagnosed PLWH. The population studied in this work was historical and was created by 
combining the populations of PLWH from two cohort studies. By transporting the results to 
more relevant populations, the results will be even more informative for guiding clinical practice 
and policy. 
 Third, cost-effectiveness measures should be estimated for the interventions in Chapter 5. 
While the estimates in Chapter 5 provide valuable evidence for policy-makers, they do not 
account for the cost of the interventions, nor do they account for the quality of life among PLWH 
under each intervention. Additionally, as treatment is delayed under certain DAA treatment 
policies, it will be important to account for the time value of money, so that costs incurred after 
baseline are discounted. Incorporating cost-effectiveness into these estimates will aid policy-
making in three ways. First, it will provide estimates that are relevant in a resource-constrained 
environment and will allow for policies to be adopted that optimally balance the benefit of an 
intervention with its cost. Second, it will aid in determining the timing of expenditures under 
each treatment policy, thus helping insurers and public health agencies in forecasting future 
expenditures. Finally, it will allow policy-makers to understand what mortality reduction they 
could achieve if DAA costs were reduced or budgets were increased, thus providing evidence 
that can be used in negotiations with pharmaceutical manufacturers and funding organizations. 
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 Fourth, further exploration of optimal DAA treatment policies should be undertaken. While 
we were able to show that treating people at random performed better than treating based on 
commonly used clinical criteria, gains can almost certainly be had by targeting treatment to those 
most likely to benefit. Advances in statistical and epidemiological methodology now allow us to 
estimate optimal treatment allocation policies (Athey 2017). These methods should be 
implemented in the context of DAA treatment to maximize the benefit in the population of 
PLWH+HCV. 
Lastly, population intervention effects should be estimated for other conditions that 
commonly affect PLWH, such as type 2 diabetes, cardiovascular disease, chronic kidney disease, 
non-viral liver diseases, and non-AIDS-related cancer. In isolation, the effects estimated in 
Chapter 5 are only useful for comparison with other DAA interventions. With similar estimates 
for other conditions, interventions can be compared head-to-head, and conditions and treatments 
can be prioritized against one another in specific populations. Such comparisons will take into 
account the effect of the condition on mortality, the effectiveness of the treatments, the 
prevalence of the conditions, and the proportion of people who would receive treatment, and will 
thus allow for the proper allocation of time and resources to best benefit PLWH.
  
 
1
3
1
 
Figure 6.1: Simplified causal diagram demonstrating potential lack of conditional exchangeability when estimating HCV  
treatment effects 
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APPENDIX A: FURTHER DETAILS OF ANALYSIS IN CHAPTER 4 
A.1 Notation 
The following notation will be used throughout this section. Individuals will be indexed by 
𝑖 ∈ {1,2,3, … , 𝑛}, and time (in visits) will be indexed by 𝑡 ∈ {0,1,2,3,… , 𝜏}. Uppercase letters 
will denote random variables, and lowercase letters and numbers will represent their potential 
realizations. 𝑌𝑘+1,𝑖 is 1 if subject 𝑖 died between times 𝑘 and 𝑘 + 1. 𝐴1,𝑘 = 1 if subject 𝑖 initiated 
ART between time 𝑘 − 1 and 𝑘 with 𝑘 prior to October 1, 2001; with 𝑘 on or after October 1, 
2001 𝐴1,𝑘 = 2. 𝐻𝑖 = 1 if subject 𝑖 had chronic HCV at baseline, 𝐶𝑘,𝑖 is 1 if subject 𝑖 was lost to 
follow-up at time 𝑘, and 𝑊𝑘,𝑖 is a vector of covariate values at time 𝑘 for subject 𝑖. Because the 
MACS and WIHS visits occur at regular semi-annual intervals, the time index represents visits 
since baseline, with 10-years being represented by the 20th visit. Mortality and loss to follow-up 
were thus estimated over 6-month intervals rather than continuously. An overbar (e.g. ?̅?𝑡,𝑖) 
denotes history, for example ?̅?𝑡,𝑖 = {𝐴0,𝑖, 𝐴1,𝑖, 𝐴2,𝑖, … , 𝐴𝑡,𝑖}. Superscripts on random variables 
represent potential outcomes, e.g. 𝑌𝑖
𝑎 indicates the level of 𝑌 that subject 𝑖 would have 
experienced had, possibly counter to fact, they received treatment level 𝐴 = 𝑎. Finally, 𝑓𝑋(𝑥) 
denotes a probability mass function or probability density function for the random variable 𝑋 
evaluated at 𝑥. From here forward, observations will be assumed independent and identically 
distributed, and subscripts distinguishing individuals will be dropped. Hereafter, the use of the 
parametric generalized computation algorithm formula for the estimation of causal effects will be 
referred to as g-computation, and the formula itself will be referred to as the g-formula. 
A.2 Natural course and g-formula equations used in chapter 4 
The natural course distribution for this study can be represented as: 
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𝐸(𝑌𝑡+1) = ∑ ∑ ∑ ∑
{
  
 
  
 
Pr(𝑌𝑘+1 = 1|?̅?𝑘 = ?̅?𝑘, 𝐻 = ℎ, ?̅?𝑘 = ?̅?𝑘 , ?̅?𝑘 = 𝐶?̅? = 0) ×
∏
[
 
 
 
 
𝑓(𝑊𝑚|?̅?𝑚 = ?̅?𝑚, 𝐻 = ℎ, ?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚 = 𝐶?̅? = 0) ×
Pr(𝑌𝑚 = 0|?̅?𝑚−1 = ?̅?𝑚−1, 𝐻 = ℎ, ?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚−1 = 𝐶?̅?−1 = 0) ×
Pr(𝐶𝑚 = 0|?̅?𝑚−1 = ?̅?𝑚−1, 𝐻 = ℎ, ?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚 = 𝐶?̅?−1 = 0) ×
Pr(𝐴𝑚 = 𝑎𝑚|?̅?1,𝑚−1 = ?̅?1,𝑚−1, 𝐻 = ℎ, ?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚 = 𝐶?̅? = 0) ]
 
 
 
 
×
𝑘
𝑚=0
Pr (𝐻 = ℎ|𝑊0 = 𝑤0) }
  
 
  
 
ℎ∈ℋ?̅?𝑡∈𝒜𝑡?̅?𝑡∈𝒲𝑡
𝑡
𝑘=0
 
Under the conditions of causal consistency (treatment variation irrelevance) (VanderWeele 2009; Cole & 
Frangakis 2009), conditional exchangeability (Hernán & Robins 2017), positivity (Westreich & Cole 2010), 
no measurement error (Edwards et al. 2015), and properly specified models, the causal effect of setting 
HCV and ART to particular values and preventing loss to follow-up can be estimated by replacing the last 
three quantities with degenerate distributions taking value 1 at the exposure and loss to follow-up 
regimes of interest. The corresponding g-formula is thus: 
𝐸(𝑌𝑡+1
?̅?=?̅? ,𝐻=ℎ) = ∑ ∑
{
 
 
 
 
𝑃𝑟(𝑌𝑘+1 = 1|?̅?𝑘 = ?̅?𝑘, 𝐻 = ℎ, ?̅?𝑘 = ?̅?𝑘, ?̅?𝑘 = 𝐶?̅? = 0) ×
∏
[
 
 
 
𝑓𝑊𝑚(𝑤𝑚|?̅?𝑚 = ?̅?𝑚, 𝐻 = ℎ, ?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚 = 𝐶?̅? = 0) ×
𝑃𝑟(𝑌𝑚 = 0|?̅?𝑚−1 = ?̅?𝑚−1, 𝐻 = ℎ, ?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚−1 = 𝐶?̅?−1 = 0) ×
1 ×
1 ]
 
 
 
×
𝑘
𝑚=0
1 }
 
 
 
 
?̅?𝑡∈𝒲𝑡
𝑡
𝑘=0
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A.3 Final models used in chapter 4 
The first component estimated, the time-varying hazard of death, was modelled as:  
𝑃𝑟(𝑌𝑘+1 = 1|?̅?𝑘 = ?̅?𝑘, 𝐻 = ℎ, ?̅?𝑘 = ?̅?𝑘, ?̅?𝑘 = 𝐶?̅? = 0)
= 𝑒𝑥𝑝𝑖𝑡(𝛼0 + 𝛼1𝑎𝑒,𝑘 + 𝛼2𝑎𝑙,𝑘 + 𝛼3(𝑎𝑒,𝑘−1 + 𝑎𝑙,𝑘−1) + 𝛼4ℎ + 𝛼5𝐶𝐷40
+ 𝛼6𝐶𝐷40,1 + 𝛼7𝐶𝐷40,2 + 𝛼8𝐶𝐷40,3 + 𝛼9𝑉𝐿0 + 𝛼10𝐼𝐷𝑈 + 𝛼11𝑆𝑚𝑜𝑘𝑒
+ 𝛼12𝐴𝑙𝑐𝑜ℎ𝑜𝑙 + 𝛼13𝑂𝑏𝑒𝑠𝑒 + 𝛼14𝑆𝑒𝑥 + 𝛼15𝑅𝑎𝑐𝑒𝑏𝑙𝑎𝑐𝑘 + 𝛼16𝑅𝑎𝑐𝑒𝐻𝑖𝑠𝑝𝑎𝑛𝑖𝑐
+ 𝛼17𝑅𝑎𝑐𝑒𝑜𝑡ℎ𝑒𝑟 + 𝛼18𝐴𝑔𝑒 + 𝛼19𝐴𝑔𝑒
1 + 𝛼20𝐴𝑔𝑒
2 + 𝛼21𝐴𝑔𝑒
3 + 𝛼22𝑘 + 𝛼23𝑘
1
+ 𝛼24𝑘
2 + 𝛼25𝑘
3 + 𝛼26𝐶𝐷4𝑘 + 𝛼27𝐶𝐷4𝑘
1 + 𝛼28𝐶𝐷4𝑘
2 + 𝛼29𝐶𝐷4𝑘
3 + 𝛼30𝐷𝑉𝐿𝑘
+ 𝛼31𝐶𝐷4𝑘−1 + 𝛼32𝐶𝐷4𝑘−1
1 + 𝛼33𝐶𝐷4𝑘−1
2 + 𝛼34𝐶𝐷4𝑘−1
3 + 𝛼35𝐷𝑉𝐿𝑘−1
+ 𝛼36(𝑎𝑒,𝑘 + 𝑎𝑙,𝑘)ℎ + 𝛼37(𝑎𝑒,𝑘 + 𝑎𝑙,𝑘)𝑘 + 𝛼38ℎ𝑘) 
where 𝑎𝑒,𝑘 = 1 if 𝑎𝑘 = 1, 𝑎𝑙,𝑘 = 1 if 𝑎𝑘 = 2, 𝑉𝐿𝑘 is the viral load at time 𝑘 (set to lower limit of 
detection if undetectable), 𝐷𝑉𝐿𝑘 = 1 if HIV virus was detectable at time k, 𝑍
𝑠 is the 𝑠 spline 
term for variable 𝑍, and 𝑒𝑥𝑝𝑖𝑡(∙) =
exp(∙)
1+exp(∙)
 is the inverse logit function.   
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Time-varying detectable viral load was modelled as: 
𝑃𝑟(𝑉𝐿𝑘 = 1|?̅?𝑘 = ?̅?𝑘, 𝐻 = ℎ, ?̅?𝑘−1 = ?̅?𝑘−1, ?̅?𝑘 = 𝐶?̅? = 0)
= 𝑒𝑥𝑝𝑖𝑡(𝛽0 + 𝛽1𝑎𝑒,𝑘 + 𝛽2𝑎𝑙,𝑘 + 𝛽3(𝑎𝑒,𝑘−1 + 𝑎𝑙,𝑘−1) + 𝛽4ℎ + 𝛽5𝐶𝐷40
+ 𝛽6𝐶𝐷40,1 + 𝛽7𝐶𝐷40,2 + 𝛽8𝐶𝐷40,3 + 𝛽9𝑉𝐿0 + 𝛽10𝐼𝐷𝑈 + 𝛽11𝑆𝑚𝑜𝑘𝑒
+ 𝛽12𝐴𝑙𝑐𝑜ℎ𝑜𝑙 + 𝛽13𝑂𝑏𝑒𝑠𝑒 + 𝛽14𝑆𝑒𝑥 + 𝛽15𝑅𝑎𝑐𝑒𝑏𝑙𝑎𝑐𝑘 + 𝛽16𝑅𝑎𝑐𝑒𝐻𝑖𝑠𝑝𝑎𝑛𝑖𝑐
+ 𝛽17𝑅𝑎𝑐𝑒𝑜𝑡ℎ𝑒𝑟 + 𝛽18𝐴𝑔𝑒 + 𝛽19𝐴𝑔𝑒
1 + 𝛽20𝐴𝑔𝑒
2 + 𝛽21𝐴𝑔𝑒
3 + 𝛽22𝑘 + 𝛽23𝑘
1
+ 𝛽24𝑘
2 + 𝛽25𝑘
3 + 𝛽26𝐶𝐷4𝑘−1 + 𝛽27𝐶𝐷4𝑘−1
1 + 𝛽28𝐶𝐷4𝑘−1
2 + 𝛽29𝐶𝐷4𝑘−1
3
+ 𝛽30𝐷𝑉𝐿𝑘−1 + 𝛽31𝐶𝐷4𝑘−2 + 𝛽32𝐶𝐷4𝑘−2
1 + 𝛽33𝐶𝐷4𝑘−2
2 + 𝛽34𝐶𝐷4𝑘−2
3
+ 𝛽35𝐷𝑉𝐿𝑘−2 + 𝛽36(𝑎𝑒,𝑘 + 𝑎𝑙,𝑘)ℎ + 𝛽37(𝑎𝑒,𝑘 + 𝑎𝑙,𝑘)𝑘 + 𝛽38ℎ𝑘) 
Finally, time-varying CD4+ T-cell count was modelled as: 
𝐶𝐷4𝑘 = 𝛾0 + 𝛾1𝑎𝑒,𝑘 + 𝛾2𝑎𝑙,𝑘 + 𝛽3(𝑎𝑒,𝑘−1 + 𝑎𝑙,𝑘−1) + 𝛾4ℎ + 𝛾5𝐶𝐷40 + 𝛾6𝐶𝐷40,1 + 𝛾7𝐶𝐷40,2
+ 𝛾8𝐶𝐷40,3 + 𝛾9𝑉𝐿0 + 𝛾10𝐼𝐷𝑈 + 𝛾11𝑆𝑚𝑜𝑘𝑒 + 𝛾12𝐴𝑙𝑐𝑜ℎ𝑜𝑙 + 𝛾13𝑂𝑏𝑒𝑠𝑒
+ 𝛾14𝑆𝑒𝑥 + 𝛾15𝑅𝑎𝑐𝑒𝑏𝑙𝑎𝑐𝑘 + 𝛾16𝑅𝑎𝑐𝑒𝐻𝑖𝑠𝑝𝑎𝑛𝑖𝑐 + 𝛾17𝑅𝑎𝑐𝑒𝑜𝑡ℎ𝑒𝑟 + 𝛾18𝐴𝑔𝑒
+ 𝛾19𝐴𝑔𝑒
1 + 𝛾20𝐴𝑔𝑒
2 + 𝛾21𝐴𝑔𝑒
3 + 𝛾22𝑘 + 𝛾23𝑘
1 + 𝛾24𝑘
2 + 𝛾25𝑘
3
+ 𝛾26𝐶𝐷4𝑘−1 + 𝛾27𝐶𝐷4𝑘−1
1 + 𝛾28𝐶𝐷4𝑘−1
2 + 𝛾29𝐶𝐷4𝑘−1
3 + 𝛾30𝐷𝑉𝐿𝑘−1
+ 𝛾31𝐶𝐷4𝑘−2 + 𝛾32𝐶𝐷4𝑘−2
1 + 𝛾33𝐶𝐷4𝑘−2
2 + 𝛾34𝐶𝐷4𝑘−2
3 + 𝛾35𝐷𝑉𝐿𝑘−2
+ 𝛾36(𝑎𝑒,𝑘 + 𝑎𝑙,𝑘)ℎ + 𝛾37(𝑎𝑒,𝑘 + 𝑎𝑙,𝑘)𝑘 + 𝛾38ℎ𝑘 + 𝜀 
where 𝜀~𝑁(0, 𝜎2). 
For the natural course, ART initiation, baseline HCV status, and loss to follow-up were 
modelled as follows: 
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𝑃𝑟(𝐴𝑘 ≠ 0|?̅?𝑘−1 = 0,𝐻 = ℎ, ?̅?𝑘−1 = ?̅?𝑘−1, ?̅?𝑘 = 𝐶?̅? = 0)
= 𝑒𝑥𝑝𝑖𝑡(𝛿0 + 𝛿1ℎ + 𝛿2𝐶𝐷40 + 𝛿3𝐶𝐷40,1 + 𝛿4𝐶𝐷40,2 + 𝛿5𝐶𝐷40,3 + 𝛿6𝑉𝐿0
+ 𝛿7𝐼𝐷𝑈 + 𝛿8𝑆𝑚𝑜𝑘𝑒 + 𝛿9𝐴𝑙𝑐𝑜ℎ𝑜𝑙 + 𝛿10𝑂𝑏𝑒𝑠𝑒 + 𝛿11𝑆𝑒𝑥 + 𝛿12𝑅𝑎𝑐𝑒𝑏𝑙𝑎𝑐𝑘
+ 𝛿13𝑅𝑎𝑐𝑒𝐻𝑖𝑠𝑝𝑎𝑛𝑖𝑐 + 𝛿14𝑅𝑎𝑐𝑒𝑜𝑡ℎ𝑒𝑟 + 𝛿15𝐴𝑔𝑒 + 𝛿16𝐴𝑔𝑒1 + 𝛿17𝐴𝑔𝑒2 + 𝛿18𝐴𝑔𝑒3
+ 𝛿19𝑘 + 𝛿20𝑘
1 + 𝛿25𝑘
2 + 𝛿26𝑘
3 + 𝛿27𝐶𝐷4𝑘 + 𝛿28𝐶𝐷4𝑘−1
1 + 𝛿29𝐶𝐷4𝑘−1
2
+ 𝛿30𝐶𝐷4𝑘−1
3 + 𝛿31𝐷𝑉𝐿𝑘−1 + 𝛿32𝐶𝐷4𝑘−2 + 𝛿33𝐶𝐷4𝑘−2
1 + 𝛿34𝐶𝐷4𝑘−2
2
+ 𝛿35𝐶𝐷4𝑘−2
3 + 𝛿36𝐷𝑉𝐿𝑘−2 + 𝛿37ℎ𝑘) 
 𝑃𝑟(𝐻 = 1|𝑊0 = 𝑤0)
= 𝑒𝑥𝑝𝑖𝑡(𝜁0 + 𝜁1𝐶𝐷40 + 𝜁2𝐶𝐷40,1 + 𝜁3𝐶𝐷40,2 + 𝜁4𝐶𝐷40,3 + 𝜁5𝑉𝐿0 + 𝜁6𝐼𝐷𝑈
+ 𝜁7𝑆𝑚𝑜𝑘𝑒 + 𝜁8𝐴𝑙𝑐𝑜ℎ𝑜𝑙 + 𝜁9𝑂𝑏𝑒𝑠𝑒 + 𝜁10𝑆𝑒𝑥 + 𝜁11𝑅𝑎𝑐𝑒𝑏𝑙𝑎𝑐𝑘
+ 𝜁12𝑅𝑎𝑐𝑒𝐻𝑖𝑠𝑝𝑎𝑛𝑖𝑐 + 𝜁13𝑅𝑎𝑐𝑒𝑜𝑡ℎ𝑒𝑟 + 𝜁14𝐴𝑔𝑒 + 𝜁15𝐴𝑔𝑒
2 + 𝜁16𝐴𝑔𝑒
3 + 𝜁17𝐴𝑔𝑒
4) 
𝑃𝑟(𝐶𝑘 = 1|?̅?𝑘−1 = ?̅?𝑘−1, 𝐻 = ℎ, ?̅?𝑘−1 = ?̅?𝑘−1, ?̅?𝑘 = 𝐶?̅?−1 = 0)
= 𝑒𝑥𝑝𝑖𝑡(𝜂0 + 𝜂1𝑎𝑒,𝑘−1 + 𝜂2𝑎𝑙,𝑘−1 + 𝜂3(𝑎𝑒,𝑘−2 + 𝑎𝑙,𝑘−2) + 𝜂4ℎ + 𝜂5𝐶𝐷40
+ 𝜂6𝐶𝐷40,1 + 𝜂7𝐶𝐷40,2 + 𝜂8𝐶𝐷40,3 + 𝜂9𝑉𝐿0 + 𝜂10𝐼𝐷𝑈 + 𝜂11𝑆𝑚𝑜𝑘𝑒
+ 𝜂12𝐴𝑙𝑐𝑜ℎ𝑜𝑙 + 𝜂13𝑂𝑏𝑒𝑠𝑒 + 𝜂14𝑆𝑒𝑥 + 𝜂15𝑅𝑎𝑐𝑒𝑏𝑙𝑎𝑐𝑘 + 𝑣16𝑅𝑎𝑐𝑒𝐻𝑖𝑠𝑝𝑎𝑛𝑖𝑐
+ 𝜂17𝑅𝑎𝑐𝑒𝑜𝑡ℎ𝑒𝑟 + 𝜂18𝐴𝑔𝑒 + 𝜂19𝐴𝑔𝑒
1 + 𝜂20𝐴𝑔𝑒
2 + 𝜂21𝐴𝑔𝑒
3 + 𝜂22𝑘 + 𝜂23𝑘
1
+ 𝜂24𝑘
2 + 𝜂25𝑘
3 + 𝜂26𝐶𝐷4𝑘−1 + 𝜂27𝐶𝐷4𝑘−1
1 + 𝜂28𝐶𝐷4𝑘−1
2 + 𝜂29𝐶𝐷4𝑘−1
3
+ 𝜂30𝐷𝑉𝐿𝑘−1 + 𝜂31𝐶𝐷4𝑘−2 + 𝜂32𝐶𝐷4𝑘−2
1 + 𝜂33𝐶𝐷4𝑘−2
2 + 𝜂34𝐶𝐷4𝑘−2
3
+ 𝜂35𝐷𝑉𝐿𝑘−2 + 𝜂36(𝑎𝑒,𝑘−1 + 𝑎𝑙,𝑘−1)ℎ + 𝜂37(𝑎𝑒,𝑘−1 + 𝑎𝑙,𝑘−1)𝑘 + 𝜂38ℎ𝑘) 
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When modelling the natural course, if ART was initiated prior to October 1, 2001 then 𝐴1,𝑘 was 
set to 1, and if it was initiated after that date 𝐴1,𝑘 was set to 2. Note that the intent to treat 
assumption implies 𝑃𝑟(𝐴𝑘 = 1|𝐴𝑘−1 = 1, 𝐴2 = 𝑎2, ?̅?𝑘−1 = ?̅?𝑘−1, ?̅?𝑘 = 𝐶?̅? = 0) = 1. 
To estimate the effect of HCV treatment, three modifications were made to the above 
procedure. First, baseline fibrosis status entered all of the above models with two dummy 
variables representing fibrosis/no cirrhosis and cirrhosis. Second, a modification was made to 
step 2 of the g-computation procedure. Rather than sampling from the entire study population, 
only those with chronic HCV at baseline were sampled to represent the covariate distribution 
among those who would be intervened upon. Lastly, because treatment is not 100% effective, 
rather than simply comparing 𝐻 = 1 to 𝐻 = 0, a random variable was drawn to determine 
treatment success. First, a beta random variable, 𝑃, with parameters chosen to represent the 
average effectiveness and reasonable uncertainty of effectiveness was drawn (in this case, we 
chose the average effectiveness to be 0.96, with 95% of the distribution falling between 0.93 and 
0.98 (Naggie et al. 2015)). Second, a Bernoulli random variable, 𝐵 was drawn with parameter 𝑃. 
Those with 𝐵 = 1 had 𝐻 set to 0, while the others remained with 𝐻 = 1. 
A.4 Estimation of the marginal structural model for chapter 4 
In this study, the models for censoring, HCV, and ART from the natural course estimation 
were used to construct the denominators of the weights. For the numerators of the weights, only 
the time on study and prior exposure history was conditioned on to allow us to estimate effects 
that were marginal over baseline covariates at each time. The estimated weights for ART history, 
censoring history, and HCV status were multiplied together to produce the final weight for each 
subject at each time. Because of exceptionally large weights and influential outliers that led to 
unstable results, five subjects were excluded from the MSM analysis. The MSM for the risk of 
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death under ART and HCV interventions was estimated using the inverse-probability weighted 
Kaplan-Meier survival curve method on the ‘time on treatment’ time scale as follows (Westreich 
et al. 2010): 
A MSM for the discrete-time hazard was specified as 
Pr (𝑌𝑘+1
?̅?=?̅?,𝐻=ℎ = 1|?̅?𝑘
?̅?=?̅?,𝐻=ℎ = 𝐶?̅?
?̅?=?̅?,𝐻=ℎ = 0) = 𝑓(?̅?, ℎ; 𝛽𝑘) 
The MSM was then estimated in the weighted population by 
𝑃?̂?(𝑌𝑘+1 = 1|?̅?𝑘 = 𝐶?̅? = 0, ?̅?𝑘 = ?̅?𝑘, 𝐻 = ℎ) =
𝑑𝑘,𝑎,ℎ
𝑟𝑘,𝑎,ℎ
 
where  
𝑑𝑘,𝑎,ℎ =∑𝑠𝑤𝑖,𝑘 ∗ 𝑌𝑖,𝑘+1 ∗ 𝐼(𝐴𝑖,𝑘 = 𝑎𝑘, 𝐻𝑖 = ℎ, 𝐶?̅?,𝑘 = ?̅?𝑖,𝑘 = 0)
𝑛
𝑖=1
 
and 
𝑟𝑘,𝑎,ℎ =∑𝑠𝑤𝑖,𝑘 ∗ 𝐼(𝐴𝑖,𝑘 = 𝑎𝑘, 𝐻 = ℎ, 𝐶?̅?,𝑘 = ?̅?𝑖,𝑘 = 0)
𝑛
𝑖=1
 
Because the time scale is time on treatment, 𝑘 indexes the time since entering the study for times 
prior to ART initiation, and time since initiating ART for times after ART initiation. With 
properly specified weights, 𝑃?̂?(𝑌𝑘+1 = 1|?̅?𝑘 = 𝐶?̅? = 0, ?̅?𝑘 = ?̅?𝑘, 𝐻 = ℎ) is a valid estimate of an 
analogously specified model for 𝑃𝑟 (𝑌𝑘+1
?̅?=?̅?,𝐻=ℎ = 1|𝑌𝑘+1
?̅?=?̅?,𝐻=ℎ = 𝐶?̅?
?̅?=?̅?,𝐻=ℎ = 0). The risk of 
mortality at time 𝑘 + 1 under a given ART and HCV regime is thus 
𝑃?̂? (𝑌𝑡+1
?̅?=?̅?,𝐻=ℎ = 1) = 𝑅𝑡+1
?̅?=?̅?,𝐻=ℎ = 1 −∏ (1 − 𝑃?̂?(𝑌𝑘+1 = 1|?̅?𝑘 = 𝐶?̅? = 0,𝐴𝑘 = 𝑎𝑘 , 𝐻 = ℎ))
𝑡
𝑘=0 . 
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A.5 Comparison of observed and modelled natural course in chapter 4 
Table A.1: Comparison of observed versus modelled variable distributions under the natural 
course using models from chapter 4, Women’s Interagency HIV Study and Multicenter AIDS 
Cohort Study, 1994-2015 
Variable Data Model 
% Subjects   
HCV+ 18.79 18.53 
Censored 51.23 51.10 
Lost to follow-up 34.66 34.78 
   
% Person-Time   
ART 53.54 54.09 
Detectible Viral Load 70.45 70.56 
   
Average value   
CD4+ T-Cell Count 479.64 503.50 
   
Kaplan-Meier Estimate   
10-year All-Cause Mortalitya 19.90 19.84 
Abbreviations: HCV, hepatitis C virus; ART, antiretroviral therapy 
aRisk, expressed as percent 
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Figure A.1: Comparison of observed versus modelled mortality under the natural course using 
models from chapter 4. 
 
Grey lines are cumulative incidence curves from 200 bootstrap samples from the observed data. 
Blue line is the modelled cumulative incidence curve
  
 
1
4
1
 
A.6 Results of sensitivity analyses for chapter 4 
Table A.2: Sensitivity analysis results for chapter 4 
Analysis Effect Population Exposure/Treatment  
Risk Differencea (95% 
CI)   
Risk Ratio (95% 
CI) 
Marginal Structural Modelb HCV Infection HIV+ HCV+  4.14% (-7.35%; 25.01%)
d 
 1.48 (0.35; 4.78)
g 
   HCV-  Ref  Ref         
None/Mild Fibrosis Only HCV Infection HIV+ HCV+  3.66% (-0.23%; 12.15%)
d 
 1.48 (0.96; 2.48)
g 
   HCV-  Ref  Ref         
 HCV Infection HCV+ HCV+  4.10% (-0.27%; 12.60%)
e 
 1.45 (0.97; 2.45)
h 
   HCV-  Ref  Ref         
No HBVc HCV Infection HIV+ HCV+  4.92% (0.78%; 10.27%)
d 
 1.48 (1.08; 1.99)
g 
   HCV-  Ref  Ref         
 HCV Infection HCV+ HCV+  6.11% (1.11%; 12.04%)
e 
 1.46 (1.08; 1.93)
h 
   HCV-  Ref  Ref         
 
HCV 
Treatment HCV+ All treated  
-4.52% (-10.34%; 
0.58%)f  0.77 (0.57; 1.04)
i 
   None treated  Ref  Ref 
Abbreviations: CI, confidence interval; HCV, hepatitis C virus; HBV, hepatitis B virus 
aExpressed as percent 
bExcludes 5 individuals with extreme weights. Time scale is time on treatment. 
cHBV defined as a positive test for hepatitis B surface antigen at baseline 
Main results for comparison: d4.34 (0.42, 8.92%); e5.29 (0.57, 10.47); f-3.80 (-9.22%, 0.89); g1.42 (1.04, 1.86); h1.40 (1.04, 1.81); i0.80 (0.61, 
1.06)
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APPENDIX B: FURTHER DETAILS OF ANALYSIS IN CHAPTER 5 
B.1 Notation 
The following notation will be used throughout this section. Individuals will be indexed by 
𝑖 ∈ {1,2,3, … , 𝑛}, and time (in visits) will be indexed by 𝑡 ∈ {0,1,2,3,… , 𝜏}. Uppercase letters 
will denote random variables, and lowercase letters and numbers will represent their potential 
realizations. 𝑌𝑘+1,𝑖 is 1 if subject 𝑖 died between times 𝑘 and 𝑘 + 1. 𝐴𝑘,𝑖 = 1 if subject 𝑖 initiated 
ART between time 𝑘 − 1 and 𝑘 with 𝑘 prior to October 1, 2001; 𝐴𝑘,𝑖 = 2 with 𝑘 on or after 
October 1, 2001. 𝐻𝑘,𝑖 = 1 if subject 𝑖 had chronic HCV at time 𝑘, 𝐷𝑘,𝑖 = 1 if subject 𝑖 received 
DAAs at time 𝑘, 𝐶𝑘,𝑖 is 1 if subject 𝑖 was lost to follow-up at time 𝑘, and 𝑊𝑘,𝑖 is a vector of 
covariate values for subect 𝑖 at time 𝑘. Because the MACS and WIHS visits occur at regular 
semi-annual intervals, the time index represents visits since baseline, with 10-years being 
represented by the 20th visit. Mortality and loss to follow-up were thus estimated over 6-month 
intervals rather than continuously. An overbar (e.g. 𝐶?̅?,𝑖) denotes history, for example 𝐶?̅?,𝑖 =
{𝐶0,𝑖, 𝐶1,𝑖, 𝐶2,𝑖, … , 𝐶𝑡,𝑖}. Superscripts on random variables represent potential outcomes, e.g. 𝑌𝑖
𝐴=𝑎 
indicates the level of 𝑌 that subject 𝑖 would have experienced had, possibly counter to fact, they 
received treatment level 𝐴 = 𝑎. Finally, 𝑓𝑋(𝑥) denotes a probability mass function or probability 
density function for the random variable 𝑋 evaluated at 𝑥. From here forward, observations will 
be assumed independent and identically distributed, and subscripts distinguishing individuals 
will be dropped. Hereafter, the use of the parametric generalized computation algorithm formula 
for the estimation of causal effects will be referred to as g-computation, and the formula itself 
will be referred to as the g-formula.  
B.2 Natural course and g-formula equations used in chapter 5.  
The natural course distribution for this study can be represented as: 
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𝐸(𝑌𝑡+1) = ∑ ∑ ∑ ∑
{
 
 
 
 
 
 
𝑃𝑟(𝑌𝑘+1 = 1|?̅?𝑘 = ?̅?𝑘 , ?̅?𝑘 = ℎ̅𝑘 , ?̅?𝑘 = ?̅?𝑘 , ?̅?𝑘 = 𝐶?̅? = 0) ×
∏
[
 
 
 
 
 
 
𝑓(𝑊𝑚|?̅?𝑚 = ?̅?𝑚, ?̅?𝑚−1 = ℎ̅𝑚−1, ?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚 = 𝐶?̅? = 0) ×
𝑃𝑟(𝑌𝑚 = 0|?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚−1 = ℎ̅𝑚−1, ?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚−1 = 𝐶?̅?−1 = 0) ×
𝑃𝑟(𝐶𝑚 = 0|?̅?𝑚−1 = ?̅?𝑚−1, ℎ̅𝑚−1 = ℎ𝑚−1, ?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚 = 𝐶?̅?−1 = 0) ×
𝑃𝑟(𝐴𝑚 = 𝑎𝑚|?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚−1 = ℎ̅𝑚−1, ?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚 = 𝐶?̅? = 0) ×
𝑃𝑟(𝐻𝑚 = ℎ𝑚|?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚−1 = ℎ̅𝑚−1, ?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚 = 𝐶?̅? = 0) ]
 
 
 
 
 
 
𝑘
𝑚=0
 }
 
 
 
 
 
 
ℎ̅𝑡∈ℋ𝑡?̅?𝑡∈𝒜𝑡?̅?𝑡∈𝒲𝑡
𝑡
𝑘=0
 
where the value for each variable at time -1 was set to the observed value for that variable at 
baseline. We assume causal consistency (treatment variation irrelevance) (VanderWeele 2009; 
Cole & Frangakis 2009), conditional exchangeability (Hernán & Robins 2017), positivity 
(Westreich & Cole 2010), no measurement error (Edwards et al. 2015), properly specified 
models, and a treatment that, when successful, works instantaneously (or nearly so), completely 
eliminates the effect of exposure at the time of treatment and all times thereafter, and has no side 
effects. The causal effect of setting ART to a particular value, applying an intervention to treat 
certain people with HCV, and preventing loss to follow-up then involves modifying the last three 
probabilities to reflect the intervention of interest. The g-formula corresponding to having all 
participants initiate ART at baseline, not become lost to follow-up, and follow a given HCV 
treatment regime is thus: 
𝐸 (𝑌𝑡+1
?̅?=1̅ ,?̅?=𝑑∗) = ∑ ∑ ∑
{
  
 
  
 
Pr(𝑌𝑘+1 = 1|?̅?𝑘 = 1̅, ?̅?𝑘 = ℎ̅𝑘, ?̅?𝑘 = ?̅?𝑘, ?̅?𝑘 = 𝐶?̅? = 0) ×
∏
[
 
 
 
 
 
𝑓(𝑊𝑚|?̅?𝑚 = 1̅, ?̅?𝑚−1 = ℎ̅𝑚−1, ?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚 = 𝐶?̅? = 0) ×
Pr(𝑌𝑚 = 0|?̅?𝑚−1 = 1̅, ?̅?𝑚−1 = ℎ̅𝑚−1, ?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚−1 = 𝐶?̅?−1 = 0) ×
1 ×
1 ×
Pr∗(𝐻𝑚 = ℎ𝑚|?̅?𝑚−1 = 1̅, ?̅?𝑚−1 = ℎ̅𝑚−1, ?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚 = 𝐶?̅? = 0) ]
 
 
 
 
 
𝑘
𝑚=0
 }
  
 
  
 
ℎ̅𝑡∈ℋ𝑡?̅?𝑡∈𝒲𝑡
𝑡
𝑘=0
 
where ?̅?∗is the treatment regime of interest and 
Pr∗(𝐻𝑚 = ℎ𝑚|?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚−1 = ℎ̅𝑚−1, ?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚 = 𝐶?̅? = 0) is the probability 
that HCV takes value ℎ𝑚 at time 𝑚 under the treatment regime of interest. For instance, if the 
intervention is to treat all HCV at baseline with a treatment with perfect effectiveness, 
Pr∗(𝐻𝑚 = 0|?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚−1 = ℎ̅𝑚−1, ?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚 = 𝐶?̅? = 0) = 1 for all 𝑚. 
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B.3 Final models used in chapter 5 
The first component estimated, the time-varying hazard of death, was modelled as:  
𝑃𝑟(𝑌𝑘+1 = 1|?̅?1 = ?̅?1, ?̅?𝑘 = ℎ̅𝑘, ?̅?𝑘 = ?̅?𝑘, ?̅?𝑘 = 𝐶?̅? = 0)
= 𝑒𝑥𝑝𝑖𝑡(𝛼0 + 𝛼1𝑎𝑒,𝑘 + 𝛼2𝑎𝑙,𝑘 + 𝛼3(𝑎𝑒,𝑘−1 + 𝑎𝑙,𝑘−1) + 𝛼4ℎ𝑘 + 𝛼5𝐶𝐷40
+ 𝛼6𝐶𝐷40,1 + 𝛼7𝐶𝐷40,2 + 𝛼8𝐶𝐷40,3 + 𝛼9𝑉𝐿0 + 𝛼10𝐼𝐷𝑈0 + 𝛼11𝑆𝑚𝑜𝑘𝑒0
+ 𝛼12𝐴𝑙𝑐𝑜ℎ𝑜𝑙0 + 𝛼13𝑂𝑏𝑒𝑠𝑒0 + 𝛼14𝑆𝑒𝑥 + 𝛼15𝑅𝑎𝑐𝑒𝑏𝑙𝑎𝑐𝑘 + 𝛼16𝑅𝑎𝑐𝑒𝐻𝑖𝑠𝑝𝑎𝑛𝑖𝑐
+ 𝛼17𝑅𝑎𝑐𝑒𝑜𝑡ℎ𝑒𝑟 + 𝛼18𝐴𝑔𝑒 + 𝛼19𝐴𝑔𝑒
1 + 𝛼20𝐴𝑔𝑒
2 + 𝛼21𝐴𝑔𝑒
3 + 𝛼22𝑘 + 𝛼23𝑘
1
+ 𝛼24𝑘
2 + 𝛼25𝑘
3 + 𝛼26𝐶𝐷4𝑘 + 𝛼27𝐶𝐷4𝑘
1 + 𝛼28𝐶𝐷4𝑘
2 + 𝛼29𝐶𝐷4𝑘
3 + 𝛼30𝐷𝑉𝐿𝑘
+ 𝛼31𝐶𝐷4𝑘−1 + 𝛼32𝐶𝐷4𝑘−1
1 + 𝛼33𝐶𝐷4𝑘−1
2 + 𝛼34𝐶𝐷4𝑘−1
3 + 𝛼35𝐷𝑉𝐿𝑘−1
+ 𝛼36(𝑎𝑒,𝑘 + 𝑎𝑙,𝑘)ℎ𝑘 + 𝛼37(𝑎𝑒,𝑘 + 𝑎𝑙,𝑘)𝑘 + 𝛼38ℎ𝑘𝑘 + 𝛼39𝑁𝑜𝐹𝑖𝑏0 + 𝛼40𝐹𝑖𝑏0
+ 𝛼41𝐶𝑖𝑟𝑘 + 𝛼42𝐼𝐷𝑈𝑘 + 𝛼43𝑆𝑚𝑜𝑘𝑒𝑘 + 𝛼44𝐴𝑙𝑐𝑜ℎ𝑜𝑙𝑘 + 𝛼45𝑂𝑏𝑒𝑠𝑒𝑘) 
where 𝑎𝑒,𝑘 = 1 if 𝑎𝑘 = 1, 𝑎𝑙,𝑘 = 1 if 𝑎𝑘 = 2, 𝑉𝐿𝑘 is the viral load at time 𝑘 (set to lower limit of 
detection if undetectable), 𝐷𝑉𝐿𝑘 = 1 if HIV virus was detectable at time k, 𝑁𝑜𝐹𝑖𝑏𝑘 = 1 if the 
person had no significant fibrosis at time 𝑘, 𝐹𝑖𝑏𝑘 = 1 if a person had moderate fibrosis t time 𝑘, 
𝐶𝑖𝑟𝑘 = 1 if a person had severe fibrosis/cirrhosis at time 𝑘, 𝑍
𝑠 is the 𝑠 spline term for variable 𝑍, 
and 𝑒𝑥𝑝𝑖𝑡(∙) =
exp(∙)
1+exp(∙)
 is the inverse logit function.   
Time-varying detectable viral load was modelled as: 
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𝑃𝑟(𝑉𝐿𝑘 = 1|?̅?𝑘 = ?̅?𝑘, ?̅?𝑘−1 = ℎ̅𝑘−1, ?̅?𝑘−1 = ?̅?𝑘−1, ?̅?𝑘 = 𝐶?̅? = 0)
= 𝑒𝑥𝑝𝑖𝑡(𝛽0 + 𝛽1𝑎𝑒,𝑘 + 𝛽2𝑎𝑙,𝑘 + 𝛽3(𝑎𝑒,𝑘−1 + 𝑎𝑙,𝑘−1) + 𝛽4ℎ𝑘−1 + 𝛽5𝐶𝐷40
+ 𝛽6𝐶𝐷40,1 + 𝛽7𝐶𝐷40,2 + 𝛽8𝐶𝐷40,3 + 𝛽9𝑉𝐿0 + 𝛽10𝐼𝐷𝑈0 + 𝛽11𝑆𝑚𝑜𝑘𝑒0
+ 𝛽12𝐴𝑙𝑐𝑜ℎ𝑜𝑙0 + 𝛽13𝑂𝑏𝑒𝑠𝑒0 + 𝛽14𝑆𝑒𝑥 + 𝛽15𝑅𝑎𝑐𝑒𝑏𝑙𝑎𝑐𝑘 + 𝛽16𝑅𝑎𝑐𝑒𝐻𝑖𝑠𝑝𝑎𝑛𝑖𝑐
+ 𝛽17𝑅𝑎𝑐𝑒𝑜𝑡ℎ𝑒𝑟 + 𝛽18𝐴𝑔𝑒 + 𝛽19𝐴𝑔𝑒
1 + 𝛽20𝐴𝑔𝑒
2 + 𝛽21𝐴𝑔𝑒
3 + 𝛽22𝑘 + 𝛽23𝑘
1
+ 𝛽24𝑘
2 + 𝛽25𝑘
3 + 𝛽26𝐶𝐷4𝑘−1 + 𝛽27𝐶𝐷4𝑘−1
1 + 𝛽28𝐶𝐷4𝑘−1
2 + 𝛽29𝐶𝐷4𝑘−1
3
+ 𝛽30𝐷𝑉𝐿𝑘−1 + 𝛽31𝐶𝐷4𝑘−2 + 𝛽32𝐶𝐷4𝑘−2
1 + 𝛽33𝐶𝐷4𝑘−2
2 + 𝛽34𝐶𝐷4𝑘−2
3
+ 𝛽35𝐷𝑉𝐿𝑘−2 + 𝛽36(𝑎𝑒,𝑘 + 𝑎𝑙,𝑘)ℎ𝑘−1 + 𝛽37(𝑎𝑒,𝑘 + 𝑎𝑙,𝑘)𝑘 + 𝛽38ℎ𝑘−1𝑘
+ 𝛽39𝑁𝑜𝐹𝑖𝑏0 + 𝛽40𝐹𝑖𝑏0 + 𝛽41𝐶𝑖𝑟𝑘−1 + 𝛽42𝐼𝐷𝑈𝑘−1 + 𝛽43𝑆𝑚𝑜𝑘𝑒𝑘−1
+ 𝛽44𝐴𝑙𝑐𝑜ℎ𝑜𝑙𝑘−1 + 𝛽45𝑂𝑏𝑒𝑠𝑒𝑘−1) 
The models for time-varying smoking, heavy alcohol use, injection drug use, and obesity were 
specified analogously to the viral load model. 
Time-varying CD4+ T-cell count was modelled as: 
𝐶𝐷4𝑘 = 𝛾0 + 𝛾1𝑎𝑒,𝑘 + 𝛾2𝑎𝑙,𝑘 + 𝛽3(𝑎𝑒,𝑘−1 + 𝑎𝑙,𝑘−1) + 𝛾4ℎ𝑘−1 + 𝛾5𝐶𝐷40 + 𝛾6𝐶𝐷40,1
+ 𝛾7𝐶𝐷40,2 + 𝛾8𝐶𝐷40,3 + 𝛾9𝑉𝐿0 + 𝛾10𝐼𝐷𝑈0 + 𝛾11𝑆𝑚𝑜𝑘𝑒0 + 𝛾12𝐴𝑙𝑐𝑜ℎ𝑜𝑙0
+ 𝛾13𝑂𝑏𝑒𝑠𝑒0 + 𝛾14𝑆𝑒𝑥 + 𝛾15𝑅𝑎𝑐𝑒𝑏𝑙𝑎𝑐𝑘 + 𝛾16𝑅𝑎𝑐𝑒𝐻𝑖𝑠𝑝𝑎𝑛𝑖𝑐 + 𝛾17𝑅𝑎𝑐𝑒𝑜𝑡ℎ𝑒𝑟
+ 𝛾18𝐴𝑔𝑒 + 𝛾19𝐴𝑔𝑒
1 + 𝛾20𝐴𝑔𝑒
2 + 𝛾21𝐴𝑔𝑒
3 + 𝛾22𝑘 + 𝛾23𝑘
1 + 𝛾24𝑘
2 + 𝛾25𝑘
3
+ 𝛾26𝐶𝐷4𝑘−1 + 𝛾27𝐶𝐷4𝑘−1
1 + 𝛾28𝐶𝐷4𝑘−1
2 + 𝛾29𝐶𝐷4𝑘−1
3 + 𝛾30𝐷𝑉𝐿𝑘−1
+ 𝛾31𝐶𝐷4𝑘−2 + 𝛾32𝐶𝐷4𝑘−2
1 + 𝛾33𝐶𝐷4𝑘−2
2 + 𝛾34𝐶𝐷4𝑘−2
3 + 𝛾35𝐷𝑉𝐿𝑘−2
+ 𝛾36(𝑎𝑒,𝑘 + 𝑎𝑙,𝑘)ℎ𝑘−1 + 𝛾37(𝑎𝑒,𝑘 + 𝑎𝑙,𝑘)𝑘 + 𝛾38ℎ𝑘−1𝑘 + 𝛾39𝑁𝑜𝐹𝑖𝑏0 + 𝛾40𝐹𝑖𝑏0
+ 𝛾41𝐶𝑖𝑟𝑘−1 + +𝛾42𝐼𝐷𝑈𝑘−1 + 𝛾43𝑆𝑚𝑜𝑘𝑒𝑘−1 + 𝛾44𝐴𝑙𝑐𝑜ℎ𝑜𝑙𝑘−1 + 𝛾45𝑂𝑏𝑒𝑠𝑒𝑘−1
+ 𝜀 
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where 𝜀~𝑁(0, 𝜎2). 
Finally, time-varying severe fibrosis/cirrhosis was modelled as: 
𝑃𝑟(𝐶𝑖𝑟𝑘 = 1|?̅?𝑘 = ?̅?𝑘, 𝐻𝑘−1 = ℎ̅𝑘−1, ?̅?𝑘−1 = ?̅?𝑘−1, ?̅?𝑘 = 𝐶?̅? = 0)
= 𝑒𝑥𝑝𝑖𝑡(𝜃0 + 𝜃1𝑎𝑒,𝑘 + 𝜃2𝑎𝑙,𝑘 + 𝜃3(𝑎𝑒,𝑘−1 + 𝑎𝑙,𝑘−1) + 𝜃4ℎ𝑘−1 + 𝜃5𝐶𝐷40
+ 𝜃6𝐶𝐷40,1 + 𝜃7𝐶𝐷40,2 + 𝜃8𝐶𝐷40,3 + 𝜃9𝑉𝐿0 + 𝜃10𝐼𝐷𝑈0 + 𝜃11𝑆𝑚𝑜𝑘𝑒0
+ 𝜃12𝐴𝑙𝑐𝑜ℎ𝑜𝑙0 + 𝜃13𝑂𝑏𝑒𝑠𝑒0 + 𝜃14𝑆𝑒𝑥 + 𝜃15𝑅𝑎𝑐𝑒𝑏𝑙𝑎𝑐𝑘 + 𝜃16𝑅𝑎𝑐𝑒𝐻𝑖𝑠𝑝𝑎𝑛𝑖𝑐
+ 𝜃17𝑅𝑎𝑐𝑒𝑜𝑡ℎ𝑒𝑟 + 𝜃18𝐴𝑔𝑒 + 𝜃19𝐴𝑔𝑒
1 + 𝜃20𝐴𝑔𝑒
2 + 𝜃21𝐴𝑔𝑒
3 + 𝜃22𝑘 + 𝜃23𝑘
1
+ 𝜃24𝑘
2 + 𝜃25𝑘
3 + 𝜃26𝐶𝐷4𝑘−1 + 𝜃27𝐶𝐷4𝑘−1
1 + 𝜃28𝐶𝐷4𝑘−1
2 + 𝜃29𝐶𝐷4𝑘−1
3
+ 𝜃30𝐷𝑉𝐿𝑘−1 + 𝜃31𝐶𝐷4𝑘−2 + 𝜃32𝐶𝐷4𝑘−2
1 + 𝜃33𝐶𝐷4𝑘−2
2 + 𝑣34𝐶𝐷4𝑘−2
3
+ 𝜃35𝐷𝑉𝐿𝑘−2 + 𝜃36(𝑎𝑒,𝑘 + 𝑎𝑙,𝑘)ℎ𝑘−1 + 𝜃37(𝑎𝑒,𝑘 + 𝑎𝑙,𝑘)𝑘 + 𝜃38ℎ𝑘−1𝑘
+ 𝜃39𝑁𝑜𝐹𝑖𝑏0 + 𝜃40𝐹𝑖𝑏0 + 𝜃41𝐼𝐷𝑈𝑘−1 + 𝜃42𝑆𝑚𝑜𝑘𝑒𝑘−1 + 𝜃43𝐴𝑙𝑐𝑜ℎ𝑜𝑙𝑘−1
+ 𝜃44𝑂𝑏𝑒𝑠𝑒𝑘−1) 
We assumed that once someone has cirrhosis, it does not reverse, so 𝑃𝑟(𝐶𝑖𝑟𝑘 = 1|𝐶𝑖𝑟𝑘−1 = 1) =
1. 
For the natural course, ART initiation, baseline HCV status, and loss to follow-up were 
modelled as follows: 
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𝑃𝑟(𝐴𝑘 ≠ 0|?̅?𝑘−1 = 0, ?̅?𝑘−1 = ℎ̅𝑘−1, ?̅?𝑘−1 = ?̅?𝑘−1, ?̅?𝑘 = 𝐶?̅? = 0)
= 𝑒𝑥𝑝𝑖𝑡(𝛿0 + 𝛿1ℎ𝑘−1 + 𝛿2𝐶𝐷40 + 𝛿3𝐶𝐷40,1 + 𝛿4𝐶𝐷40,2 + 𝛿5𝐶𝐷40,3 + 𝛿6𝑉𝐿0
+ 𝛿7𝐼𝐷𝑈0 + 𝛿8𝑆𝑚𝑜𝑘𝑒0 + 𝛿9𝐴𝑙𝑐𝑜ℎ𝑜𝑙0 + 𝛿10𝑂𝑏𝑒𝑠𝑒0 + 𝛿11𝑆𝑒𝑥 + 𝛿12𝑅𝑎𝑐𝑒𝑏𝑙𝑎𝑐𝑘
+ 𝛿13𝑅𝑎𝑐𝑒𝐻𝑖𝑠𝑝𝑎𝑛𝑖𝑐 + 𝛿14𝑅𝑎𝑐𝑒𝑜𝑡ℎ𝑒𝑟 + 𝛿15𝐴𝑔𝑒 + 𝛿16𝐴𝑔𝑒1 + 𝛿17𝐴𝑔𝑒2 + 𝛿18𝐴𝑔𝑒3
+ 𝛿19𝑘 + 𝛿20𝑘
1 + 𝛿25𝑘
2 + 𝛿26𝑘
3 + 𝛿27𝐶𝐷4𝑘 + 𝛿28𝐶𝐷4𝑘−1
1 + 𝛿29𝐶𝐷4𝑘−1
2
+ 𝛿30𝐶𝐷4𝑘−1
3 + 𝛿31𝐷𝑉𝐿𝑘−1 + 𝛿32𝐶𝐷4𝑘−2 + 𝛿33𝐶𝐷4𝑘−2
1 + 𝛿34𝐶𝐷4𝑘−2
2
+ 𝛿35𝐶𝐷4𝑘−2
3 + 𝛿36𝐷𝑉𝐿𝑘−2 + 𝛿37ℎ𝑘−1𝑘 + 𝛿39𝑁𝑜𝐹𝑖𝑏0 + 𝛿40𝐹𝑖𝑏0 + 𝛿41𝐶𝑖𝑟𝑘−1
+ 𝛿42𝐼𝐷𝑈𝑘−1 + 𝛿43𝑆𝑚𝑜𝑘𝑒𝑘−1 + 𝛿44𝐴𝑙𝑐𝑜ℎ𝑜𝑙𝑘−1 + 𝛿45𝑂𝑏𝑒𝑠𝑒𝑘−1) 
 𝑃𝑟(𝐻0 = 1|𝑊0 = 𝑤0)
= 𝑒𝑥𝑝𝑖𝑡(𝜁0 + 𝜁1𝐶𝐷40 + 𝜁2𝐶𝐷40,1 + 𝜁3𝐶𝐷40,2 + 𝜁4𝐶𝐷40,3 + 𝜁5𝑉𝐿0 + 𝜁6𝐼𝐷𝑈0
+ 𝜁7𝑆𝑚𝑜𝑘𝑒0 + 𝜁8𝐴𝑙𝑐𝑜ℎ𝑜𝑙0 + 𝜁9𝑂𝑏𝑒𝑠𝑒0 + 𝜁10𝑆𝑒𝑥 + 𝜁11𝑅𝑎𝑐𝑒𝑏𝑙𝑎𝑐𝑘
+ 𝜁12𝑅𝑎𝑐𝑒𝐻𝑖𝑠𝑝𝑎𝑛𝑖𝑐 + 𝜁13𝑅𝑎𝑐𝑒𝑜𝑡ℎ𝑒𝑟 + 𝜁14𝐴𝑔𝑒 + 𝜁15𝐴𝑔𝑒
2 + 𝜁16𝐴𝑔𝑒
3 + 𝜁17𝐴𝑔𝑒
4
+ 𝜁18𝑁𝑜𝐹𝑖𝑏0 + 𝜁19𝐹𝑖𝑏0) 
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𝑃𝑟(𝐶𝑘 = 1|?̅?𝑘−1 = ?̅?𝑘−1, ?̅?𝑘−1 = ℎ̅𝑘−1, ?̅?𝑘−1 = ?̅?𝑘−1, ?̅?𝑘 = 𝐶?̅?−1 = 0)
= 𝑒𝑥𝑝𝑖𝑡(𝜂0 + 𝜂1𝑎𝑒,𝑘−1 + 𝜂2𝑎𝑙,𝑘−1 + 𝜂3(𝑎𝑒,𝑘−2 + 𝑎𝑙,𝑘−2) + 𝜂4ℎ𝑘−1 + 𝜂5𝐶𝐷40
+ 𝜂6𝐶𝐷40,1 + 𝜂7𝐶𝐷40,2 + 𝜂8𝐶𝐷40,3 + 𝜂9𝑉𝐿0 + 𝜂10𝐼𝐷𝑈0 + 𝜂11𝑆𝑚𝑜𝑘𝑒0
+ 𝜂12𝐴𝑙𝑐𝑜ℎ𝑜𝑙0 + 𝜂13𝑂𝑏𝑒𝑠𝑒0 + 𝜂14𝑆𝑒𝑥 + 𝜂15𝑅𝑎𝑐𝑒𝑏𝑙𝑎𝑐𝑘 + 𝑣16𝑅𝑎𝑐𝑒𝐻𝑖𝑠𝑝𝑎𝑛𝑖𝑐
+ 𝜂17𝑅𝑎𝑐𝑒𝑜𝑡ℎ𝑒𝑟 + 𝜂18𝐴𝑔𝑒 + 𝜂19𝐴𝑔𝑒
1 + 𝜂20𝐴𝑔𝑒
2 + 𝜂21𝐴𝑔𝑒
3 + 𝜂22𝑘 + 𝜂23𝑘
1
+ 𝜂24𝑘
2 + 𝜂25𝑘
3 + 𝜂26𝐶𝐷4𝑘−1 + 𝜂27𝐶𝐷4𝑘−1
1 + 𝜂28𝐶𝐷4𝑘−1
2 + 𝜂29𝐶𝐷4𝑘−1
3
+ 𝜂30𝐷𝑉𝐿𝑘−1 + 𝜂31𝐶𝐷4𝑘−2 + 𝜂32𝐶𝐷4𝑘−2
1 + 𝜂33𝐶𝐷4𝑘−2
2 + 𝜂34𝐶𝐷4𝑘−2
3
+ 𝜂35𝐷𝑉𝐿𝑘−2 + 𝜂36(𝑎𝑒,𝑘−1 + 𝑎𝑙,𝑘−1)ℎ𝑘−1 + 𝜂37(𝑎𝑒,𝑘−1 + 𝑎𝑙,𝑘−1)𝑘 + 𝜂38ℎ𝑘−1𝑘
+ 𝜂39𝑁𝑜𝐹𝑖𝑏0 + 𝜂40𝐹𝑖𝑏0 + 𝜂41𝐶𝑖𝑟𝑘−1 + 𝜂42𝐼𝐷𝑈𝑘−1 + 𝜂43𝑆𝑚𝑜𝑘𝑒𝑘−1
+ 𝜂44𝐴𝑙𝑐𝑜ℎ𝑜𝑙𝑘−1 + 𝜂45𝑂𝑏𝑒𝑠𝑒𝑘−1) 
When modelling the natural course, if ART was initiated prior to October 1, 2001 then 𝑎𝑘 was 
set to 1, and if it was initiated after that date 𝑎𝑘 was set to 2. Note that the intent to treat 
assumption implies 𝑃𝑟(𝐴𝑘 = 1|𝐴𝑘−1 = 1, ?̅?𝑘−1 = ℎ̅, ?̅?𝑘−1 = ?̅?𝑘−1, ?̅?𝑘 = 𝐶?̅? = 0) = 1. We 
additionally assumed no incident HCV infections and that no HCV infections would be resolved 
without intervention, so 
𝑃𝑟(𝐻𝑚 = ℎ|?̅?𝑚−1 = ?̅?𝑚−1, 𝐻𝑚−1 = ℎ̅𝑚−1, ?̅?𝑚−1 = ?̅?𝑚−1, ?̅?𝑚 = 𝐶?̅? = 0) = 1if 𝐻0 = ℎ. 
Treatment success was determined with a beta-Bernoulli distributed random variable. First, a 
beta random variable, 𝑃, with parameters chosen to represent the average effectiveness and 
reasonable uncertainty of effectiveness was drawn (in this case, we chose the average 
effectiveness to be 0.96, with 95% of the distribution falling between 0.93 and 0.98(Naggie et al. 
2015)). Second, a Bernoulli random variable, 𝐵 was drawn with parameter 𝑃. Those with 𝐵 = 1 
had 𝐴2 set to 0, while the others remained with 𝐴2 = 1. 
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B.4 Comparison of observed and modelled natural course in chapter 5 
Table B.1: Comparison of observed versus modelled variable distributions under the natural 
course using models from chapter 5, Women’s Interagency HIV Study and Multicenter AIDS 
Cohort Study, 1994-2015 
Variable Data Model 
% Subjects   
HCV 19.02 18.79 
Censored 51.23 51.03 
LTFU 34.66 35.10 
   
% Person-Time   
ART 53.54 54.03 
Detectible viral load 70.37 70.39 
Injection drug use 3.30 3.48 
Smoke 41.42 41.63 
Drink 8.98 9.22 
Obese 24.17 24.56 
Severe fibrosis/Cirrhosis 23.24 22.11 
   
Average value   
CD4 Count 479.64 503.90 
   
Kaplan-Meier Estimate   
10-year All-Cause Mortalitya 19.90 19.67 
Abbreviations: HCV, hepatitis C virus; ART, antiretroviral therapy 
aRisk, expressed as percent
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Figure B.1: Comparison of observed versus modelled mortality under the natural course using 
models from chapter 5. 
 
Grey lines are cumulative incidence curves from 200 bootstrap samples from the observed data. 
Blue line is the modelled cumulative incidence curve  
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B.5 Timing of DAA treatment under dynamic interventions in chapter 5 
 
Figure B.2: Timing of DAA treatment under dynamic interventions in chapter 5 
Solid line is treating those with suppressed HIV viral load. Short dashed line is treating those 
with severe fibrosis/cirrhosis. Long dashed line is treating those with suppressed HIV viral load 
and severe fibrosis/cirrhosis.
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